Compounds useful for the preparation of various pesticides and their markers

A novel synthesis process using Grignard reagents for unsaturated precursors and intermediates addresses the inefficiencies of existing methods, reducing costs and improving yield and selectivity in the production of chiral herbicides and pesticides.

JP2024545270APending Publication Date: 2024-12-05ADAMA AGAN LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024536320
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-15
Filing Date
2022-12-15
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing methods for preparing chiral compounds used in herbicides and pesticides are expensive, involve multiple synthetic steps, and require the use of heavy metals like palladium, rhodium, and iridium, making it difficult to selectively prepare the desired syn or anti isomer.

Method used

A novel process using Grignard or organolithium reagents to synthesize unsaturated precursors and intermediates, avoiding the need for expensive catalysts and heavy metals, and allowing for selective preparation of chiral compounds through late-stage chirality introduction.

Benefits of technology

This method reduces costs, minimizes waste, and improves yield and selectivity, providing efficient synthesis of chiral compounds like 2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide with novel polymorphic forms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545270000659
    Figure 2024545270000659
  • Figure 2024545270000660
    Figure 2024545270000660
  • Figure 2024545270000661
    Figure 2024545270000661
Patent Text Reader

Abstract

The present invention relates to certain compounds referred to as saturated targets and their amorphous and crystalline forms, as well as various compounds which are novel and useful intermediates in novel methods for the preparation of certain marker compounds, including preserved marker compounds, methods for their preparation, their uses, and compositions containing them, including methods for minimizing the content of preserved markers in products and compositions of saturated targets.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates in particular to the field of chemical and pesticide synthesis, and in particular to synthetic intermediates, polymorphs and marker compounds, as well as salts thereof, processes for their preparation and their uses. [Background technology]

[0002] WO 2015 / 084796 and WO 2016 / 196593 are reported to disclose various substituted cyclic amides, their use as herbicides, and methods for preparing them. WO 2016 / 094117 discloses certain 3-oxo-3-(arylamino)propanoates, their salts and compositions, processes for preparing them, and their use in preparing certain pyrrolidinones that are reportedly useful, inter alia, as pesticides, particularly as herbicides.

[0003] WO 2018 / 175226 reportedly discloses certain pyrrolidinones, intermediates, and methods for preparing them. The inventors also note the publications WO 2020 / 242946, WO 2020 / 064260, U.S. Pat. No. 10,676,431, WO 2019 / 025156, WO 2018 / 222647, WO 2018 / 222646, WO 2018 / 184890, U.S. Pat. App. Pub. No. 2018 / 099935, EP 3650430, U.S. Pat. App. Pub. No. 2018 / 077931, WO 2016 / 164201, U.S. Pat. App. Pub. No. 2017 / 158638 and U.S. Pat. No. 2020010415. The inventors further note WO 01 / 76566, which teaches the use of amido- or amino-group-containing polymeric compounds exemplified by polyvinylpyrrolidone, crosslinked polyvinylpyrrolidone, copolymers of vinylpyrrolidone and vinyl acetate, and polynoxylin, in stabilizing compounds sensitive to acidic environments. Summary of the Invention [Problem to be solved by the invention]

[0004] The intermediates, markers, compositions, processes for preparing them, and their use in processes, mixtures, compositions, crystalline forms, and amorphous solid forms of the present invention disclosed herein are not disclosed in these prior publications. The known methods for preparing the chiral compounds mentioned herein are generally expensive due to the use of expensive starting materials; involve multiple synthetic steps; involve or are based on the use of catalysis using heavy metals such as palladium, rhodium, and iridium; involve a ring-closure step; or introduce chirality into the system early in the synthesis, making it difficult to selectively prepare the desired syn or anti isomer of Compound I. There is a continuing need for alternative processes and novel synthetic intermediates that can alleviate at least some of these problems. Several additional novel and unobviously useful aspects and embodiments of the present invention are a direct result of the inventive processes and novel synthetic intermediates disclosed herein. [Means for solving the problem]

[0005] The present invention relates to certain compounds called saturated targets and their amorphous and crystalline forms, as well as various compounds that are novel and useful intermediates in novel methods for preparing certain marker compounds, including preserved marker compounds, methods for their preparation, their uses, and compositions containing them, including methods for minimizing the content of preserved markers in products and compositions of saturated targets. [Brief explanation of the drawings]

[0006] [Figure 1] Tetoflurilpyrrolimet Formation I-DSC [Figure 2] Tetoflurilpyrrolimet Form II-DSC [Figure 3] Tetoflurilpyrrolimet Form I-TGA [Figure 4] Tetoflurilpyrrolimet Form II-TGA [Figure 5] Tetoflurilpyrrolimet Form I-XRD [Figure 6] Tetoflurilpyrrolimet Form II-XRD [Figure 7] Tetoflurilpyrrolimet Form I and Form II - XRD overlay [Figure 8] Tetoflurilpyrrolimet 9:1 Mixture Form I and Form II - XRD [Figure 9] Tetoflurilpyrrolimet Form I IR Spectrum [Figure 10] Tetoflurilpyrrolimet Form II IR Spectrum [Figure 11] Tetoflurilpyrrolimet Form I and Form II - IR overlay spectra [Figure 12] Storage Marker - LC / MS - Storage Marker for Tetoflurilpyrrolimet, molecular weight 286 [Figure 13] Tetoflurilpyrrolimet + Storage Marker - LC / MS [Figure 14] Storage marker molecular weight 286-LC / MS DETAILED DESCRIPTION OF THE INVENTION

[0007] definition Before describing the present subject matter in detail, it may be useful to provide definitions of certain terms used herein. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this subject matter belongs.

[0008] As used herein, the terms "a" or "an" include the singular and the plural unless otherwise specified. Thus, the terms "a," "an," or "at least one" can be used interchangeably in this application.

[0009] Furthermore, unless expressly stated otherwise, "or" refers to an inclusive or, not an exclusive or. For example, condition A or B is satisfied by any one of the following: A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and both A and B are true (or exist).

[0010] Throughout this application, descriptions of various embodiments use the term "comprising," but it will be understood by those skilled in the art that in some specific instances, embodiments may alternatively be described using the terms "containing," "consisting essentially of," or "consisting of."

[0011] To better understand the present teachings, and not to limit the scope of the teachings in any way, all numbers expressing amounts, percentages or proportions, as well as other numerical values ​​used in the specification and claims, unless otherwise indicated, should be understood as being modified in all instances by the term "about."

[0012] Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, each numerical parameter should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. In this regard, use of the term "about" herein specifically includes + / - 10% of the stated value within the range, unless otherwise stated. Furthermore, the endpoints of all ranges directed to the same component or property herein are inclusive, independently combinable, and include all intermediate points and ranges.

[0013] In the present invention, the following terms have the following meanings:

[0014] All figures and references herein to saturated target compounds, unsaturated precursor compounds, Compound III, Compound IV, or conservative marker compounds are intended to include analogs, isomers, salts, N-oxides, esters, etc. thereof, having the function and utility intended or ascribed to the referenced compound, as would be reasonably understood by one of ordinary skill in the art, unless otherwise defined, or unless the context in which they are referred to expressly limits them to a particular structure, or unless their inclusion would introduce unpatentable subject matter or scope.

[0015] The saturated target, unsaturated precursor, compound III, compound IV, and conserved marker may be referred to in the plural, e.g., saturated target, unsaturated precursor, compound III, compound IV, and conserved marker, to reflect the multiple compounds encompassed by the general structures that describe them, but no significance should be ascribed thereto, and no inference should be drawn when the singular terms are used for convenience of context.

[0016] Where appropriate, the disclosed structures of particular compounds are labeled with numbers to facilitate more specific identification of the compounds.

[0017] In many cases, where appropriate, specific structures disclosed are further labeled with letters and numbers to facilitate comparison to the general synthetic schemes disclosed herein.

[0018] The saturated target compounds and some of the intermediates of the present invention that can produce them, the unsaturated precursors, Compound III and Compound IV, and the preservative marker compounds prepared using the preparation methods of the present invention described herein, can exist as isomers, particularly one or more stereoisomers. Various stereoisomers include enantiomers, diastereomers, atropisomers, and geometric isomers. For example, saturated targets are understood to be chiral. When only one structure is depicted or labeled "1" or described as a saturated target, the companion enantiomers, diastereomers, or optical isomers of the saturated target, including both 1 and its optically active and racemic mixtures, are expressly intended and should not be inferred from the omission of the corresponding structure of the partner compound unless otherwise specified or clear from the context in which the structure appears. Similarly, the intermediate and marker compounds of the present invention, the unsaturated precursors, Compound III and Compound IV, and the preservative markers and corresponding examples of saturated targets are isomers, including, for example, cis-trans and / or EZ isomers. Where only one isomeric structure is depicted or labeled, all companion isomers are expressly intended if it is clear to one skilled in the art that they have similar functions / properties, and no inference should be made from the omission of the corresponding structure for convenience of illustration unless otherwise stated or apparent from the context in which the structure appears.

[0019] Although it is generally understood that the crystalline form of a compound cannot be fully characterized by a single peak in a powder X-ray diffraction pattern, it should be noted that, in distinguishing between the two known crystalline forms of tetflupyrrolimet described herein, each powder X-ray diffraction pattern exhibits at least one peak that is absent or has an intensity below the detection limit in the powder X-ray diffraction pattern of the other polymorphic form. Therefore, if a crystalline form has already been chemically identified as tetflupyrrolimet, the two novel polymorphs disclosed herein can be distinguished by this single characteristic peak. Therefore, the inventors refer to this type of peak as a differential peak. Obviously, each of the differential peaks is also part of the respective list of characteristic peaks.

[0020] In the definition of the disclosed structures, the term "carbonyl" is intended to include the corresponding "carbonyl" protected as an acetal of a C1-C8 alcohol, such as ethanol, or a C1-C8 diol, such as ethylene glycol, 1,3-propanediol, propylene glycol. As an example, the term "dimethylcarbonyl" would include the corresponding acetal exemplified by MeC(OCH2CHO)Me.

[0021] As used herein, the term "metal" is intended to include metals in all forms, including but not limited to metal salts, metal complexes, and the like.

[0022] In embodiments of the inventive synthetic processes disclosed herein, where the use of a Grignard reagent is indicated, a Grignard reagent that is not aliphatic, e.g., not an alkyl-type Grignard reagent, is particularly preferred.

[0023] Furthermore, in embodiments of the synthetic processes of the present invention disclosed herein, where the use of Grignard reagents is indicated, it will be apparent to those skilled in the art that similar organometallic compounds or alternative nucleophiles can replace the Grignard reagents. Preferred examples of these alternative nucleophiles are organolithiums. Organocopper and organozinc compounds, such as phenyl(3-(trifluoromethyl)phenyl)zinc, 3-(trifluoromethyl)phenyl)lithium, bis(3-(trifluoromethyl)phenyl)zinc, (3-(trifluoromethyl)phenyl)zinc(II) bromide, bis(3-(trifluoromethyl)phenyl)cuprate(I), bis(3-(trifluoromethyl)phenyl)copper, and the like, and combinations of these types of reagents are expressly included.

[0024] In embodiments of the inventive synthetic processes disclosed herein, where the use of a nucleophile, e.g., a Grignard reagent, is indicated, the use of a hydrogen / hydride source or hydrogenation is also contemplated as an option within the concept of using a nucleophile, as exemplified by the use of H2 / Pd, NaBH4, CuH, or H2 / Raney Ni, etc., as well as electron sources exemplified by the use of Zn / AcOH, Na / NH3, etc.

[0025] The term Grignard reagent includes organomagnesium compounds in which Mg is bound to carbon including Ate complexes, turbo Grignards, etc., exemplified by iPrMgCl, MeMgCl2Li, etc.

[0026] In the generic structures representing groups of compounds, unless otherwise specified, each instance of a substituent may be independently selected from any of the definitions of that substituent. For example, compounds within the group represented by CH(R')3, where R' is defined as F, Cl, or I, may include the compound CH(F)(Cl)(I).

[0027] The present invention relates inter alia to compounds of each of formulas 2, 3 and 4, as defined below, referred to herein as unsaturated precursors, and intermediates III and IV: [ka] As further defined below, this is a novel, useful intermediate in novel processes for the preparation of certain pesticidal compounds, particularly pyrrolidinones (defined below), commonly referred to as saturated targets, identified herein as compounds of formula 1. An example of these processes is shown in the following scheme: [ka]

[0028] However, each unsaturated precursor, compounds III and IV, is individually useful as an intermediate for the preparation of a saturated target, independent of the others in the reaction sequence as illustrated. Advantageously, the saturated target is a pyrrolidinone, an anilide insecticide, best exemplified by 2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide, [ka] Most particularly, enantiomers and / or diastereomers thereof useful as herbicides, which enantiomers and / or diastereomers include the following structures: [ka] Includes:

[0029] The present invention also relates to a compound of formula D [ka] The present invention also relates to certain marker compounds, including those identified herein as conserved markers, exemplified by the compound This has the following structure: [ka] and most specifically, can be further prepared from an exemplary saturated target compound having the following scheme: [ka] In the method, the conversion rate and degree of conversion and amount of the produced storage marker of formula D, as well as its content in a mixture with the composition of the saturated target compound from which it was produced, are mediated by the properties of the composition and its storage history under various defined environmental conditions, particularly exposure to sunlight, and thus the storage marker of formula D is novelly utilized in the present invention as a marker that provides evidence of the properties of the composition and past storage conditions.

[0030] Thus, the present invention also relates to methods for preparing saturated target compounds, as well as unsaturated precursors and compounds III, which are the subject of embodiments of the present invention, and each of the various individual intermediates herein referred to as IV and preserved marker compounds of formula D, and in particular to industrially useful methods for the efficient preparation of certain pyrrolidinones, which are anilide insecticides, as exemplified by the optically active compound 2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide from the aforementioned intermediate compounds.

[0031] The present invention also relates to novel mixtures and compositions comprising saturating target and storage marker compounds, exemplified by mixtures of the anilide pesticides with the respective markers described above, which are indicative of or evidence of, for example, suboptimal storage conditions and / or adverse compositional properties or components of the mixture.

[0032] The present invention further relates to methods, ingredients, and packaging useful for minimizing the content of such preservative marker compounds in compositions of saturated targets, inter alia, by minimizing, avoiding, or mitigating the effects of exposure of such compositions to, for example, sunlight.

[0033] The present invention is clearly intimately related to the novel physical / chemical properties and / or attributes of the saturated target compounds that result from being produced by processes that utilize the unsaturated precursors of the present invention and compounds III and IV as intermediates in their preparation.

[0034] Thus, chemically, the saturated target compound as an intermediate prepared using any of the unsaturated precursors, compounds III or IV, can have a novel impurity profile, which can include at least trace amounts of any of the unsaturated intermediates, III or IV, as impurities carried over from the process, thus providing new evidence that the saturated target compound was prepared using the compounds of the present invention, unsaturated intermediates, III or IV, as intermediates. The combination of the saturated target with any of the unsaturated precursors III or IV is novel in itself and has utility, inter alia, in the analysis of the test saturated target to determine its preparation route and other uses unrelated to being a preparation intermediate.

[0035] As noted above, the saturated target compounds produced by processes utilizing the unsaturated precursors of the present invention, designated compounds III and IV, as intermediates in their preparation also result in novel physical properties and / or attributes. In one non-limiting example, these characteristics include, but are not limited to: When produced by the methods and intermediates of the present invention, novel and useful polymorphic forms of 2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide and its individual enantiomers / diastereomers, as well as mixtures thereof, are included.

[0036] Thus, the present invention also relates to both amorphous and non-crystalline solid forms, as well as to each of the crystalline polymorphs of Form I and Form II of (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide (tetflupyrrolimet), whether as a pure active ingredient or in combination with an amorphous form, a carrier, or additional components, and mixtures of both Form I and Form II. All of these mixtures are encompassed by the term "composition" herein. Thus, in general, the term "composition" herein should be understood to include all mixtures of two or more materials, including mixtures of active ingredients, intermediates, and markers, even if no inactive or inert ingredients or carrier materials are included.

[0037] It is well understood that in many cases, compounds with different crystalline polymorphic forms can typically exhibit different physical properties in a wide range of parameters depending on the polymorph, such as solubilization rate, flowability, stability, compressibility, or even reflection brightness. Considering the large array of pesticide compositions, especially herbicidal compositions, each has its own requirements. Having alternative new and useful polymorphs of agricultural active ingredients that allow them to be formulated in a wider range of delivery forms is advantageous in itself. In particular, it is useful for enabling a wider range of formulation techniques. Similar advantages are often obtained by producing non-crystalline or amorphous forms, for example, because they generally have a faster dissolution rate. Spray drying, freeze drying, solid solution, and adsorption onto a carrier substrate are some typical methods for obtaining such solid forms, but the stability of sensitive compounds must be considered.

[0038] The present invention specifically includes novel tetflupyrrolimet polymorph Form I, which exhibits at least one of the following properties: Infrared spectrum substantially as shown in FIG. Powder X-ray diffraction pattern substantially as shown in FIG. Powder X-ray diffraction pattern with a differential peak at 9.6 2θ (±0.20); A powder X-ray diffraction pattern having at least four characteristic peaks at 2θ (±0.20) of 9.6, 15.0, 17.3, 17.9, 21.6 and 24.6.

[0039] The present invention specifically includes novel tetflupyrrolimet polymorph Form II that exhibits at least one of the following properties: Infrared (IR) absorption spectrum substantially as shown in FIG. An infrared (IR) absorption spectrum having at least one characteristic peak selected from values ​​expressed as cm −1 (±1 cm −1 ) at 1678, 1546, 1395, 946, 924, 885, 825 and 662. Powder X-ray diffraction pattern substantially as shown in FIG. a powder X-ray diffraction pattern having a differential peak at 6.9 2θ (±0.20); A powder X-ray diffraction pattern having at least four characteristic peaks expressed in 2θ (±0.20) selected from the following values: 6.9, 11.2, 17.7, 23.5 and 26.3.

[0040] The present invention further relates to a process for the preparation of the crystalline polymorphic Form I and Form II of (3S,4S)—N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide (tetoflurolimet) described in this invention.

[0041] Embodiments and Description The compounds of formulas 2, 3 and 4, also referred to as unsaturated precursors III and IV, respectively, defined below and in the following embodiments, can each be individually prepared by one skilled in the art by common methods known in the art of synthetic organic chemistry. [ka]

[0042] Each of the compounds, unsaturated precursors, III and IV, is a. Novel compounds not previously disclosed for chemical, biological or agricultural purposes; b. Novel synthetic intermediates not previously disclosed as having utility in methods for preparing corresponding saturated target compounds; c. a novel combination partner with the saturated target compound that remains as a synthetic impurity after its use as a synthetic intermediate in the preparation of said saturated target; and d. At least one, and preferably all, of the marker compounds evidence the use of the novel method of preparation of the tested sample of saturated target substance.

[0043] In one aspect, the methods of the present invention for preparing saturated target compounds can include schemes utilizing all of the compounds, unsaturated precursors, III and IV, and also expressly include individual aspects of the method for preparing each intermediate compound without reference to their subsequent use as intermediates in a multi-step preparation. [ka]

[0044] However, it is fully within the scope of the present invention and specifically contemplated by the inventors that the inventive process for preparing a saturated target compound involves the use of only one and / or two of the three corresponding novel intermediate compounds, and none of the others. Thus, it is useful to consider each of the claimed compounds as inventively independent of one another.

[0045] Specifically contemplated by the inventors are processes for preparing saturated targets of Formula 1 directly from the corresponding intermediate compounds of Formula 3 or saturated targets of Formula 4, without involving any of the other disclosed intermediate compounds and / or via other unclaimed intermediates. Examples include the processes of the following general schemes, the details of which will be readily apparent to those skilled in the art of synthetic chemistry after and as a result of the material disclosed herein. [ka]

[0046] Similarly, in some cases, unsaturated precursors of formula 2 may be prepared directly from some compounds IV of formula 4. [ka]

[0047] Thus, each of the compounds, unsaturated precursors, III and IV, is individually useful as an intermediate for the preparation of the saturated target, independent of the others in the reaction sequence illustrated above.

[0048] Known methods for preparing saturated targets of formula 1 are generally expensive because they use expensive starting materials, involve multiple synthetic steps, involve the use of heavy metals such as palladium, rhodium, iridium, and / or involve closure of the ring label P in the following structure based on catalysis with heavy metals, and / or introduce chirality into the system at an early stage of the synthesis, making the selective preparation of the desired syn or anti isomer of the compound of formula 1 difficult. [ka]

[0049] Thus, in one aspect, the present invention provides novel intermediate compounds that can be used in a novel method for synthesizing saturated targets of formula 1 via reaction at the cyclic double bond in the ring system of an unsaturated precursor of formula 2, a step that does not require the same expensive catalysts, such as Pd, Rh, or Ir, as were required in previous processes. [ka]

[0050] The present invention also teaches and provides inexpensive ring-closure starting materials and intermediates that can be used in the synthesis of unsaturated precursors, avoiding the need for the ring-closure synthetic step illustrated in the scheme below. [ka]

[0051] This embodiment can be illustrated by the following scheme, which uses the inexpensive and readily available solvent N-methylpyrrolidone (NMP) as a starting material. [ka]

[0052] Of note, lactams / secondary amides of the following structure [ka] Reactions involving Grignard or organolithium reagents result in 1,4 addition instead of simple deprotonation and deactivation of the lactam / secondary amide, or other undesired reactions such as attack on the amide.

[0053] Implementation of the synthetic preparative methods of the present invention allows for a process that does not require expensive metals such as Pd, Rh, Pt, Ir, etc., and the use of relatively inexpensive and readily available Grignard or organolithium reagents can also advantageously often produce some marker compounds useful in demonstrating the use of the methods of the present invention, although not all or any of the markers are always produced.

[0054] For example, in the following scheme: [ka] Markers that can be formed by the above scheme can include some of the following structures: [ka] Another example can be seen in the following scheme: [ka] Markers that can be formed in this scheme can include some of the following structures: [ka]

[0055] As mentioned above, the use of Grignard and / or organolithium reagents of this type can be highly desirable for industrial scale production, reducing and / or eliminating waste issues, including heavy metals, B, etc., the use of expensive metals, e.g., Rh, Pd, Ir, Pt, etc., reducing the number of synthetic steps, and eliminating the need to purify the desired saturated target product from remaining problematic impurities.

[0056] The use of the inventive intermediates and processes disclosed herein may also entail some or all of the following potential advantages: improving syn-anti selectivity and introducing chirality at later stages of the synthesis reduces the risk of partial or even complete racemization in the final saturated target product, thus improving the yield of the desired chiral compound and therefore reducing production costs.

[0057] The disclosed process also reduces the number of synthetic steps required to prepare saturated target products and allows for synthesis starting from cyclic compounds, thus avoiding the need for cyclization as part of the synthesis.

[0058] The starting materials can also be significantly cheaper than previously disclosed starting materials, and the process requires cheaper reagents and catalysts, eliminating the need for expensive heavy metals such as palladium and ruthenium.

[0059] Some more detailed exemplary process methods disclosed below may be useful in understanding some of the aspects and embodiments of the present invention. None of the process details described herein below should be considered in any way to limit the scope of the invention as conceived by the inventors. Conversely, the individual steps and process details in the following examples should not be considered solely as part of a specific complete synthetic scheme, and other steps are not necessarily taught herein, but can be viewed as individual steps, each having value.

[0060] As will be readily apparent to those skilled in the art, the methods disclosed below are not necessarily preferred methods, but are intended to provide some color, scope, depth, and breadth to the more general description.

[0061] Embodiments of the present invention include the following.

[0062] Embodiment A1 Unsaturated precursors of formula 2 and salts thereof, for example [ka] (In the formula, R α is halogen; a carbon-containing group exemplified by substituted or unsubstituted alkyl, aryl, heterocycle, naphthyl; an ester, including aliphatic and aromatic esters exemplified by -C(O)OC6H5, -C(O)OC6H4F; an amide, including aliphatic and aromatic amides exemplified by -C(O)NHC6H5; aliphatic and aromatic hydrazine amides exemplified by -C(O)NHNHC6H5, thioesters, thionoesters, and similar compounds such as -C(O)NHOC6F5; -C(S)SC6H5, with the proviso that R α is not attached to the ring through an O or N, so for example, R α cannot be -OMe.

[0063] R β is a hydrogen or carbon-containing group exemplified by substituted or unsubstituted alkyl, aryl, naphthyl, heterocycle, etc., attached to the ring via a C atom or, where applicable, a Si atom, However, R β cannot be an amine attached to the ring through the N. R β may not be ether-linked to the ring via O R β is not a thioether attached to the ring via S, A αis a substituted or unsubstituted C, N, O or S atom, exemplified by -N(Me)-; -O-.

[0064] If present, A α The substituents of Q can be used, for example, in the following types of structures: α , A β It may be attached to another part of the molecule, such as [ka]

[0065] Each A β are each independently a C, N, O or S atom, with or without substitution as exemplified by -CH2- or -O-.

[0066] If present, each A β The substituents of A α , A β , R β may be attached to another part of the molecule such as, but not limited to, A β At least one of the is a saturated atom exemplified by CH2. nα is 1, 2 or 3. Each Q α are each independently O, S or NR ε is. R ε is a C, N, O or S atom with or without substitution as exemplified by -N(Me)2.

[0067] R ε The above substituents may be hydrogen or carbon and / or nitrogen containing groups, such as substituted or unsubstituted alkyl, aryl, naphthyl, heterocycles, etc., bonded to the ring via a C atom, or optionally a Si atom.

[0068] If present, R ε The substituents in the formula (I) are connected to the Q in the ring via a C atom or, where relevant, a Si atom, for example in the following structures: α , A βIt may be attached to another part of the molecule, such as [ka]

[0069] Generally, the ring moiety of the unsaturated precursor labeled below with P is not aromatic, i.e., not all atoms are capable of conjugation. Furthermore, the double bond of that ring moiety, shown below, is also not part of the outer aromatic addition ring. [ka]

[0070] Embodiment A2 Unsaturated precursors of formula 2 and, for example, salts thereof, [ka] The unsaturated precursor does not contain a covalent nitrogen-halogen bond; R α is halogen (Hal.), C1 to C 10 Alkyl, C1-C 10 Haloalkyl, R μ or -C(Q α )Q β R μ is. In some situations, R α can also be used in other parts of the molecule, e.g. Q in the ring α , A β may be bonded to the same Q β O, S, NR ε , N.R. π -NR π , N.R. π -O, NR π -S, S-NR π , or O-NR π and R β H, R ε , or Si(R ε )3, A αis a C, N, O or S atom bearing 0-2 substituents. The substituents, if present, are H and / or R as defined below. θ You can choose from A α Examples include -N(Me)-, -C(Et)H-, and -O-.

[0071] In some situations, A α The substituents of are, for example, Q α , A β It may be attached as a ring to another part of the molecule such as: [ka] Each A β are each independently a C, N, O or S atom having 0 to 2 substituents, For example, A β can be -N(Me)-, -C(Et)H-, -O-, etc. β The above substituents are A on a ring β H and / or R as defined below, provided that at least one of the atoms is a saturated atom exemplified by CH2. θ is selected from. Furthermore, in some situations, each A β Q α , A α Another part of the molecule or another A β They may also be bonded to each other to form a ring. nα is 1 to 3.

[0072] Q α O, S, NR ε and in certain circumstances, A in the ring β It may be attached to another part of the molecule, such as

[0073] Each R θare each independently selected from halogen (Hal.), hydroxy (OH), cyano (CN), nitro, amino, C1-C8 alkyl, C1-C8 cyanoalkyl, C1-C8 cyanoalkoxy, C1-C8 haloalkyl, C1-C8 hydroxyalkyl, C1-C8 nitroalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 nitroalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, C2-C8 alkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 haloalkoxyhaloalkoxy, C3-C6 cycloalkyl, cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C4-C 10 Cycloalkylalkyl, C4-C 10 Halocycloalkylalkyl, C5-C 12 Alkylcycloalkylalkyl, C5-C 12 Cycloalkylalkenyl, C5-C 12 Cycloalkylalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C 10 Alkylcycloalkyl, C6-C 12 Cycloalkylcycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C2-C8 haloalkoxyalkoxy, C2-C8 alkoxyalkoxy, C4-C 10 Cycloalkoxyalkyl, C3-C 10 Alkoxyalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylamino, C2-C8 dialkylamino, C2-C8 halodialkylamino, C2-C8 alkylaminoalkyl, C2-C8 haloalkylaminoalkyl, C4-C 10 Cycloalkylaminoalkyl, C3-C 10 Dialkylaminoalkyl, -CHO, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, -C(=O)OH, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, -C(=O)NH2, C2-C8 alkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C2-C8 alkoxyalkoxy, C2-C8 alkenyloxy, C2-C8 haloalkenyloxy, C3-C8 alkynyloxy, C3-C8 haloalkynyloxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C 10 Cycloalkylalkoxy, C3-C 10 Alkylcarbonylalkoxy, C2-C8 alkylcarbonyloxy, C2-C8 haloalkylcarbonyloxy, C4-C 10 Cycloalkylcarbonyloxy, C1-C8 alkylsulfonyloxy, C1-C8 haloalkylsulfonyloxy, C1-C8 alkylthio, C1-C8 haloalkylthio, C3-C8 cycloalkylthio, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 alkylsulfonyl, C1-C8 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, formylamino, C2-C8 alkylcarbonylamino, C2-C8 haloalkylcarbonylamino, C3-C8 cycloalkylamino, C2-C8 alkoxycarbonylamino, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino, -SF5, -SCN, SO2NH2, C3-C 12 Trialkylsilyl, C4-C 12 Trialkylsilylalkyl, C4-C 12 Trialkylsilylalkoxy, R σ , R η S(=O)=N-, R η S(=O)2N, R η -C(=O)-, R η (R η N=) q S(=O) p-cyano, formyl, C3-C8 alkylcarbonylalkyl, -C(C1-C4 alkyl), NO(C1-C4 alkyl), -C(O)NH2, C2-C6 cyanoalkyl, C3-C6 cycloalkyl, C4-C8 cycloalkenyl, arylcarbonyl, arylalkenylalkyl, arylcarbonylalkyl, or -CPhisN-O(C1-C4 alkyl), each of which is η is optionally substituted on the ring members with up to five substituents independently selected from:

[0074] R θ In the situation where is attached to another part of the molecule, the attachment is via a saturated, partially unsaturated or fully unsaturated chain containing 2 to 4 atoms selected from up to 4 C atoms, up to 1 O atom, up to 1 S atom and up to 2 N atoms, wherein up to 2 carbon members of the chain are independently selected from C(=O) and C(=S), and the sulfur atom member of the chain is S(-O) u (-NR ζ ) v and the chain is selected from R substituted on the carbon and / or nitrogen atoms η and optionally substituted with up to five substituents independently selected from R λ is H or R μ and R λ Q α , A β It may be attached to another part of the molecule, such as

[0075] R μ is a phenyl ring or a naphthalenyl ring system, and each ring or ring system is ζ; or a 4- to 7-membered heterocyclic ring; or an 8- to 10-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O atoms, up to 2 S atoms, and up to 5 N atoms, wherein up to 3 C ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently S(=O). u (=NR ζ )v and each ring or ring system is selected from the group consisting of carbon atom ring members R ζ and R is a nitrogen atom ring member independently selected from η and is substituted or unsubstituted with up to five substituents selected from R π is H or R θ is. R ε are R π is a C, N, O or S atom having 0 to 2 substituents selected from An example of the substituent is -N(Me). Q in the ring α , A β The carboxyl group may be further attached to another part of the molecule such as a carboxyl group.

[0076] Each R ζ are each independently selected from Hal, OH, CN, nitro, amino, C1-C8 alkyl, C1-C8 cyanoalkyl, C1-C8 cyanoalkoxy, C1-C8 haloalkyl, C1-C8 hydroxyalkyl, C1-C8 nitroalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 nitroalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, C2-C8 alkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 haloalkoxyhaloalkoxy, C3-C6 cycloalkyl, cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C4-C 10 Cycloalkylalkyl, C4-C 10 Halocycloalkylalkyl, C5-C 12 Alkylcycloalkylalkyl, C5-C 12 Cycloalkylalkenyl, C5-C 12 Cycloalkylalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C 10 Alkylcycloalkyl, C6-C 12 Cycloalkylcycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C2-C8 haloalkoxyalkoxy, C2-C8 alkoxyalkoxy, C4-C 10Cycloalkoxyalkyl, C3-C 10 Alkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylamino, C2-C8 dialkylamino, C2-C8 halodialkylamino, C2-C8 alkylaminoalkyl, C2-C8 haloalkylaminoalkyl, C4-C 10 Cycloalkylaminoalkyl, C3-C 10 Dialkylaminoalkyl, -CHO, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, -C(=O)OH, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, -C(=O)NH2, C2-C8 alkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C2-C8 alkoxyalkoxy, C2-C8 alkenyloxy, C2-C8 haloalkenyloxy, C3-C8 alkynyloxy, C3-C8 haloalkynyloxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C 10 Cycloalkylalkoxy, C3-C 10 Alkylcarbonylalkoxy, C2-C8 alkylcarbonyloxy, C2-C8 haloalkylcarbonyloxy, C4-C 10Cycloalkylcarbonyloxy, C1-C8 alkylsulfonyloxy, C1-C8 haloalkylsulfonyloxy, C1-C8 alkylthio, C1-C8 haloalkylthio, C3-C8 cycloalkylthio, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 alkylsulfonyl, C1-C8 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, formylamino, C2-C8 alkylcarbonylamino, C2-C8 haloalkylcarbonylamino, C3-C8 cycloalkylamino, C2-C8 alkoxycarbonylamino, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino, -SF5, -SCN, SO2NH2, C3-C 12 Trialkylsilyl, C4-C 12 Trialkylsilylalkyl, C4-C 12 Trialkylsilylalkoxy, R η , R η S(=O)=N-, R η S(=O)2NR η -C(=O)- or R η (R η N=) q S(=O) p - and the free bond protruding to the right is, for example, R μ indicates the point of attachment to In some situations, R ζ Q α , A β It may be linked to another part of the molecule, such as to form a ring.

[0077] Each R η are each independently CN, C1-C3 alkyl, C1-C8 hydroxyalkyl, or C2-C3 alkenyl; C2-C3 alkynyl, C3-C6 cycloalkyl, C2-C3 alkoxyalkyl, C1-C3 alkoxy, C2-C3 alkylcarbonyl, It is C2-C3 alkoxycarbonyl, C2-C3 alkylaminoalkyl, or C3-C4 dialkylaminoalkyl.

[0078] R ηmay be linked to other parts of the molecule, such as Qα, Aβ, etc., to form a ring.

[0079] Each R σ are each independently phenyl, phenylmethyl (benzyl), pyridinylmethyl, phenylcarbonyl (i.e., benzoyl), phenoxy, phenylethynyl, phenylsulfonyl, or a 5- or 6-membered heterocyclic ring, and each R λ and wherein the ring member is substituted or unsubstituted at the ring member with up to five substituents independently selected from q is 0 to 4; p is 0 to 4; u is 0 to 4, v is 0 to 4

[0080] Embodiment A2a Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein nα is 1, R α , R β , Q α , Q β , A β , A α and R μ has the same meaning as defined in embodiment A2).

[0081] Embodiment A2b Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein nα is 2, R α , R β , Q α , Q β , A β , A α and R μ has the same meaning as defined in embodiment A2).

[0082] Embodiment A2c The unsaturated precursors of embodiment A2 and salts thereof, for example, βは , H, R α , Q α , Q β , Aβ , A α , R μ and nα have the same meaning as defined in embodiment A2).

[0083] Embodiment A2d The unsaturated precursors of embodiment A2 and salts thereof, for example, α , R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in embodiment A2, except that R β is not H).

[0084] Embodiment A3 Unsaturated precursors of any one of embodiments A2; A2a; A2b; A2c; and A2d, and salts thereof, for example, wherein R α is -C(Q α )Q β R μ , [ka] R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in embodiment A2).

[0085] Embodiment A4 Unsaturated precursors of any one of embodiments A2; A2a; A2b; A2c; and A2d, and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- [ka] Rβ , Q α , Q β , A β , R π , R μ and nα have the same meaning as defined in embodiment A2).

[0086] Embodiment A5 Unsaturated precursors of any one of embodiments A2; A2c; and A2d, and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 1, [ka] R β , Q α , Q β , A β , R π and R μ has the same meaning as defined in embodiment A2).

[0087] Embodiment A6 Unsaturated precursors of any one of embodiments A2; A2c; and A2d, and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 1, A β is CH2, [ka] where R β , Q α , Q β , R π and R μhas the same meaning as defined in embodiment A2).

[0088] Embodiment A7 Unsaturated precursors of any one of embodiments A2; A2c; and A2d, and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 2, A β is CH2, [ka] and R β , Q α , Q β , R π and R μ has the same meaning as defined in embodiment A2).

[0089] Embodiment A8 Unsaturated precursors of any one of embodiments A2; A2c; and A2d, and salts thereof, for example, wherein R α is -C(O)Q β R μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α , O, [ka] and R β , Q β , R π and R μ has the same meaning as defined in embodiment A2).

[0090] Embodiment A9 Unsaturated precursors of any one of embodiments A2; A2c; and A2d, and salts thereof, for example, wherein R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β ,NH, [ka] and R β , R π and R μ has the same meaning as defined in embodiment A2).

[0091] Embodiment A10 Unsaturated precursors of any one of embodiments A2; A2c; and A2d, and salts thereof, for example, wherein R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ [ka] is a phenyl ring substituted with up to five substituents independently selected from R β , R π and R ζhas the same meaning as defined in embodiment A2.

[0092] Embodiment A11 The unsaturated precursors of embodiment A2, and for example salts thereof, wherein R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is unsubstituted or R ζ [ka] (In the formula, R π and R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ (It is).

[0093] Embodiment A12 The unsaturated precursors of embodiment A2, and for example salts thereof, wherein R α is -C(O)NHR μ and A α is -N(Me)-, nα is 1, A β is CH2, Q α is O, Q β is NH, R μis unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ and [ka] R ζ has the same meaning as defined in embodiment A2).

[0094] Embodiment A13 The unsaturated precursors of embodiment A2, and for example salts thereof, wherein Unsaturated Precursors R α is -C(O)NHR μ and A α is -NH-, nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ and [ka] R ζ has the same meaning as defined in embodiment A2).

[0095] Embodiment A14 The unsaturated precursors of embodiment A2, and for example salts thereof, wherein Rα is -C(O)NHR μ and A α is -NH-, nα is 2, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ and [ka] R ζ has the same meaning as defined in embodiment A2).

[0096] Embodiment A15 The unsaturated precursors of embodiment A2, and for example salts thereof, wherein R α is -C(O)NHR μ and A α is -N(Me)-, nα is 2, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ and [ka] R ζ has the same meaning as defined in embodiment A2).

[0097] Embodiment A16 An unsaturated precursor having the structure: [ka]

[0098] Embodiment A16a An intermediate compound for the synthesis of an agricultural chemical having the following structure: [ka]

[0099] Embodiment A17 An unsaturated precursor having the structure: [ka]

[0100] Embodiment A17a An intermediate compound for the synthesis of an agricultural chemical having the following structure: [ka]

[0101] Embodiment A18 An unsaturated precursor having the structure: [ka]

[0102] Embodiment A19 An unsaturated precursor having the structure: [ka]

[0103] Embodiment A20 An unsaturated precursor having the structure: [ka]

[0104] Embodiment A21 An unsaturated precursor having the structure: [ka]

[0105] Embodiment A22 An unsaturated precursor having the structure: [ka]

[0106] Embodiment A23 An unsaturated precursor having the structure: [ka]

[0107] Embodiment A24 An unsaturated precursor having the structure: [ka]

[0108] Embodiment A25 An unsaturated precursor having the structure: [ka]

[0109] Embodiment A26 An unsaturated precursor having the structure: [ka]

[0110] Embodiment A27 An unsaturated precursor having the structure: [ka]

[0111] Embodiment A28 An unsaturated precursor having the structure: [ka]

[0112] Embodiment A29 An unsaturated precursor having the structure: [ka]

[0113] Embodiment A30 An unsaturated precursor having the structure: [ka]

[0114] Embodiment A31 Unsaturated precursors of the embodiments and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is H, [ka] R π and R ζ has the same meaning as defined in embodiment A2).

[0115] Embodiment A32 Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein R α is -C(O)NHR μ and A α is -NH, nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is H, [ka] R ζ has the same meaning as defined in embodiment A2).

[0116] Embodiment A33 Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein R α is -C(O)NHR μ and A α is -NH, nα is 2, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζis a phenyl ring substituted with up to five substituents independently selected from R β is H, [ka] R ζ has the same meaning as defined in embodiment A2).

[0117] Embodiment A34 Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein R α is -C(O)NHR μ and A α is -N(Me)-, nα is 2, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is H, [ka] R ζ has the same meaning as defined in embodiment A2).

[0118] Embodiment A35a An unsaturated precursor defined by any of the following structures: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6, Y1 and Y2, etc. have the meanings defined in Claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796.) The text extracted from Claim 1 from page 286, line 6 to page 289, line 23 of WO 2015 / 084796 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment.

[0119] Q 1 is a phenyl ring or a naphthalenyl ring system, and each ring or ring system is 7 or a 5-6 or 8-10 membered heteroaromatic bicyclic ring system, wherein each ring or ring system contains ring members selected from carbon atoms and 1-4 heteroatoms each independently selected from up to 2 O atoms, up to 2 S atoms, and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring member is S(=O). u (=NR 8 ) v and each ring or ring system is independently selected from R on a carbon atom ring member. 7 R on the nitrogen atom ring member is independently selected from 9 and optionally substituted with up to five substituents selected from Q 2 is a phenyl ring or a naphthalenyl ring system, and each ring or ring system is 10 or a 5-6 membered fully unsaturated heterocyclic ring or an 8-10 membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1-4 heteroatoms each independently selected from up to 2 O atoms, up to 2 S atoms, and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring member is S(=O). u (=NR 8 ) v and each ring or ring system is independently selected from R on a carbon atom ring member. 10R on the nitrogen atom ring member is independently selected from 11 and optionally substituted with up to five substituents selected from Y 1 and Y 2 are each independently O, S, or NR 12 and R 1 is H, hydroxy, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C4-C8 cycloalkylalkyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C1-C 10 Trialkylsilyl, or G 1 and R 2 and R 3 are each independently H, halogen, or C1-C4 alkyl; R 2 and R 3 together with the carbon atoms to which they are attached form a C3-C7 cycloalkyl ring, R 4 and R 5are each independently H, halogen, or C1-C4 alkyl, R 6 is H, hydroxy, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C4-C 10 Alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 Trialkylsilyl or G 1 and Each R 7 and R 10 are independently selected from halogen, cyano, nitro, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 nitroalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 nitroalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, C4-C 10 Cycloalkylalkyl, C4-C 10 Halocycloalkylalkyl, C5-C 12 Alkylcycloalkylalkyl, C5-C 12 Cycloalkylalkenyl, C5-C 12Cycloalkylalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C 10 Alkylcycloalkyl, C6-C 12 Cycloalkylcycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C3-C8 haloalkoxyalkoxy, C3-C8 alkoxyalkoxy, C4-C 10 Cycloalkoxyalkyl, C3-C 10 Alkoxyalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylaminoalkyl, C2-C8 haloalkylaminoalkyl, C4-C 10 Cycloalkylaminoalkyl, C3-C 10 Dialkylaminoalkyl, -CHO, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, -C(=O)OH, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, -C(=O)NH2, C2-C8 alkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C3-C 10 dialkylaminocarbonyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C2-C8 alkoxyalkoxy, C2-C8 alkenyloxy, C2-C8 haloalkenyloxy, C3-C8 alkynyloxy, C3-C8 haloalkynyloxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C 10 Cycloalkylalkoxy, C3-C 10 Alkylcarbonylalkoxy, C2-C8 alkylcarbonyloxy, C2-C8 haloalkylcarbonyloxy, C4-C 10Cycloalkylcarbonyloxy, C1-C8 alkylsulfonyloxy, C1-C8 haloalkylsulfonyloxy, C1-C8 alkylthio, C1-C8 haloalkylthio, C3-C8 cycloalkylthio, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 alkylsulfonyl, C1-C8 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, formylamino, C2-C8 alkoxycarbonylamino, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino, -SF5, -SCN, SO2NH2, C3-C 12 Trialkylsilyl, C4-C 12 Trialkylsilylalkyl, C4-C 12 Trialkylsilylalkoxy or G 2 and Each R 8 are independently H, cyano, C2-C3 alkylcarbonyl, or C2-C3 haloalkylcarbonyl; Each R 9 and R 11 are independently cyano, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C6 cycloalkyl, C2-C3 alkoxyalkyl, C1-C3 alkoxy, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl, C2-C3 alkylaminoalkyl or C3-C4 dialkylaminoalkyl; Each R 12 are independently H, cyano, C1-C4 alkyl, C1-C4 haloalkyl, —(C═O)CH3, or —(C═O)CF3; each G 1 are independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl, phenoxy, phenylethynyl, phenylsulfonyl, or a 5- or 6-membered heteroaromatic ring, each of which is R 13 and optionally substituted on ring members with up to five substituents independently selected from each G 2are independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl, phenoxy, phenylethynyl, phenylsulfonyl, or a 5- or 6-membered heteroaromatic ring, each of which is R 14 and optionally substituted on ring members with up to five substituents independently selected from Each R 13 and R 14 are independently selected from halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=O)NH2, -SO2NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C2-C8 alkoxycarbonyl, C4-C 10 Cycloalkylcarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C8 alkylcarbonyloxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 trialkylsilyl, C1-C6 alkylamino, C2-C8 dialkylamino, C2-C8 alkylcarbonylamino, C1-C6 alkylsulfonylamino, phenyl, pyridinyl or thienyl; Each u and v is S(=O) u (=NR 8 ) v is independently 0, 1, or 2 at each occurrence, provided that the sum of u and v is 0, 1, or 2; however, (a) the compound of Formula 1 is other than N-1H-benzotriazol-1-yl-2-oxo-4-phenyl-3-pyrrolidinecarboxamide; (b)Q 1When contains a 3-furanyl or 3-pyridinyl ring directly attached to the remainder of formula l, that ring may be 7 and is substituted with at least one substituent selected from (c)Q 1 is an unsubstituted phenyl ring, and Q 2 When Q contains a phenyl ring directly attached to the remainder of formula 1, 2 The ring is R except that it is optionally substituted at the 2-position with phenoxy or F and at the 4-position with cyano or -CF. 10 is substituted with R 5 is H or a halogen, (d)Q 1 is unsubstituted phenyl and Q 2 When R contains a pyridinyl ring directly attached to the remainder of formula 1, the pyridinyl ring is 10 and is substituted with at least one substituent selected from (e)Q 1 When Q is a phenyl ring substituted with 4-phenyl or 4-phenoxy, 1 The ring is R 7 is further substituted with (f)Q 1 contains a phenyl ring directly bonded to the remainder of Formula I, and said ring has R 7 When substituted with, the ring may also independently have at least one additional position R 7 is replaced by (g)Q 1 When Q is unsubstituted 1-naphthalenyl, 2 is other than 2,3-di-ylphenyl or 2-CF3-phenyl, (h)Q 2 is other than optionally substituted 1H-pyrazol-5-yl; (i)Q 2 When contains a 1H-pyrazol-3-yl ring directly attached to the remainder of formula I, that ring is 9 is substituted at position 1 with

[0120] Embodiment A35b The following structure [ka] a saturated target having the following structure: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R6, Y1, and Y2, etc. have the meanings defined in Claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796. The text extracted from Claim 1 from page 286, line 6 to page 289, line 23 of WO 2015 / 084796 is specifically incorporated by reference solely for the purposes of defining the structure of this embodiment. Text reproduced in Embodiment A35a.

[0121] Embodiment A35c The following structure [ka] a saturated target having the following structure: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4, R6, Y1, and Y2, etc. have the meanings defined in Claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796. The text extracted from Claim 1 from page 286, line 6 to page 289, line 23 of WO 2015 / 084796 is specifically incorporated by reference solely for the purposes of defining the structure of this embodiment. Text reproduced in Embodiment A35a.

[0122] Embodiment A36a The following structure [ka] a saturated target having the following structure: [ka] (In the formula, Q, R 1 , R 6 , Y and W, etc. have the meanings defined in Claim 1 of PCT / US2020 / 034232, published as WO 2020 / 242946.) The text from Claim 1 on page 87, line 3 to page 88, line 6 of WO 2020 / 242946 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment.

[0123] In the formula, Q is [ka] is selected from the group consisting of R 1 is H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl or C4-C8 cycloalkylalkyl, R 2 is C1-C6 alkyl or C1-C6 haloalkyl, R 3is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy, Y is O or S; R 4 is H, halogen, C1-C4 alkyl or C1-C4 haloalkyl, R 5 is halogen, C1-C4 alkyl, or C1-C4 haloalkyl, n is 1, 2, 3 or 4; R 6 is H, halogen, hydroxy, C1-C4 alkoxy, C1-C4 haloalkyl or C1-C4 alkyl; W is phenyl or pyridyl, and each phenyl or pyridyl may contain up to five R 9 is optionally replaced by Each R 9 are independently halogen, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C1-C4 nitroalkyl, C2-C4 nitroalkenyl, C2-C4 alkoxyalkyl, C2-C4 haloalkoxyalkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl, cyclopropylmethyl, methylcyclopropyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkenyloxy, C2-C4 haloalkenyloxy, C3-C4 alkynyloxy. C3-C4 haloalkynyloxy, C3-C4 cycloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, C1-C4 alkylsulfinyl, C1-C4 haloalkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl, hydroxy, formyl, C2-C4 alkylcarbonyl, C2-C4 alkylcarbonyloxy, C1-C4 alkylsulfonyloxy, C1-C4 haloalkylsulfonyloxy, amino, C1-C4 alkylamino, C2-C4 dialkylamino, formylamino, C2-C4 alkylcarbonylamino, -SF5, -SCN, C3-C4 trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy, provided that the compound is such that Q is Q-1 and R 1 is H and R 2 is CH3 and R 3 is C(CH3)3 and R 4 is H and R 6 is H, Y is 0, W is second and R 9 and R 9 is a compound other than the compound of formula 1 in which

[0124] Embodiment A37a An unsaturated precursor defined by any of the following structures: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 7 , Y, A, J, etc. have the meanings defined in Claim 1 of PCT / US2016 / 030450, published as WO 2016182780. The text of Claim 1 from page 101, line 3 to page 106, line 28 of WO 2016 / 182780 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment.

[0125] Q 1 is a phenyl or benzyl ring, or a naphthalenyl ring system, each ring or ring system optionally substituted with up to five substituents independently selected from R, or a 5-6 membered fully unsaturated heteroaromatic ring or an 8-10 membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1-4 heteroatoms each independently selected from up to 2 O atoms, up to 2 S atoms, and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring member is S(=O). u (=NR 8 ) v and each ring or ring system is independently selected from R on a carbon atom ring member. 9R on the nitrogen atom ring member is independently selected from 10 and optionally substituted with up to five substituents selected from Q 2 is a phenyl ring or a naphthalenyl ring system, and each ring or ring system is 11 or a 5-6 membered fully unsaturated heteroaromatic ring or an 8-10 membered heteroaromatic bicyclic ring system, each ring or ring system containing carbon atoms and 1-4 heteroatoms independently selected from up to 2 O atoms, up to 2 S atoms, and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring member is S(=O). u (=NR 8 ) v and each ring or ring system is independently selected from R on a carbon atom ring member. 11 R on the nitrogen atom ring member is independently selected from 12 and optionally substituted with up to five substituents selected from R 1 and R 2 are each independently H, halogen, hydroxy, or C1-C4 alkyl; Y is O, S or NR 15 and A is a saturated, partially unsaturated, or fully unsaturated chain containing 2 to 4 atoms selected from up to 4 carbon atoms, up to 1 O atom, up to 1 S atom, and up to 2 N atoms, wherein the up to 2 carbon members are independently selected from C(=0) and C(=S), and the sulfur atom member is S(=0). u (=NR 8 ) v and the chain is selected from R 3 and R on the nitrogen atom 4 and optionally substituted with up to five substituents independently selected from Each R 3are independently halogen, cyano, hydroxy, —CO2H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C3-C6 cycloalkyl, or C4-C6 cycloalkylalkyl, or The Two R's 3 together with the carbon atoms to which they are attached form a C3-C7 cycloalkyl ring, Each R 4 are independently cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, or C3-C6 cycloalkyl; J is -CR 5 R 6 - or CR 5 R 6 -CR 5a R 6a and -CR 5 R 6 The moiety is directly attached to N, R 5 and R 6 are each independently H, halogen, hydroxy, C1-C4 alkyl, or C1-C4 alkoxy; R 5 and R 6 together with the carbon atoms to which they are attached form a C3-C7 cycloalkyl ring, R 5a and R 6a are each independently H, halogen, or C1-C4 alkyl; R 5a and R 6a together with the carbon atoms to which they are attached form a C3-C7 cycloalkyl ring, R 7is H, hydroxy, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 Trialkylsilyl or G 1 and Each R 8 are independently H, cyano, C2-C3 alkylcarbonyl, or C2-C3 haloalkylcarbonyl; Each R 9 are independently selected from halogen, cyano, nitro, C1-C8 alkyl, C1-C4 cyanoalkyl, C1-C4 cyanoalkoxy, C1-C8 haloalkyl, C1-C8 nitroalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 nitroalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, C4-C 10 Cycloalkylalkyl, C4-C 10 Halocycloalkylalkyl, C5-C 12 Alkylcycloalkylalkyl, C5-C 12 Cycloalkylalkenyl, C5-C 12Cycloalkylalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C 10 Alkylcycloalkyl, C6-C 12 Cycloalkylcycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C3-C8 haloalkoxyalkoxy, C1-C4 hydroxyalkyl, C1-C 10 Cycloalkoxyalkyl, C3-C 10 Alkoxyalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylaminoalkyl, C2-C8 haloalkylaminoalkyl, C4-C 10 Cycloalkylaminoalkyl, C3-C 10 Dialkylaminoalkyl, -CHO, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, -C(=O)OH, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, -C(=O)NH2, C2-C8 alkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C2-C8 alkoxyalkoxy, C2-C8 alkenyloxy, C2-C8 haloalkenyloxy, C2-C8 haloalkoxyhaloalkoxy, C3-C8 alkynyloxy, C3-C8 haloalkynyloxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C 10 Cycloalkylalkoxy, C3-C 10 Alkylcarbonylalkoxy, C2-C8 alkylcarbonyloxy, C2-C8 haloalkylcarbonyloxy, C4-C 10Cycloalkylcarbonyloxy, C1-C8 alkylsulfonyloxy, C1-C8 haloalkylsulfonyloxy, C1-C8 alkylthio, C1-C8 haloalkylthio, C3-C8 cycloalkylthio, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 alkylsulfonyl, C1-C8 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, formylamino, C2-C8 alkylcarbonylamino, C2-C8 haloalkylcarbonylamino, C2-C8 alkoxycarbonylamino, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino, -SF5, -SCN, SO2NH2, C3-C 12 Trialkylsilyl, C4-C 12 Trialkylsilylalkyl, C4-C 12 Trialkylsilylalkoxy or G 2 and Each R 11 are independently selected from halogen, cyano, nitro, C1-C8 alkyl, C1-C4 cyanoalkyl, C1-C4 cyanoalkoxy, C1-C8 haloalkyl, C1-C8 nitroalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 nitroalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, C4-C 10 Cycloalkylalkyl, C4-C 10 Halocycloalkylalkyl, C5-C 12 Alkylcycloalkylalkyl, C5-C 12 Cycloalkylalkenyl, C5-C 12 Cycloalkylalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C 10 Alkylcycloalkyl, C6-C 12 Cycloalkylcycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C3-C8 haloalkoxyalkoxy, C1-C4 hydroxyalkyl, C4-C 10 Cycloalkoxyalkyl, C3-C 10Alkyl sulfonyl alkyl, C2-C8 alkylthio alkyl, C2-C8 alkylsulfinyl alkyl, C2-C8 alkylsulfonyl alkyl, C2-C8 alkylamino alkyl, C2-C8 haloalkylamino alkyl, C4-C 10 Cycloalkylaminoalkyl, C4-C 10 Dialkylaminoalkyl, -CHO, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, -C(=O)OH, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, -C(=O)NH2, C2-C8 alkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C2-C8 alkoxyalkoxy, C2-C8 alkenyloxy, C2-C8 haloalkenyloxy, C2-C8 haloalkoxyhaloalkoxy, C3-C8 alkynyloxy, C3-C8 haloalkynyloxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C 10 Cycloalkylalkoxy, C3-C 10 Alkylcarbonylalkoxy, C2-C8 alkylcarbonyloxy, C2-C8 haloalkylcarbonyloxy, C4-C 10Cycloalkylcarbonyloxy, C1-C8 alkylsulfonyloxy, C1-C8 haloalkylsulfonyloxy, C1-C8 alkylthio, C1-C8 haloalkylthio, C3-C8 cycloalkylthio, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 alkylsulfonyl, C1-C8 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, formylamino, C2-C8 alkylcarbonylamino, C2-C8 haloalkylcarbonylamino, C2-C8 alkoxycarbonylamino, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino, -SF5, -SCN, SO2NH2, C3-C 12 Trialkylsilyl, C4-C 12 Trialkylsilylalkyl, C4-C 12 Trialkylsilylalkoxy or G 3 and Each R 10 and R 12 are independently cyano, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C6 cycloalkyl, C2-C3 alkoxyalkyl, C1-C3 alkoxy, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl, C2-C3 alkylaminoalkyl or C3-C4 dialkylaminoalkyl; R 15 is H, cyano, C1-C4 alkyl, C1-C4 haloalkyl, —(C═O)CH3, or —(C═O)CF3; each G 1 are independently phenyl, phenylmethyl, pyridinylmethyl, pyridinyloxy, phenylcarbonyl, phenoxy, phenylethynyl, phenylsulfonyl, phenylcarbonyl(C1-C4 alkyl), or a 5- or 6-membered heteroaromatic ring, each of which is 13 and optionally substituted on ring members with up to five substituents independently selected from each G 2are independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl, phenylcarbonylalkyl, phenoxy, phenylethynyl, phenylsulfonyl, or pyridyloxy, or each is R 14 or R 16 ON=CR 17 -, (R 18 )2C=NO-, (R 19 )2NN=CR 17 -, (R 18 )2C=NNR 20 -, R 21 N=CR 17 -, (R 18 )2C=N-, R 22 ON=CR 17 C(R 23 )2-, or (R 18 )2C=NOC(R 23 )2-, and the free bond protruding to the right is Q 1 indicates the point of attachment to each G 3 are independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl, phenylcarbonylalkyl, phenoxy, phenylethynyl, phenylsulfonyl, phenylcarbonyl(C1-C4 alkyl), or a 5- or 6-membered heteroaromatic ring, each of which is 15 and optionally substituted on ring members with up to five substituents independently selected from Each R 13 , R 14 and R 15 are independently selected from halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=O)NH2, -SO2NH2, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C2-C8 alkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C10 Dialkylaminocarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C8 alkylcarbonyloxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 trialkylsilyl, C1-C6 alkylamino, C2-C8 dialkylamino, C2-C8 alkylcarbonylamino, or C1-C6 alkylsulfonylamino; Each R 16 are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 Trialkylsilyl or G 1 and Each R 17are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C3-C 10 Trialkylsilyl or G 1 and Each R 18 are independently selected from H, hydroxy, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 Trialkylsilyl or G 1 and Each R 19are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C4-C 10 Alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 trialkylsilyl or G1, Each R 20 are independently selected from H, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C1-C6 alkoxyC3-C 10 Trialkylsilyl or G 1 and Each R 21are independently selected from H, hydroxy, amino, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 trialkylsilyl or G1, Each R 22 are independently H, C1-C4 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl or C1-C6 cycloalkyl; Each R 23 are independently H, halogen, cyano, hydroxy, C1-C4 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl or C3-C6 cycloalkyl; Each u and v is S(=O) u (=NR 8 )v is independently 0, 1, or 2 in each instance, provided that the sum of u and v is 0, 1, or 2, provided that the compound is 1 is Ph(3-CF3) and Q 2 is Ph(2-F) and R 1 is H and R 2 is H, Y is O, A is -CH2CH2-, and J is -CR 5 R 6 - and R 5 is H and R 6 is H and R 7 is a compound other than the compound where is H.

[0126] Embodiment A37b An intermediate compound for the synthesis of a pesticide defined by any one of the following structures: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 7 , Y, A, J, etc. have the meanings defined in Claim 1 of PCT / US2016 / 030450, published as WO 2016 / 182780. The text of Claim 1 from page 101, line 3 to page 106, line 28 of WO 2016 / 182780 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in Embodiment A37a.

[0127] Embodiment A37c The following structure [ka] a saturated target having the following structure in combination, admixture, mixture, etc. with at least one unsaturated precursor defined by any one of: [ka] (In the formula, Q 1 , Q2 , R 1 , R 2 , R 7 , Y, A, J, etc. have the meanings defined in Claim 1 of PCT / US2016 / 030450, published as WO 2016182780. The text of Claim 1 from page 101, line 3 to page 106, line 28 of WO 2016 / 182780 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in Embodiment A37a.

[0128] Embodiment A38 an unsaturated precursor defined by any one of the following formulas: [ka] (In the formula, Q 1 , Q 2 , R B1 and X etc. have the meanings defined in Claim 1 of PCT / EP2020 / 052780, published as WO 2020 / 161147.) The text from Claim 1 on page 74, line 10 to page 75, line 10 of WO 2020 / 161147 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment.

[0129] R B1 is H, methyl, or methoxy; X is O or S; Q 1 is R on one ring nitrogen. B2 and substituted on at least one ring carbon by R B3 is a di- or tri-substituted pyrazole substituted by R B2 is C1-C3 alkyl or C1-C3 fluoroalkyl, and each R B3are independently halogen, C1-C3 fluoroalkyl, C1-C3 haloalkoxy, C1-C3 alkoxy, or C1-C3 haloalkyl, C1-C3 fluoroalkyl, C1-C3 haloalkoxy, C1-C3 alkoxy, or C1-C3 alkyl, or Q 1 is R on one ring nitrogen. B2 By this, R 53 and R is a disubstituted pyrazole substituted by B2 is a C1-C3 alkyl, and R B3 is C1-C3 fluoroalkyl or CC1-C3 alkyl, and R B2 and R B3 together with the atom to which they are attached form an 8- or 9-membered fused heterocyclic bicyclic ring system; Q 2 optionally 1, 2, or 3 R B5 a substituted phenyl, pyridinyl, or thienyl ring system; Each R B5 are independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, nitro, C1-C6 alkylthio, C1-C6 alkylsulfinyl, or C1-C6 alkylsulfonyl, or an N-oxide or a salt form thereof.

[0130] Embodiment A38a Each has the following structure: [ka] a saturated target according to claim 1 of PCT / EP2020 / 052780, published as WO 2020 / 161147, in combination, admixture, mixture, etc. with at least one unsaturated precursor defined by any one of [ka] (In the formula, Q 1 , Q 2 , R B1and X, etc. have the meaning defined in Claim 1 of PCT / EP2020 / 052780, published as WO 2020 / 161147. The text from Claim 1 on page 74, line 10 to page 75, line 10 of WO 2020 / 161147 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in Embodiment A38.

[0131] Embodiment A39 an unsaturated precursor defined by any one of the following formulas: [ka] (In the formula, Q, W 2 , R 1 , Y and Z, etc. have the meanings defined in Claim 1 of PCT / EP2018 / 069001, published as WO 2019 / 025156. The German text from Claim 1 on page 109, line 3 to page 112, line 6 of WO 2019 / 025156 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment.

[0132] Embodiment A40 An unsaturated precursor having the following structure: [ka]

[0133] Embodiment A41 An unsaturated precursor defined by any one of the following structures: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 9 , J, L, Y and Y 2etc. have the meaning defined in Claim 1 of PCT / US2018 / 035017, published as WO 2018 / 222647.) The text from Claim 1 on page 84, line 5 to page 89, line 27 of WO 2018 / 222647 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment.

[0134] L is selected from the following: [ka] and R A are C1-C7 alkyl, C1-C7 haloalkyl, C3-C9 cycloalkyl, C3-C9 halocycloalkyl, C1-C7 alkoxy, C1-C7 haloalkoxy, C3-C9 cycloalkoxy, C3-C9 halocycloalkoxy, C2-C8 alkenyl, C2-C8 haloalkenyl, C1-C7 alkylalumino, C1-C7 haloalkylamino, C2-C9 dialkylamino, C2-C9 halodialkylamino, C3-C9 cycloalkylamino, or C3-C9 halocycloalkylamino, and each is R 8 or unsubstituted with up to three substituents independently selected from G 1 or R A is G 1 Or OG 1 or R A is -C(R I )(R J )C(=O)- as R 9 Together with R B is H, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 alkyl, or is phenyl unsubstituted or substituted with halogen or C1-C4 alkyl; R Cis H, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 alkyl, or is phenyl unsubstituted or substituted with halogen or C1-C4 alkyl; R D is H, C1-C4 alkyl, or C2-C4 alkylcarbonyl, R E is H, hydroxy, amino, cyano, formyl, -C(O)NH2, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 cyanoalkyl, C3-C6 cycloalkyl, C4-C8 cycloalkylalkyl, C2-C8 alkoxyalkyl, C3-C8 alkoxyalkoxyarsyl, C2-C8 haloalkoxyalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 alkenylalkyl, C2-C8 haloalkenylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkoxycarbonyl C5~C 10 Cycloalkoxycarbonylalkyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkyllisulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl or C2-C8 dialkylaminosulfonyl, or G E Or W E G E and R F is H, formyl, -C(O)NH2, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, -P(=O)(OH)2-, C1-C6 dialkyphosphoryl, C1-C6 haloalkylphosphoryl, C3-C8 cycloalkylphosphoryl, C2-C8 dialkoxyphosphoryl, C6-C 14 Dicycloalkoxyphosphoryl, C2-C 12 Bis(alkylamino)phosphoryl, C4-C 24 Bis(dialkylamino)phosphoryl, or G F Or W F G F and R G is formyl, -C(O)NH2, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, -P(=O)(OH)2, C1-C6 dialkylphosphoryl, C1-C6 haloalkylphosphoryl, C2-C8 cycloalkylphosphoryl, C2-C8 dialkoxyphosphoryl, C6-C 14 Dicycloalkoxyphosphoryl, C8-C 16Dicycloalkylalkoxyphosphoryl, C2-C 12 Bis(alkylamino)phosphoryl, C4-C 24 bis(dialkylamino)phosphoryl, or phenyl or R 16 or substituted or unsubstituted with W G G G and R I is H, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 alkyl, or is phenyl unsubstituted or substituted with halogen or C1-C4 alkyl; R J is H, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 alkyl, or is phenyl unsubstituted or substituted with halogen or C1-C4 alkyl; Q 1 is a phenyl ring or a naphthalenyl ring system, and each ring or ring system is 7 or a 4- to 7-membered heterocyclic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 5 heteroatoms each independently selected from up to 2 O atoms, up to 2 S atoms, and up to 5 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring member is S(=O). u (=NR 14 ) v and each ring or ring system is independently selected from R on a carbon atom ring member. 10 R on the nitrogen atom ring member is independently selected from 12 optionally substituted with up to five substituents selected from Q 2 is a phenyl ring or a naphthalenyl ring system, and each ring or ring system is 10or a 4-7 membered heterocyclic ring or an 8-10 membered heteroaromatic bicyclic ring system, each ring or ring system containing carbon atoms and 1-4 heteroatoms independently selected from up to 2 O atoms, up to 2 S atoms, and up to 5 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring member is S(=O). u (=NR 14 ) v and each ring or ring system is independently selected from R on a carbon atom ring member. 11 R on the nitrogen atom ring member is independently selected from 13 optionally substituted with up to five substituents selected from J is -CR 2 R 3 -, -CR 2 R 3 -CR 4 R 5 -, -NR 6 - or O-, Y 1 and Y 2 are each independently O, S, or NR 15 and R 1 is H, hydroxy, amino, cyano, formyl, C3-C8 alkylcarbonylalkyl, -C(C1-C4 alkyl)=NO(C1-C4 alkyl), -C(O)NH2, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C6 cyanoalkyl, C3-C6 cycloalkyl, C3-C8 cycloalkenyl, C4-C8 cycloalkylalkyl, C2-C8 alkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 haloalkenylkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C5-C 10Cycloalkylcarbonylalkyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 trialkylsilyl, or -CPh=NO(C1-C4 alkyl), each of which is R 13 or unsubstituted with up to five substituents independently selected from G 1 and R 2 and R 3 are each independently H, halogen, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy; R 2 and R 3 together with the carbon atoms to which they are attached form a C3-C7 cycloalkyl ring, R 4 and R 5 are each independently H, halogen, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy; R 6 is C1-C6 alkyl, C2-C6 alkenyl, C3-C6 alkynyl, or C1-C6 alkoxy, or R 1 and R 6 are taken together as a C3-C6 alkylene or -CH2OCH2-, R 7is H, halogen, hydroxy, C1-C4 alkoxy, C1-C4 haloalkyl or C1-C4 alkyl; R 8 are each independently cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=O)NH2, -SO2NH2, C2-C6 alkenyl, C2-C6 alkynyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C2-C8 alkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C8 alkylcarbonyloxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 trialkylsilyl, C1-C6 alkylamino, C2-C8 dialkylamino, C2-C8 alkylcarbonylamino, or C1-C6 alkylsulfonylamino; R 9 is H, hydroxy, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, or C3-C 10 Trialkylsilyl, or G 1 and Each R 10 and R 11 are independently selected from halogen, hydroxy, cyano, nitro, amino, C1-C8 alkyl, C1-C8 cyanoalkyl, C1-C8 cyanoalkoxy, C1-C8 haloalkyl, C1-C8 hydroxyalkyl, C1-C8 nitroalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 alkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 haloalkoxyhaloalkoxy, C3-C6 cycloalkyl, cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C4-C 10 Cycloalkylalkyl, C4-C 10 Halocycloalkylalkyl, C5-C 12 Alkylcycloalkylalkyl, C5-C 12 Cycloalkylalkenyl, C5-C 12 Cycloalkylalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C 10 Alkylcycloalkyl, C6-C 12 Cycloalkylcycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C1-C8 haloalkoxyalkoxy, C2-C8 alkoxyalkoxy, C4-C 10Cycloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylamino, C2-C8 dialkylamino, C2-C8 halodialkylamino, C2-C8 alkylaminoalkyl, C2-C8 haloalkylaminoalkyl, C4-C 10 Cycloalkylaminoalkyl, C3-C 10 Dialkylaminoalkyl, -CHO, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, -C(=O)OH, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, -C(=O)NH2, C2-C8 alkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C2-C8 alkenyloxy, C2-C8 haloalkenyloxy, C3-C8 alkynyloxy, C3-C8 haloalkynyloxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C 10 Cycloalkylalkoxy, C3-C 10 Alkylcarbonylalkoxy, C2-C8 alkylcarbonyloxy, C2-C8 haloalkylcarbonyloxy, C4-C 10Cycloalkylcarbonyloxy, C1-C8 alkylsulfonyloxy, C1-C8 haloalkylsulfonyloxy, C1-C8 alkylthio, C1-C8 haloalkylthio, C3-C8 cycloalkylthio, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 alkylsulfonyl, C1-C8 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, formylamino, C2-C8 alkylcarbonylamino, C2-C8 haloalkylcarbonylamino, C3-C8 cycloalkylamino, C2-C8 alkoxycarbonylamino, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino, -SF5, -SCN, SO2NH2, C3-C 12 Trialkylsilyl, C4-C 12 Trialkylsilylalkyl or C4-C 12 trialkylsilylalkoxy, or G 2 or R 20 S(=O)=N-, R 20 S(=O)2NR 19 -C(=O)- or R 20 (R 19 N=) q S(=O) p - and the free bond protruding to the right is Q 1 indicates the point of attachment to Each R 12 and each R 13 are each independently cyano C1-C3 alkyl, C1-C8 hydroxyalkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C6 cycloalkyl, C2-C3 alkoxyalkyl, C1-C3 alkoxy, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl, C2-C3 alkylaminoalkyl or C3-C4 dialkylaminoalkyl; Each R 14 are independently H, cyano, C-C alkylcarbonyl, or C-C haloalkylcarbonyl, and each R 15are independently H, cyano, hydroxy, CHO, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, —(C═O)CH3, or (C═O)CF3; each G 1 are independently phenyl or a 5- or 6-membered heterocyclic ring, and each is R 17 or unsubstituted with up to five substituents independently selected from Each W E , W F and W G are independently —C(═O)—, —C(═O)O—, —C(═O)NH—, or —S(═O)—; each G E , G F and G G are independently 16 or a 5- or 6-membered heterocyclic ring, Each heterocyclic ring can be R 16 or is unsubstituted on the ring members with up to five substituents independently selected from each G 2 are independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl, phenoxy, phenylethynyl, phenylsulfonyl, or a 5- or 6-membered heterocyclic ring, each of which is R 18 or is unsubstituted on the ring members with up to five substituents independently selected from Each R 16 , R 17 and R 18 are independently selected from halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=O)NH2, -SO2NH2, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C2-C8 alkoxycarbonyl, C4-C 10 Cycloalkylcarbonyl, C5-C 12Cycloalkylalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 dialkylaminocarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C8 alkylcarbonyloxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 trialkylsilyl, C1-C6 alkylamino, C2-C8 dialkylamino, C2-C8 alkylcarbonylamino, C1-C6 alkylsulfonylamino, phenyl, pyridinyl or thienyl; Each R 19 are independently H, cyano, C2-C3 alkylcarbonyl, or C2-C3 haloalkylcarbonyl; Each R 20 are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C1-C6 alkoxy or C3-C 10 Trialkylsilyl, or G 1 and Each u and v is S(=O) u (=NR 14 ) v is independently 0, 1, or 2 at each occurrence, provided that the sum of u and v is 0, 1, or 2; Each p and q is R 20 (R 19 N=) q S(=O) p - is independently 0, 1, or 2 at each occurrence, with the proviso that the sum of u and v is 0, 1, or 2, and when p is 0 then q is other than 1 or 2.

[0135] Embodiment A41a Each has the following structure: [ka] saturated targets, N-oxides and salts thereof, of the formula: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 9 , J, L, Y and Y 2 etc. have the meaning defined in Claim 1 of PCT / US2018 / 035017, published as WO 2018 / 222647.) The text from Claim 1 on page 84, line 5 to page 89, line 27 of WO 2018222647 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in Embodiment A41.

[0136] Embodiment A42 an unsaturated precursor defined by any one of the formulas, [ka] (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 8 , R 9 , J, Y, and W, etc. have the meanings defined in Claim 1 of PCT / US2018 / 035015, published as WO 2018 / 222646. The text from Claim 1 on page 82, line 6 to page 86, line 21 of WO 2018 / 222646 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment.

[0137] W is -NR A R B OR C and R A is H, cyano, CHO, C1-C4 alkylcarbonyl, C1-C4 alkyl, or phenyl unsubstituted or substituted with halogen or C1-C4 alkyl; R B is H, cyano, hydroxy, CHO, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cyclosulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, or C3-C 10 trialkylsilyl, or a phenyl or naphthalenyl ring, each ring or ring system being R 16 or unsubstituted with up to five substituents independently selected from R 16 or a 4- to 7-membered heterocyclic ring unsubstituted or substituted with up to five substituents independently selected from R A and R Bare taken together with the nitrogen atom to which they are attached to form a 4-, 5-, or 6-membered ring containing ring members selected from carbon, oxygen, nitrogen, and —C(═O)—, or taken together as a 6- to 10-membered bicyclic ring system, or taken together as an 8- to 13-membered cyclic ring system, each ring or ring system containing ring members selected from carbon, nitrogen, and —C(═O)—, and substituted or unsubstituted with halogen, cyano, or C1-C4 alkyl; R C is C1-C4 haloalkyl, C2-C4 haloalkylcarbonyl, C3-C6 cycloalkyl, or phenyl unsubstituted or substituted with halogen, cyano, or C1-C4 alkyl, or a 6-membered nitrogen-containing aromatic ring unsubstituted or substituted with halogen, cyano, or C1-C4 alkyl; J is -CR 2 R 3 -, -CR 2 R 3 -CR 4 R 5 -, -NR 6 - or O-, Y is O, S or NR 15 and R 1 is H, hydroxy, amino, cyano, CHO, C3-C8 alkylcarbonylalkyl, C(C1-C4 alkyl)=NO(C1-C4 alkyl), -C(O)NH2, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C6 cyanoalkyl, C3-C6 cycloalkyl, C3-C8 cycloalkenyl, C4-C8 cycloalkylalkyl, C2-C8 alkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 haloalkenylalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5~ 10Cycloalkylcarbonylalkyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 Trialkylsilyl, or Cph=NO(C1-C4 alkyl) (phenyl is R 13 or unsubstituted with up to five substituents independently selected from 1 and Q 1 is a phenyl ring or a naphthalenyl ring system, and each ring or ring system is 11 or a 4-7 membered heterocyclic ring or an 8-10 membered heteroaromatic bicyclic ring system, each ring or ring system containing carbon atoms and 1-4 heteroatoms independently selected from up to 2 O atoms, up to 2 S atoms, and up to 5 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring member is S(=O). u (=NR 14 ) v and each ring or ring system is independently selected from R on a carbon atom ring member. 11 R on the nitrogen atom ring member is independently selected from 13 and optionally substituted with up to five substituents selected from Q 2 is a phenyl ring or a naphthalenyl ring system, and each ring or ring system is 11or a 4-7 membered heterocyclic ring or an 8-10 membered heteroaromatic bicyclic ring system, each ring or ring system containing carbon atoms and 1-4 heteroatoms independently selected from up to 2 O atoms, up to 2 S atoms, and up to 5 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring member is S(=O). u (=NR 14 ) v and each ring or ring system is independently selected from R on a carbon atom ring member. 11 R on the nitrogen atom ring member is independently selected from 13 and optionally substituted with up to five substituents selected from R 2 and R 3 are each independently H, halogen, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy; R 2 and R 3 together with the carbon atoms to which they are attached form a C3-C7 cycloalkyl ring, R 4 and R 5 are each independently H, halogen, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy; R 6 is C1-C6 alkyl, C2-C6 alkenyl, C3-C6 alkynyl or C1-C6 alkoxy, R 1 and R 6 are taken together as a C3-C6 alkylene or -CH2OCH2-, R 7 and R 8 are each independently H, halogen, hydroxy, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 alkyl; R 9is H, hydroxy, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C6 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C3-C8 cycloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10 Trialkylsilyl, or G 1 and R 10 and R 11 are each independently halogen, hydroxy, cyano, nitro, amino, C1-C8 alkyl, C1-C8 cyanoalkyl, C1-C8 cyanoalkoxy, C1-C8 haloalkyl, C1-C8 hydroxyalkyl, C1-C8 nitroalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 nitroalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, C2-C8 alkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 haloalkoxyhaloalkoxy, C3-C6 cycloalkyl, cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C4-C 10 Cycloalkylalkyl, C4-C 10 Halocycloalkylalkyl, C5-C12 Alkylcycloalkylalkyl, C5-C 12 Cycloalkylalkenyl, C5-C 12 Cycloalkylalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C 10 Alkylcycloalkyl, C6-C 12 Cycloalkylcycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C2-C8 haloalkoxyalkoxy, C2-C8 alkoxyalkoxy, C4-C 10 Cycloalkoxyalkyl, C3-C 10 Alkoxyalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C2-C8 alkylamino, C2-C8 dialkylamino, C2-C8 halodialkylamino, C2-C8 alkylaminoalkyl, C2-C8 haloalkylaminoalkyl, C4-C 10 Cycloalkylaminoalkyl, C3-C 10 Dialkylaminoalkyl, -CHO, C2-C8 alkylcarbonyl, C2-C8 haloalkylcarbonyl, C4-C 10 Cycloalkylcarbonyl, -C(=O)OH, C2-C8 alkoxycarbonyl, C2-C8 haloalkoxycarbonyl, C4-C 10 Cycloalkoxycarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, -C(=O)NH2, C2-C8 alkylaminocarbonyl, C4-C 10 Cycloalkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C2-C8 alkoxyalkoxy, C2-C8 alkenyloxy, C2-C8 haloalkenyloxy, C3-C8 alkynyloxy, C3-C8 haloalkynyloxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C 10 Cycloalkylalkoxy, C3-C 10 Alkylcarbonylalkoxy, C2-C8 alkylcarbonyloxy, C2-C8 haloalkylcarbonyloxy, C4-C10 Cycloalkylcarbonyloxy, C1-C8 alkylsulfonyloxy, C1-C8 haloalkylsulfonyloxy, C1-C8 alkylthio, C1-C8 haloalkylthio, C3-C8 cycloalkylthio, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 alkylsulfonyl, C1-C8 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, formylamino, C2-C8 alkylcarbonylamino, C2-C8 haloalkylcarbonylamino, C3-C8 cycloalkylamino, C2-C8 alkoxycarbonylamino, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino, -SF5, -SCN, SO2NH2, C3-C 12 Trialkylsilyl, C4-C 12 Trialkylsilylalkyl or C4-C 12 trialkylsilylalkoxy, or G2, or R 20 S(=O)=N-, R 20 S(=O)2NR 19 -C(=O)- or R 20 (R 19 N=) q S(=O) p - and the free bond protruding to the right is Q 1 indicates the point of attachment to Each R 12 and each R 13 are each independently cyano C1-C3 alkyl, C1-C8 hydroxyalkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C6 cycloalkyl, C2-C3 alkoxyalkyl, C1-C3 alkoxy, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl, C2-C3 alkylaminoalkyl, or C3-C4 dialkylaminoalkyl; Each R 14 are independently H, cyano, C2-C3 alkylcarbonyl, or C2-C3 haloalkylcarbonyl; R 15is H, cyano, hydroxy, CHO, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C2-C6 alkylcarbonyl, or C2-C6 haloalkylcarbonyl, each G 1 are independently phenyl or a 5- or 6-membered heterocyclic ring, and each is R 17 or unsubstituted with up to five substituents independently selected from each G 2 are independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl, phenoxy, phenylethynyl, phenylsulfonyl, or a 5- or 6-membered heterocyclic ring, each of which is R 18 or is unsubstituted on the ring members with up to five substituents independently selected from Each R 16 , R 17 and R 18 are independently halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=O)NH2, -SO2NH2, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C8 alkylcarbonyl, C1-C8 hydroxyalkyl, C2-C8 haloalkylcarbonyl, C2-C6 alkoxyalkyl, C2-C6 alkylaminoalkyl, C2-C8 alkoxycarbonyl, C3-C8 cycloalkyl, C4-C 10 Cycloalkylcarbonyl, C5-C 12 Cycloalkylalkoxycarbonyl, C2-C8 alkylaminocarbonyl, C3-C 10 Dialkylaminocarbonyl, C3-C8 dialkylaminoalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C8 alkylcarbonyloxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylaminosulfonyl, C2-C8 dialkylaminosulfonyl, C3-C 10trialkylsilyl, C1-C6 alkylamino, C2-C8 dialkylamino, C2-C8 alkylcarbonylamino, C1-C6 alkylsulfonylamino, phenyl, pyridinyl or thienyl; Each R 19 are independently H, cyano, C2-C3 alkylcarbonyl, or C2-C3 haloalkylcarbonyl; Each R 20 are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C2-C8 alkoxyalkyl, C2-C8 haloalkoxyalkyl, C2-C8 alkylthioalkyl, C2-C8 alkylsulfinylalkyl, C2-C8 alkylsulfonylalkyl, C1-C6 alkoxy or C3-C 10 Trialkylsilyl, or G 1 and each u and v is independently 0, 1, or 2, provided that the sum of u and v is 0, 1, or 2; Each p and q is independently 0, 1, or 2, provided that the sum of u and v is 0, 1, or 2, and when p is 0, then q is other than 1 or 2.

[0138] Embodiment A42a Each has the following structure: [ka] a saturated target, which is a compound as defined in claim 1 of PCT / US2018 / 035015, published as WO 2018 / 222646, of the following formula, in combination with at least one saturated precursor defined by any one of: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 7 , R8 , R 9 , J, Y, and W, etc. have the meanings defined in Claim 1 of PCT / US2018 / 035015, published as WO 2018 / 222646. The text from Claim 1 on page 82, line 6 to page 86, line 21 of WO 2018 / 222646 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in Embodiment A42.

[0139] Embodiment A43 an unsaturated precursor defined by any one of the following formulas: [ka] (In the formula, Q, W 2 , R 1 , R 2 , Y and Z, etc. have the meanings defined in Claim 1 of PCT / EP2018 / 057628, published as WO 2018 / 184890. The German text from Claim 1 on page 133, line 9 to page 136, line 4 of WO 2018 / 184890 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment.

[0140] Embodiment A43a Each structure [ka] and salts thereof, wherein the saturated target is a compound as defined in claim 1 of PCT / EP2018 / 057628, published as WO 2018 / 184890, of the formula: [ka] (In the formula, Q, W 2 , R 1 , R 2, Y and Z, etc. have the meanings defined in Claim 1 of PCT / EP2018 / 057628, published as WO 2018 / 184890.) The German text from Claim 1 on page 133, line 9 to page 136, line 4 of WO 2018184890 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment.

[0141] Embodiment A44 Unsaturated precursors of any one of embodiments A1 to A16, A31 to A34 and salts thereof, for example, R α is -C(Q α )-CHA, CHA is a chiral carbon-containing group and is exemplified by substituted or unsubstituted, cyclic or acyclic amino alcohols, 2-oxazolidones, alcohols, amines, sulfinamide sugars, amino acid derivatives (including amino acids), alkyl, aryl, heterocyclic, naphthyl, esters including aliphatic and aromatic esters exemplified by (S)-1-(2-fluorophenyl)ethan-1-amine, (S)-1-phenylethan-1-ol; R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in embodiments A1 to A16, A31 to A34).

[0142] Embodiment A45 Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein R α is -C(Q α )-CHA, and [ka] (It is). CHA is a chiral carbon-containing group exemplified by substituted or unsubstituted, cyclic or acyclic, amino alcohols, 2-oxazolidones, alcohols, amines, sulfinamides, sugars, esters including alkyl, aryl, heterocyclic, naphthyl, aliphatic and aromatic esters; R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in embodiment A2.

[0143] Embodiment A46 Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein R α is -C(Q α )-CHA, [ka] CHA is the chiral auxiliary described in Chirality. 2019; 1-37 and referenced in Key Chiral Auxiliary Applications (Second Edition) (ed.: Roos, G.), Academic Press, Boston, 2014 ISBN 978-0-12-417034-6, and Glorius, F.; Gnas, Y. (2006). "Chiral Auxiliaries - Principles and Recent Applications". Synthesis. 2006(12):1899-1930. Jamali, Fakhreddin (1993). "Chapter 14: Stereochemically Pure Drugs: An Overview." In Wainer, Irving W. (ed.). Drug Stereochemistry: Analytical Methods and Pharmacology. Marcel Dekker, Inc. pp. 375-382. Evans, D.A.; Helmchen, G.; Rueping, M. (2007). "Chiral Auxiliaries in Asymmetric Synthesis". In Christmann, M. (ed.). Asymmetric Synthesis - The Essentials. Wiley-VCH Verlag GmbH & Co. pp. 3-9, as referenced; and Referenced in J. Am. Chem. Soc. 97(23):6908-6909, R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in embodiment A2).

[0144] Embodiment A46a Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein R α is -C(Q α )-CHA, [ka] CHA is (R)-BINOL, (S)-BINOL, or trans-2-phenylcyclohexanol; [ka] R=R ζ and R β , Q α , Q β , A β , A α , R μ , R ζ and nα have the same meaning as defined in embodiment A2).

[0145] Embodiment A47 Unsaturated precursors of any one of embodiments A1 to A16, A31 to A34 and salts thereof, for example, wherein R β, Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in embodiment A2 or in any one of embodiments A1 to A16, A31 to A34, R α is -C(Q α )-CHA, wherein CHA is Chirality. 2019; 1-37, and the chiral auxiliaries referred to in Key Chiral Auxiliary Applications (Second Edition) (ed.: Roos, G.), Academic Press, Boston, 2014 ISBN 978-0-12-417034-6, and those referred to in Glorius, F.; Gnas, Y. (2006). "Chiral Auxiliaries - Principles and Recent Applications". Synthesis. 2006(12): 1899-1930, and Jamali, Fakhreddin (1993). "Chapter 14: Stereochemically Pure Drugs: An Overview." In Wainer, Irving W. (ed.). Drug Stereochemistry: Analytical Methods and Pharmacology. Marcel Dekker, Inc. pp. 375-382. Evans, D.A.; Helmchen, G.; Rueping, M. (2007). "Chiral Auxiliaries in Asymmetric Synthesis". In Christmann, M. (ed.). Asymmetric Synthesis - The Essentials. Wiley-VCH Verlag GmbH & Co. pp. 3-9. those referenced in J. Am. Chem. Soc. 97(23):6908-6909, and

[0146] Embodiment A47a Unsaturated precursors of any one of embodiments A1 to A16, A31 to A34 and salts thereof, for example, wherein R α is -C(Q α )-CHA, CHA is (R)-BINOL, (S)-BINOL, trans-2-phenylcyclohexanol, [ka] R is R ζ and R β , Q α , Q β , A β , A α , R μ , R ζ and nα have the same meaning as defined in any one of embodiments A1 to A16, A31 to A34).

[0147] Embodiment A48 Unsaturated precursors of embodiment A2 and salts thereof, for example, wherein R α is -C(Q α )-CHA, [ka] CHA is chiral Q β (R θ )3, Q β H(R θ )2, or Q β H2R θ and R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in embodiment A2).

[0148] Embodiment A49 Unsaturated precursors of embodiments A1 to A16, A31 to A34 and salts thereof, for example, wherein R αis -C(Q α )-CHA, [ka] CHA is chiral Q β (R θ )3, Q β H(R θ )2, or Q β H2R θ and R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in any one of embodiments A1 to A16, A31 to A34).

[0149] Embodiment A50 An unsaturated precursor having the following structure: [ka]

[0150] Embodiment B1 A process, generally as described above, for preparing saturated targets of formula 1 from unsaturated precursors of formula 2, comprising: [ka] including 1,4-based substitutions exemplified by 1,4-additions using Grignard reagents, organolithium reagents, organozinc reagents, hydrogenation, hydride sources, electron sources (reduction exemplified by Zn / AcOH) or enzymes, wherein: R β , A α , A β , nα, Q α and R ε each has the same meaning as defined in embodiment A2, R αis a carbon-containing group exemplified by H, halogen, or substituted or unsubstituted alkyl, aryl, heterocyclic, naphthyl, C(O)OC6H5, esters including aliphatic and aromatic esters exemplified by -C(O)OC6H4F, amides including aliphatic and aromatic esters exemplified by -C(O)NHC6H5), hydrazine amides including aliphatic and aromatic esters exemplified by -C(O)NHNHC6H5), thioesters, thionoesters, and -C(O)NHOC6F5); and -C(S)SC6H5), and similar compounds exemplified by R α is not attached to the ring through an O or N atom, so for example, R α is not -OMe, and whenever H is added to the 4-position of a 1,4 system, R α is not H, R γ is H or a carbon-containing group such as a substituted or unsubstituted alkyl, aryl, naphthyl, etc., R δ is H or a carbon-containing group such as substituted or unsubstituted alkyl, aryl, naphthyl, etc.

[0151] Embodiment B1a A saturated target of Formula 1 as defined in embodiment B1 combined with an amount of an intermediate unsaturated precursor as defined in any one of embodiments A1 to A52 and B1 produced therefrom as an impurity.

[0152] Embodiment B1b A process, generally as described above, for preparing saturated targets of formula 1 from unsaturated precursors of formula 2, comprising: [ka] including 1,4-based substitutions exemplified by 1,4-addition using Grignard reagents, organolithium reagents, organozinc reagents, hydrogenation, hydride sources, electron sources, reduction, Zn / AcOH or enzymes; R β , A α , A β , nα, Q α and Rε each has the same meaning as defined in embodiment A2, R α is H, halogen, or a carbon-containing group exemplified by substituted or unsubstituted alkyl, aryl, heterocyclic, naphthyl, esters including aliphatic and aromatic esters, e.g., C(O)OC6H5 or -C(O)OC6H4F), amides including aliphatic and aromatic, e.g., -C(O)NHC6H5), hydrazine amides including aliphatic and aromatic, e.g., -C(O)NHNHC6H5), thioesters, thionoesters, and similar compounds such as -C(O)NHOC6F5; -C(S)SC6H5), R γ is H or a substituted or unsubstituted carbon-containing group such as alkyl, aryl, naphthyl, etc. R δ is H or a carbon-containing group such as a substituted or unsubstituted alkyl, aryl, naphthyl, etc., however, R α is not attached to the ring through an O or N atom, so for example, R α is not -OMe, and whenever H is added to the 4-position of a 1,4 system, A α is N(Me) and R β R is m-(trifluoromethyl)benzene α is not H, In the case of m-(trifluoromethyl)benzene or 6-(trifluoromethyl)pyridin-3-yl, R α can be, for example, H in the following scheme: [ka]

[0153] Embodiment B1c According to any one of the processes exemplified by embodiments B1 and B1b, etc., a process for preparing a saturated target from a corresponding unsaturated precursor, the process comprising combining the unsaturated precursor, a nucleophile exemplified by a Grignard reagent, an organolithium reagent, an organozinc reagent, a hydrogen source, for example H / Pd / C, or a hydride source, or an electron source exemplified by Zn / AcOH, and at least one solvent to perform a 1,4-based substitution, for example a 1,4-addition reaction, on the unsaturated precursor to obtain a saturated target generally defined by the following formula: [ka]

[0154] Preferably, depending on the reaction conditions, one or more isomers, such as the trans or cis isomer, are in excess. [ka]

[0155] Embodiment B1d The generally previously described processes for preparing saturated targets from corresponding unsaturated precursors, including 1,4-based substitution, e.g., 1,4-addition, of the unsaturated precursor using Grignard reagents, organolithium reagents, organozinc reagents, hydrogenation, or a hydride source, in which the resulting saturated target product has an excess of one or more possible isomers, each of which is represented by a general scheme selected from the group consisting of: [ka] [ka]

[0156] Embodiment B2 The process according to any one of the processes exemplified by embodiments B1 and B1b, etc., comprising combining an unsaturated precursor, a nucleophile exemplified by a Grignard reagent, an organolithium reagent, an organozinc reagent, a hydrogen source, e.g., H / Pd / C or a hydride source or an electron source exemplified by Zn / AcOH, and a solvent to effect a 1,4-based substitution of the unsaturated precursor, e.g., a 1,4-addition reaction to give a saturated target.

[0157] Embodiment B2a A process, generally as described above, for preparing saturated targets of formula 1 from unsaturated precursors of formula 2, comprising: [ka] including 1,4-based substitutions exemplified by 1,4-addition with Grignard reagents, organolithium reagents, organozinc reagents, hydrogenation or hydride sources; In this process, the saturated target product has one or more possible isomers, where R α , R β , A α , A β , nα, Q α and R ε each has the same meaning as defined in embodiment A2, R γ But H or R α and R δ But H or R α That is the process.

[0158] Embodiment B3 The process of any one of embodiments B2 and B2a, comprising combining an unsaturated precursor, a nucleophile exemplified by a Grignard reagent, an organolithium reagent, an organozinc reagent, or a hydride source, a solvent, and one or more catalytic components selected from a catalyst; a pre-catalyst, and a co-catalyst, respectively, to carry out a 1,4-based substitution, e.g., a 1,4-addition reaction, of the unsaturated precursor to obtain a saturated target.

[0159] Embodiment B3a The process of any one of embodiments B2 and B2a, comprising combining an unsaturated precursor, a nucleophile exemplified by a Grignard reagent, an organolithium reagent, an organozinc reagent, or a hydride source, a solvent, and one or more catalytic components selected from a catalyst, a pre-catalyst, and a co-catalyst, respectively, to effect 1,4-based substitution of the unsaturated precursor, exemplified by a 1,4-addition reaction, to obtain a saturated target, wherein the saturated target product has an excess of one or more possible isomers.

[0160] Embodiment B4 The process of any one of embodiments B2; B2a; B3; B3a, wherein RGA is a reversibly bound adduct, further comprising in the combination an additive that is a source of a reversibly bound adduct to an unsaturated precursor, such as a Lewis acid, to provide an improved 1,4-addition reaction to the unsaturated precursor to obtain a saturated target, in any of the following schemes or any combination thereof: [ka] The improvements provided are: protecting a portion of the unsaturated precursor from undesired reactions; increasing route selectivity; Increased selectivity for a particular desired isomer; Increasing the reactivity of the unsaturated precursor; and Required R δ Allowing for a reduction in the amount of a source, e.g., Grignard reagent A process that is either (In the formula, R α , R β , R γ , A α , A β , nα, Q α and R ε and R δ has the same meaning as defined in any one of embodiments B1; B1a, B1b; B2 and B2a).

[0161] Embodiment B5 The process of any one of embodiments B2; B2a; B3; B3a; and B4, further comprising purifying the resulting saturated target product.

[0162] Embodiment B6 The process of any one of embodiments B2; B2a; B3; B3a; B4; and B5, further comprising crystallizing the resulting saturated target product.

[0163] Embodiment B6a The process of any one of embodiments B2; B2a; B3; B3a; B4; and B5, further comprising a step of obtaining an amorphous solid saturated target product by subjecting the saturated target obtained by the process of any one of embodiments B2; B2a; B3; B3a; B4 to spray drying, freeze drying, etc., or by adsorbing the solution onto a solid support material.

[0164] Embodiment B7 The process of any one of embodiments B2-B6, comprising combining an unsaturated precursor, a nucleophile exemplified by a Grignard reagent, an organolithium reagent, an organozinc reagent, or a hydride source, one or more catalytic components each selected from: a solvent; a catalyst; a pre-catalyst; a co-catalyst, and an additive that is a source of an adduct that reversibly binds to the unsaturated precursor to perform a 1,4-addition reaction to obtain a saturated target, and further comprising purifying and crystallizing the reaction product to obtain a crystalline purified saturated target product.

[0165] Embodiment B8 The process of embodiment B7, wherein the combining step comprises an organozinc reagent or hydride source having two or more catalytic components each selected from a Grignard reagent; an organolithium reagent; a solvent such as diethyl ether; and a catalyst; a pre-catalyst; a co-catalyst and mixtures thereof; and a Lewis acid.

[0166] Embodiment B9 The process of any one of embodiments B1-B8, comprising dissolving an unsaturated precursor in a solvent exemplified by diethyl ether, and adding catalyst components preferably including one or more of a catalyst; a pre-catalyst; a co-catalyst, such as a combination of both CuBr.SMe2 (copper(I) bromide dimethylsulfide complex) and R-BINAP or (S)—N-((S)-1-(butylamino)-1-oxo-3-phenylpropan-2-yl)-2-(((E)-2-(diphenylphosphanyl)benzylidene)amino)-3-methylbutanamide; [ka] agitating the reaction mass, for example by stirring or mixing in a continuous reactor or the like, optionally adding a source of reversibly bound adduct to the unsaturated precursor, such as a Lewis acid exemplified by trimethylsilyl chloride, and continuing stirring for an appropriate time, exemplified by about 20 minutes; adjusting the temperature to an optimum level, preferably a low temperature, for example, between −20° C. and −25° C.; adding a nucleophile, for example a Grignard reagent or a hydride source, and stirring for a period of time to achieve an optimum product by balancing parameters typified by considering the desired quality and acceptable yield within a reasonable reaction time; quenching the reaction mass, for example, into aqueous NHCl solution, and optionally extracting with a suitable solvent; and optionally washing the combined organic layers, for example, with saturated brine solution, and optionally drying, for example, with NaSO, and optionally concentrating to obtain the saturated target product.

[0167] Embodiment B10 The process of embodiment B9, further comprising purifying the obtained saturated target product.

[0168] Embodiment B11 The process of any one of embodiments B9 or B10, further comprising crystallizing the obtained saturated target product.

[0169] Embodiment B12 The process of embodiment B1, comprising: In a first vessel A, dissolving the unsaturated precursor in a solvent exemplified by diethyl ether and stirring at a suitable temperature, optionally cooling the reaction mass to a suitable temperature such as -20°C to -25°C, adding a Lewis acid, for example trimethylsilyl chloride, and stirring for a suitable period of time; introducing into a second vessel B catalyst components including one or more of a catalyst; a pre-catalyst; a co-catalyst exemplified by a combination of both CuBr.SMe2 (copper(I) bromide dimethyl sulfide complex) and R-BINAP; [ka] A process comprising adding a nucleophilic component such as a Grignard reagent, organolithium reagent, organozinc reagent or hydride source to vessel B at a suitable temperature (preferably cold) and stirring for a while, adding the contents of vessel A to vessel B at a suitable temperature (preferably cold) and at a suitable addition rate and stirring the mass for a suitable time, typically 20 minutes, quenching the reaction mass into, for example, aqueous NHCl solution and optionally extracting with a suitable solvent, optionally washing the combined organic layers with, for example, saturated brine solution and drying, for example, over NaSO, as needed and optionally concentrating to obtain the saturated target product.

[0170] Embodiment B13 The process of embodiment B12, further comprising purifying the obtained saturated target.

[0171] Embodiment B14 The process of any one of embodiments B12 and B13, further comprising crystallizing the obtained saturated target product.

[0172] Embodiment B15 The process of any one of Embodiments B1 to B14, wherein the unsaturated precursor is any of Embodiments A1 to A35 as defined above, and which comprises a 1,4-based substitution of the unsaturated precursor, for example, a 1,4-addition using a Grignard reagent, an organolithium reagent, an organozinc reagent, or a hydride source.

[0173] Embodiment B15a Use of an unsaturated precursor of any one of embodiments A1 to A35 as defined above as an intermediate in a process for the preparation of a saturated target as defined in any one of embodiments B1 to B14.

[0174] Embodiment B15b A saturated target as defined in B1 combined with an intermediate unsaturated precursor produced using any one of the methods of embodiments B1-B14 as an impurity.

[0175] Embodiment B15c Use of the unsaturated precursor of any one of embodiments B1 as defined above as an intermediate in a process for the preparation of a saturated target as defined in any one of embodiments B1 to B14.

[0176] Embodiment B15d A saturated target as defined in B1 combined as an impurity with an intermediate unsaturated precursor produced by the method of any one of embodiments B1-B14.

[0177] Embodiment B16 The unsaturated precursor is [ka] The process of any one of Embodiments B1-B15, wherein the compound of Embodiment A10 is illustrated by the scheme: Markers that can be formed by the above scheme include those having the following structures: [ka] may include one, some, or all of the following: Processes involving the displacement of unsaturated precursor 1,4 systems such as 1,4-addition with Grignard reagents or / and organolithium reagents, exemplified by (3-(trifluoromethyl)phenyl)lithium).

[0178] Embodiment B16a The unsaturated precursor is represented by the following scheme: [ka] The process of any one of Embodiments B1-B15, wherein the compound of Embodiment A10 is exemplified by: Processes involving the displacement of unsaturated precursor 1,4 systems such as 1,4-addition with Grignard reagents exemplified by 3-(trifluoromethyl)phenylmagnesium bromide and 3-(trifluoromethyl)phenyl]magnesium chloride.

[0179] Embodiment B16b The unsaturated precursor is represented by the following scheme: [ka] The process of any one of Embodiments B1-B15, wherein the compound of Embodiment A10 is exemplified by: Processes involving displacement of unsaturated precursor 1,4 systems such as 1,4-addition using organolithium reagents exemplified by 3-(trifluoromethyl)phenyllithium.

[0180] Embodiment B16c The unsaturated precursor is [ka] The process of any one of Embodiments B1-B15, wherein the compound of Embodiment A10 is exemplified by: Processes involving displacement of unsaturated precursor 1,4 systems such as 1,4-addition using organozinc reagents exemplified by 3-(trifluoromethyl)phenylzinc(II) bromide.

[0181] Embodiment B16d The unsaturated precursor is represented by the following scheme: [ka] The process of any one of Embodiments B1-B15, wherein the compound of Embodiment A10 is exemplified by: Markers that can be formed by the above scheme include those having the following structures: [ka] may include one, some, or all of the following: Processes involving the displacement of unsaturated precursor 1,4 systems such as 1,4-addition with Grignard reagents or / and organolithium reagents, exemplified by (3-(trifluoromethyl)phenyl)lithium).

[0182] Embodiment B17 The following scheme [ka] A process exemplified by: Processes involving displacement of unsaturated precursor 1,4 systems such as 1,4-addition with Grignard reagents exemplified by 3-(trifluoromethyl)phenylmagnesium bromide.

[0183] Embodiment B18 Scheme [ka] A process exemplified by: Processes involving substitution of 1,4 systems such as 1,4-addition with Grignard reagents exemplified by 3-(trifluoromethyl)phenylmagnesium bromide.

[0184] Embodiment B18a Scheme [ka] The process of embodiment B18 as exemplified by: Processes involving substitution of 1,4 systems such as 1,4-addition with Grignard reagents exemplified by 3-(trifluoromethyl)phenylmagnesium bromide.

[0185] Embodiment B18b Scheme [ka] The process of embodiment B18 as exemplified by: Processes involving 1,4-based substitutions such as 1,4-addition with Grignard reagents exemplified by [3-(trifluoromethyl)phenyl]magnesium bromide).

[0186] Embodiment B18c The following scheme [ka] A process exemplified by: Processes involving substitution of 1,4 systems such as 1,4-added organolithium reagents exemplified by 3-(trifluoromethyl)phenyllithium.

[0187] Embodiment B18d The following scheme [ka] A process exemplified by: Processes involving substitution of 1,4 systems such as 1,4-added organozinc reagents exemplified by 3-(trifluoromethylphenylzinc(II) bromide).

[0188] Embodiment B19 The following scheme [ka] A process exemplified by: 1-methyl-2H-pyrrol-5-one, a process involving displacement of the 1,4 system by reduction of the double bond, exemplified by the use of a hydride source.

[0189] Embodiment B19a Scheme [ka] The process of embodiment B19 as illustrated by: A process involving substitution of the 1,4 system by reduction of the double bond in the 1-methyl-2H-pyrrol-5-one group, exemplified by the use of a hydride source.

[0190] Embodiment B19b The following scheme [ka] A process exemplified by: A process involving substitution of the 1,4 system by reduction of the double bond in the 1-methyl-2H-pyrrol-5-one group, exemplified by the use of a hydride source.

[0191] Embodiment B19c The following scheme [ka] A process exemplified by: A process involving substitution of the 1,4 system by reduction of the double bond in the 1-methyl-2H-pyrrol-5-one group, exemplified by the use of a hydride source.

[0192] Embodiment B20 Scheme [ka] A process represented by A process involving substitution of the 1,4 system by reduction of the double bond in the 1-methyl-2H-pyrrol-5-one group, exemplified by the use of a hydride source.

[0193] Embodiment B21a A process for obtaining saturated targets from unsaturated precursors represented by the following scheme: [ka] The process involves a 1,4-based substitution, such as a 1,4-addition, using a Grignard reagent or a hydride source, and the saturated target is a compound as defined in claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796; and Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6 , Y 1 and Y 2 etc. have the meaning defined in Claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796. The text from Claim 1 on page 286, line 6 to page 289, line 23 of WO 2015 / 084796 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment. Text reproduced in Embodiment A35a.

[0194] Embodiment B21b A process for obtaining saturated targets from unsaturated precursors represented by the following scheme: [ka] The process involves a 1,4-based substitution, such as a 1,4-addition, using a Grignard reagent or a hydride source, and the saturated target is a compound as defined in claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796; and Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6 , Y 1 and Y 2etc. have the meaning defined in Claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796. The text from Claim 1 on page 286, line 6 to page 289, line 23 of WO 2015 / 084796 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment. Text reproduced in Embodiment A35a.

[0195] Embodiment B21c 1. A process for obtaining saturated targets from unsaturated precursors, comprising: [ka] The process involves a 1,4-based substitution, such as a 1,4-addition, using a Grignard reagent or a hydride source, and the saturated target is a compound as defined in claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796; and Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6 , Y 1 and Y 2 etc. have the meaning defined in Claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796. The text from Claim 1 on page 286, line 6 to page 289, line 23 of WO 2015 / 084796 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment. Text reproduced in Embodiment A35a.

[0196] Embodiment B22 The following scheme [ka] A process exemplified by: A process involving the substitution of unsaturated precursors 1,4 systems.

[0197] Embodiment B23 The following scheme [ka] A process exemplified by: A process involving the substitution of unsaturated precursors 1,4 systems.

[0198] Embodiment B24 The following scheme [ka] A process exemplified by: A process involving the substitution of unsaturated precursors 1,4 systems.

[0199] Embodiment B25 The following scheme [ka] A process exemplified by: A process involving the substitution of unsaturated precursors 1,4 systems.

[0200] Embodiment B26 The following scheme [ka] A process exemplified by: A process involving the substitution of unsaturated precursors 1,4 systems.

[0201] Embodiment B27a The following scheme [ka] A process exemplified by: A process involving the substitution of unsaturated precursors 1,4 systems.

[0202] Embodiment B27b The following scheme [ka] A process exemplified by: A process involving the substitution of unsaturated precursors 1,4 systems.

[0203] Embodiment B28a Scheme [ka] A process exemplified by: Processes involving 1,4-based substitutions such as 1,4-addition.

[0204] Embodiment B28b The following scheme [ka] A process exemplified by: Processes involving displacement of 1,4 systems such as 1,4-addition using organolithium reagents exemplified by 1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yllithium.

[0205] Embodiment B29a The following scheme [ka] A process exemplified by: Processes involving 1,4-based substitutions such as 1,4-addition.

[0206] Embodiment B29b The following scheme [ka] A process exemplified by: Processes involving substitution of 1,4 systems such as 1,4-addition organolithium reagents exemplified by (6-(trifluoromethyl)pyridin-3-yl)lithium.

[0207] Embodiment B30a The following scheme [ka] A process exemplified by: Processes involving 1,4-based substitutions such as 1,4-addition.

[0208] Embodiment B30b The following scheme [ka] A process exemplified by: Processes involving displacement of 1,4 systems such as 1,4-addition using organolithium reagents exemplified by 1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yllithium.

[0209] Embodiment B31 The process of any one of embodiments B1 through B30b, wherein an excess of one or more of the possible isomers is obtained.

[0210] Embodiment B32 The process of any one of embodiments B1 through B30b, wherein an excess of the anti isomer is obtained.

[0211] Embodiment B33 The process of any one of Embodiments B1 through B30b, wherein an excess of the syn-isomer is obtained.

[0212] Embodiment B34 The process of any one of Embodiments B1 through B33, wherein an excess of one or more of the possible chiral isomers is obtained relative to the other.

[0213] Embodiment B35 The process of any one of embodiments B1 through B34 wherein an excess of the chiral anti isomer is obtained.

[0214] Embodiment B36 The process of any one of embodiments B1 to B34 wherein an excess of the chiral anti isomer of the S,S configuration is obtained.

[0215] Embodiment B37 Magnesium, lithium, zinc, iPrMgCl, iPrMgBr, iPrMgI, hexyllithium, butyllithium, tert-butyllithium, The process of any one of embodiments B1 to B36, wherein 4-methyl-pentyl-lithium, isobutyllithium, or a combination thereof is used to prepare the reagent for the 1,4 system substitution in situ and / or prior to use in the substitution reaction.

[0216] Embodiment B38 The process of any one of embodiments B1 to B36, wherein magnesium halogen exchange or lithium halogen exchange is used to prepare a reagent for the substitution of 1,4 systems in situ and / or prior to use.

[0217] Embodiment B39 The process of any one of embodiments B1 to B38 carried out in the presence of a metal.

[0218] Embodiment B40 The process of embodiment B39 wherein the metal is selected from Cu; Ni; Ti; Co; and Fe.

[0219] Embodiment B41 The process of embodiment B39 wherein the metal is selected from Cu; Ni; and Ti.

[0220] Embodiment B42 The process of embodiment B39 wherein the metal is Cu.

[0221] Embodiment B43 The process of embodiment B39 wherein the metal is Ni.

[0222] Embodiment B44 The process of any one of embodiments B39-B43, wherein the metal is present in a catalytic amount.

[0223] Embodiment B45 The process of any one of embodiments B1 to B44, optionally carried out in the presence of a chiral compound bound to or part of a solid material or substrate.

[0224] Embodiment B46 The process of embodiment B45, wherein the chiral compound is selected from the group containing naturally occurring, synthetic, modified (e.g., substituted, etc.), amino acids exemplified by N,N-dimethyl-L-prolinium and L-proline; peptides exemplified by (S)—N-((S)-1-butylamino-1-oxo-3-phenylpropan-2-yl-2-(E)-2-diphenylphosphanylbenzylideneamino-3-methylbutanamide; phosphorus ligands exemplified by R-BINAP; proteins; enzymes; and sugars.

[0225] Embodiment B47 The process of any one of embodiments B45-B46 wherein the chiral compound is selected from (S)—N—(S)-1-(butylamino-1-oxo-3-phenylpropan-2-yl-2-(E)-2-diphenylphosphanylbenzylideneamino-3-methylbutanamide.

[0226] Embodiment B48 The process of any one of embodiments B45-B47, wherein the chiral compound is present in a catalytic amount.

[0227] Embodiment B49 Lewis base is NH4 + Cl - (Ammonium chloride);NH4+OH - (Ammonium hydroxide);NH3;CN - ions (e.g., from KCN or NaCN); pyridine; DMA; DMSO; DMF; TEMADA; OH - ions; PH3; and H2PO3 -The process of any one of embodiments B45 to B48, wherein the post-treatment is exemplified by ions and the like.

[0228] Embodiment B50 The Lewis base in the post-treatment is NH4 + Cl - (Ammonium chloride);NH4 + OH - (ammonium hydroxide); NH3; and CN, e.g., from KCN or NaCN. - The process of embodiment B49, wherein the cation is selected from In some cases, the presence of a Lewis base can improve workup and / or increase yield.

[0229] Embodiment B51 The process of any one of embodiments B1-B50 conducted in the presence of a strong base exemplified by MeMgCl; MeMgBr; iPrMgCl; iPrMgBr; BuLi; tert-BuLi; hexyllithium; NaH; KH, etc. In some cases, the presence of a strong base allows for a reduction in the amount of other ingredients required.

[0230] Embodiment C1a Compounds of formula 3 and salts thereof [ka] (In the formula, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, R α , R β , A α , A β , nα and Q α has the same meaning as defined in embodiment A2).

[0231] Embodiment C1b Compounds of formula 3 and salts thereof [ka] (In the formula, X α is a halogen, R α , R β , A α , A β , nα and Q α has the same meaning as defined in embodiment A2).

[0232] Embodiment C1c Compounds of formula 3 and salts thereof [ka] (In the formula, X α is N(G α )2, N + (O - )(G α )2 [i.e., N(G α )2 N-oxide], G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, R α , R β , A α , A β , nα and Q α has the same meaning as defined in embodiment A2).

[0233] Embodiment C2 Compounds of formula 3 and salts thereof [ka] wherein the compound of formula 3 does not contain a covalent nitrogen-halogen bond; X α are halogens, SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; R α , R β , A α , A β , nα and Q α has the same meaning as defined in embodiment A2).

[0234] Embodiment C2b a saturated target compound of Formula 1 in combination with (thereby produced) an intermediate compound of Formula 3 as an impurity, wherein the intermediate is a compound as defined in any one of embodiments C1a; C1b; C1c; and C2, and R γ has the same meaning as defined in any one of embodiments B1, B1a, B1b; B2 and B2a. [ka]

[0235] Embodiment C3a The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups each selected from halogen; alkyl; and haloalkyl; [ka] R β , Q α , Q β , A β , A α , R μand nα have the same meaning as defined in embodiment A2).

[0236] Embodiment C3b The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and X α is a halogen, N(G α ) 2, N + (O - )(G α )2, [ka] R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined in embodiment A2).

[0237] Embodiment C4a The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and X α SPh,SePh,SG α ,SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups each selected from halogen; alkyl; and haloalkyl; [ka] R β , Qα , Q β , A β , R π , R μ and nα have the same meaning as defined in embodiment A2).

[0238] Embodiment C4b The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and X α is a halogen, N(G α )2, N + (O - )(G α )2, [ka] R β , Q α , Q β , A β , R π , R μ and nα have the same meaning as defined in embodiment A2).

[0239] Embodiment C5a The compounds of embodiment C2 and salts thereof, for example, R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 1, X α SPh, SePh, SG α , SeG α and G αis phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R β , Q α , Q β , A β , R π and R μ has the same meaning as defined in embodiment A2).

[0240] Embodiment C5b The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 1, X α is a halogen, [ka] R β , Q α , Q β , A β , R π and R μ has the same meaning as defined in embodiment A2).

[0241] Embodiment C5c The compounds of embodiment C2 and salts thereof, for example, R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 1, X αare SPh and SePh, G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R β , Q α , Q β , A β , R π and R μ has the same meaning as defined in embodiment A2).

[0242] Embodiment C6a The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 1, A β is CH2, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R β , Q α , Q β , R π and R μ has the same meaning as defined in embodiment A2).

[0243] Embodiment C6b The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 1, A β is CH2, X α is a halogen, [ka] R β , Q α , Q β , R π and R μ has the same meaning as defined in embodiment A2).

[0244] Embodiment C7a The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 2, A β is CH2, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R β , Q α , Qβ , R π and R μ has the same meaning as defined in embodiment A2).

[0245] Embodiment C7b The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(Q α )Q β R μ and A α is -N(R π )- and nα is 2, A β is CH2, X α is a halogen, [ka] R β , Q α , Q β , R π and R μ has the same meaning as defined in embodiment A2).

[0246] Embodiment C8a The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)Q β R μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, X α SPh, SePh, SG α , SeG α and G αis phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R β , Q β , R π and R μ has the same meaning as defined in embodiment A2).

[0247] Embodiment C8b The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)Q β R μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, X α is N + (O - )(G α )2, [ka] R β , Q β , R π and R μ has the same meaning as defined in embodiment A2).

[0248] Embodiment C9a The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, Aβ is CH2, Q α is O, Q β is NH, X α SPh, SePh, SG α , SeG α and G α represents an alkyl group, a haloalkyl group, a phenyl group, a phenyl group each substituted with 0 to 5 groups selected from halogen; an alkyl group; and a haloalkyl group, [ka] R β , R π and R μ has the same meaning as defined in embodiment A2).

[0249] Embodiment C9b The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, X α are SPh and SePh, [ka] R β , R π and R μ has the same meaning as defined in embodiment A2).

[0250] Embodiment C9c The compounds of embodiment C2 and salts thereof, for example, wherein R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, X α is a halogen, [ka] R β , R π and R μ has the same meaning as defined in embodiment A2).

[0251] Embodiment C10 The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R β , R π and R ζ has the same meaning as defined in embodiment A2).

[0252] Embodiment C11 The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β , unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ and X α are SPh and SePh, [ka] R π and R ζ has the same meaning as defined in embodiment A2).

[0253] Embodiment C12 The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ and X α are SPh and SePh, [ka] R ζ has the same meaning as defined in embodiment A2).

[0254] Embodiment C12a The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ , X α is a halogen, [ka] R ζ has the same meaning as defined in embodiment A2).

[0255] Embodiment C12b The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ , X α is N + (O - )(G α )2, G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R ζ has the same meaning as defined in embodiment A2).

[0256] Embodiment C13 The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHRμ and A α is -NH-, nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ , X α SPh, SePh, SG α , SeG α , N + (O - )(G α )2, G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R ζ has the same meaning as defined in embodiment A2).

[0257] Embodiment C14 The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -NH-, nα is 2, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ , X α SPh, SePh, SG α , SeG α , N + (O - )(G α )2, G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R ζ has the same meaning as defined in embodiment A2).

[0258] Embodiment C15 The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 2, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected fromλ , X α SPh, SePh, SG α , SeG α , N + (O - )(G α )2, G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R ζ has the same meaning as defined in embodiment A2).

[0259] Embodiment C16 Compounds of any one of embodiments C1 to C15, including salts thereof (In the formula, X α is SPh, R α , R β , A α , A β , nα and Q α has the same meaning as in embodiment A2).

[0260] Embodiment C16a Compounds of any one of embodiments C1 to C15, including salts thereof (In the formula, X α is N(Me)2, R α , R β , A α , A β , nα and Q α has the same meaning as in embodiment A2).

[0261] Embodiment C16b A compound having the formula: [ka]

[0262] Embodiment C16c A compound having the formula: [ka]

[0263] Embodiment C16d A compound having the formula: [ka]

[0264] Embodiment C16e A compound for use as a pesticide, preferably a herbicide synthesis process intermediate and / or marker compound, of the following structure: [ka]

[0265] Embodiment C16f A compound for use as a pesticide, preferably a herbicide synthesis process intermediate and / or marker compound, of the following structure: [ka]

[0266] Embodiment C16g structure [ka] of compounds for use as pesticides, preferably herbicide synthesis process intermediates and / or marker compounds.

[0267] Embodiment C16h A compound for use as a pesticide, preferably a herbicide synthesis process intermediate and / or marker compound, of the following structure: [ka]

[0268] Embodiment C17a A compound having the formula: [ka]

[0269] Embodiment C17b A compound having the formula: [ka]

[0270] Embodiment C17c A compound having the formula: [ka]

[0271] Embodiment C17d A compound having the formula: [ka]

[0272] Embodiment C17f A compound for use as a pesticide, preferably a herbicide synthesis process intermediate and / or marker compound, of the following structure: [ka]

[0273] Embodiment C17g A compound for use as a pesticide, preferably a herbicide synthesis process intermediate and / or marker compound, of the following structure: [ka]

[0274] Embodiment C17h A compound for use as a pesticide, preferably a herbicide synthesis process intermediate and / or marker compound, of the following structure: [ka]

[0275] Embodiment C17i A compound for use as a pesticide, preferably a herbicide synthesis process intermediate and / or marker compound, of the following structure: [ka]

[0276] Embodiment C18a A compound having the formula: [ka]

[0277] Embodiment C18b A compound having the formula: [ka]

[0278] Embodiment C19a A compound having the formula: [ka]

[0279] Embodiment C19b A compound having the formula: [ka]

[0280] Embodiment C20a A compound having the formula: [ka]

[0281] Embodiment C20b A compound having the formula: [ka]

[0282] Embodiment C21a A compound having the formula: [ka]

[0283] Embodiment C21b A compound having the formula: [ka]

[0284] Embodiment C22a A compound having the formula: [ka]

[0285] Embodiment C22b A compound having the formula: [ka]

[0286] Embodiment C23a A compound having the formula: [ka]

[0287] Embodiment C23b A compound having the formula: [ka]

[0288] Embodiment C24a A compound having the formula: [ka]

[0289] Embodiment C24b A compound having the formula: [ka]

[0290] Embodiment C25a A compound having the formula: [ka]

[0291] Embodiment C25b A compound having the formula: [ka]

[0292] Embodiment C26a A compound having the formula: [ka]

[0293] Embodiment C26b A compound having the formula: [ka]

[0294] Embodiment C27a A compound having the formula: [ka]

[0295] Embodiment C27b A compound having the formula: [ka]

[0296] Embodiment C28a A compound having the formula: [ka]

[0297] Embodiment C28b A compound having the formula: [ka]

[0298] Embodiment C29a A compound having the formula: [ka]

[0299] Embodiment C29b A compound having the formula: [ka]

[0300] Embodiment C30a A compound having the formula: [ka]

[0301] Embodiment C30b A compound having the formula: [ka]

[0302] Embodiment C31a The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R π and R ζ has the same meaning as defined in embodiment A2).

[0303] Embodiment C31b The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π )- and nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζis a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α is a halogen, [ka] R π and R ζ has the same meaning as defined in embodiment A2).

[0304] Embodiment C32a The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -NH-, nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R ζ has the same meaning as defined in embodiment A2).

[0305] Embodiment C32b The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -NH-, nα is 1, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α is a halogen, [ka] R ζ has the same meaning as defined in embodiment A2).

[0306] Embodiment C33 The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -NH-, nα is 2, A β is CH2, Q α is O, Q β is NH, R μ is a phenyl ring that is unsubstituted or substituted with up to five substituents each independently selected from Rζ; R β is H, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R ζ has the same meaning as defined in embodiment A2).

[0307] Embodiment C34 The compounds of embodiment C2 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 2, A β is CH2, Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups, [ka] R ζ has the same meaning as defined in embodiment A2).

[0308] Embodiment C35a A compound defined by any one of the following structures: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R6, Y1, and Y2, etc. have the meanings defined in Claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796. The text extracted from Claim 1 from page 286, line 6 to page 289, line 23 of WO 2015 / 084796 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in Embodiment A35a. During the ceremony, X α =SPh, SePh, SG α , SeG α G α = an alkyl group, a haloalkyl group, a phenyl group, a phenyl group each substituted with 0 to 5 groups selected from halogen; an alkyl group; and a haloalkyl group.

[0309] Embodiment C35b The following formula [ka] in combination with at least one compound defined by any one of A saturated target compound having the structure [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4, R6, Y1, and Y2, etc. have the meanings defined in Claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796. The text extracted from Claim 1 from page 286, line 6 to page 289, line 23 of WO 2015 / 084796 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in Embodiment A35a. Also, in the formula, X α =SPh, SePh, SG α , SeG α . G α = an alkyl group, a haloalkyl group, a phenyl group, a phenyl group each substituted with 0 to 5 groups selected from halogen; an alkyl group; and a haloalkyl group.

[0310] Embodiment C36a A compound defined by any one of the following structures: [ka] (In the formula, Q, R 1 , Y, and W have the meanings defined in Claim 1 of PCT / US2020 / 034232, published as WO 2020 / 242946. The text from Claim 1 on page 87, line 3 to page 88, line 6 of WO 2020242946 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment, this text being reproduced in Embodiment A36a, wherein: X α =SPh, SePh, SG α , SeG α , and G α = alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0311] Embodiment C36b The following formula [ka] in combination with at least one compound defined by any one of the structures [ka] a saturated target compound having (In the formula, Q, R 1 , R 6 , Y, W, etc. have the meanings defined in Claim 1 of PCT / US2020 / 034232, published as WO 2020 / 242946. The text from Claim 1 on page 87, line 3 to page 88, line 6 of WO 2020 / 242946 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment, as reproduced in Embodiment A36a, wherein X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0312] Embodiment C37a A compound defined by any one of the following formulae: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 7 , Y, A, J, etc. have the meanings defined in Claim 1 of PCT / US2016 / 030450, published as WO 2016 / 182780. The text of Claim 1 from page 101, line 3 to page 106, line 28 of WO 2016 / 182780 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in embodiment A37a, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0313] Embodiment C37b A compound for use as a pesticide, preferably a herbicide synthesis process intermediate and / or marker having any one of the following structures: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 7 , Y, A, J, etc. have the meanings defined in Claim 1 of PCT / US2016 / 030450, published as WO 2016 / 182780. The text of Claim 1 from page 101, line 3 to page 106, line 28 of WO 2016 / 182780 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in embodiment A37a, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0314] Embodiment C37c The following structure [ka] in combination with at least one compound defined by any one of A saturated target compound having the structure [ka] (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 7 , Y, A, and J have the meanings defined in Claim 1 of PCT / US2016 / 030450, published as WO 2016 / 182780. The text of Claim 1 from page 101, line 3 to page 106, line 28 of WO 2016 / 182780 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, and this text is reproduced in Embodiment A37a, wherein: X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0315] Embodiment C38 A compound defined by any one of the following formulae: [ka] (In the formula, Q 1 , Q 2 , R B1 and X have the meaning defined in Claim 1 of PCT / EP2020 / 052780, published as WO 2020 / 161147. The text of Claim 1 on page 74, line 10 to page 75, line 10 of WO 2020 / 161147 is specifically incorporated by reference solely for the purposes of defining the three structures of this embodiment, and this text is reproduced in embodiment A38, During the ceremony, X α SPh, SePh, SG α , SeG α and Gα is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0316] Embodiment C38a The following structure [ka] a saturated target compound of the formula: [ka] (In the formula, Q 1 , Q 2 , R B1 and X etc. have the meanings defined in Claim 1 of PCT / EP2020 / 052780, published as WO 2020 / 161147. The text from Claim 1 on page 74, line 10 to page 75, line 10 of WO 2020 / 161147 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, this text being reproduced in Embodiment A38, wherein: X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0317] Embodiment C39 A compound defined by any one of the following formulae: [ka] (In the formula, Q, W 2 , R 1, Y and Z, etc. have the meanings defined in Claim 1 of PCT / EP2018 / 069001, published as WO 2019 / 025156.) The German text from Claim 1 on page 109, line 3 to page 112, line 6 of WO 2019025156 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment. Also, in the formula, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0318] Embodiment C40 A compound defined by any one of the following formulae: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 9 , J, L, Y and Y 2 etc. have the meaning defined in Claim 1 of PCT / US2018 / 035017, published as WO 2018 / 222647. The text from Claim 1 on page 84, line 5 to page 89, line 27 of WO 2018 / 222647 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, this text being reproduced in Embodiment A41, wherein: X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0319] Embodiment C41 Each has the following structure: [ka] saturated targets of the formula: N-oxides and salts thereof, as defined in claim 1 of PCT / US2018 / 035017, published as WO 2018 / 222647, in combination with at least one compound defined by any one of [ka] During the ceremony, Q 1 , Q 2 , R 1 , R 7 , R 9 , J, L, Y and Y 2 etc. have the meaning defined in Claim 1 of PCT / US2018 / 035017, published as WO 2018 / 222647, the text of Claim 1 on page 84, line 5 to page 89, line 27 of WO 2018 / 222647 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment, this text being reproduced in embodiment A41; X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0320] Embodiment C42 A compound defined by any one of the following formulae: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 8 , R 9, J, Y, and W, etc. have the meanings defined in Claim 1 of PCT / US2018 / 035015, published as WO 2018 / 222646. The text from Claim 1 on page 82, line 6 to page 86, line 21 of WO 2018 / 222646 is specifically incorporated by reference solely for the purpose of defining the structure of this embodiment. Also, in the formula, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0321] Embodiment C42a Each has the following structure: [ka] a saturated target, an N-oxide salt and a stereoisomer thereof, which is a compound as defined in claim 1 of PCT / US2018 / 035015, published as WO 2018 / 222646, having the formula: [ka] (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 8 , R 9, J, Y, and W, etc. have the meanings defined in Claim 1 of PCT / US2018 / 035015, published as WO 2018 / 222646. The text from Claim 1 on page 82, line 6 to page 86, line 21 of WO 2018 / 222646 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment, this text being reproduced in embodiment A42; X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0322] Embodiment C43 formula [ka] A compound defined by any one of (In the formula, Q, W 2 , R 1 , R 2 , Y and Z, etc. have the meanings defined in Claim 1 of PCT / EP2018 / 057628, published as WO 2018 / 184890. The text from Claim 1 on page 133, line 9 to page 136, line 4 of WO 2018184890 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment. Also, in the formula, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0323] Embodiment C43a The following structure [ka] a saturated target, which is a compound as defined in claim 1 of PCT / EP2018 / 057628, published as WO 2018 / 184890, in combination with at least one compound as defined in any one of [ka] (In the formula, Q, W 2 , R 1 , R 2 , Y and Z, etc. have the meanings defined in Claim 1 of PCT / EP2018 / 057628, published as WO 2018 / 184890. The German text from Claim 1 on page 133, line 9 to page 136, line 4 of WO 2018 / 184890 is specifically incorporated herein by reference solely for the purpose of defining the structure of this embodiment, wherein: X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups, alkyl groups, and haloalkyl groups.

[0324] Embodiment D1a 1. A process generally described above for preparing an unsaturated precursor of formula 2 from a compound of formula 3, comprising: [ka] a process comprising oxidation of the corresponding compound of formula 3, wherein X α , R α , R β , A α , A β , nα, and Qα each have the same meaning as in embodiment C1a). This process is α is a thioether or a selenoether.

[0325] Embodiment D1b 1. A process generally described above for preparing an unsaturated precursor of formula 2 from a compound of formula 3, comprising: [ka] A process comprising an elimination reaction utilizing an activating agent such as a base or a Lewis acid, α , R α , R β , A α , A β , nα and Q α each have the same meaning as in embodiment C1a).

[0326] Embodiment D2a The process of embodiment D1a includes dissolving the compound of formula 3 in a suitable solvent, such as acetic acid, stirring (e.g., agitating) for a period of time, such as about 20 minutes, and adding an oxidizing agent, such as meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), in small portions at a suitable temperature. The reaction mass is then stirred at substantially the same temperature for a period of time, such as about 2 hours. The reaction mass can be quenched with, for example, aqueous NaHCO solution and extracted with a suitable solvent, typically twice. The combined organic layer can be concentrated to obtain the corresponding unsaturated precursor of formula 2.

[0327] Embodiment D2b The process according to embodiment D1a includes dissolving the compound of formula 3 in a suitable solvent, such as chlorobenzene, stirring (e.g., by stirring) for a time, such as about 20 minutes, and adding an activating agent, such as a base or a Lewis acid, in small portions at a suitable temperature. The reaction mass is then stirred at substantially the same temperature for a period of time, such as about 2 hours. The reaction mass can be quenched with, for example, an NH4Cl solution and extracted with a suitable solvent, typically twice. The combined organic layer can be concentrated to obtain the corresponding unsaturated precursor of formula 2.

[0328] Embodiment D3a The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0329] Embodiment D3b The following scheme [ka] using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (H2O2), to give the corresponding unsaturated precursor: [ka] A process comprising the oxidation of a compound of

[0330] Embodiment D3c The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0331] Embodiment D4a The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0332] Embodiment D4b The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0333] Embodiment D5a The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0334] Embodiment D5b The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0335] Embodiment D6a Scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0336] Embodiment D6b The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0337] Embodiment D7a Scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0338] Embodiment D7b The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0339] Embodiment D8a The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0340] Embodiment D8b The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0341] Embodiment D9a The following scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0342] Embodiment D9b Scheme [ka] to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (HO), [ka] A process comprising the oxidation of a compound of

[0343] Embodiment E1 Compounds of formula 4, including salts thereof, for use as intermediates in the process for preparing the corresponding saturated targets of formula 1, [ka] [ka] (In the formula, R α , R β , A α , A β , nα and Q α has the same meaning as defined in embodiment A2, and R δ and R γ has the same meaning as defined in embodiment B1).

[0344] Embodiment E2 The saturated target compound combined as an impurity with the intermediate compound of Formula 4 defined in embodiment E1 through which it was produced.

[0345] Embodiment F1a A process as generally described above for preparing a compound of formula 3 from a compound of formula 4, comprising: [ka] X by using bases and electrophiles α including the addition of a "leaving" group, X α , R α , R β , A α , A β , nα and Qα each of which has the same meaning as in embodiment C1a. β is H.

[0346] Embodiment F1b A process as generally described above for preparing a compound of formula 3 from a compound of formula 4, comprising: [ka] X by using a leaving group source such as a halogenating reagent α Addition of a leaving group, X α , R α , R β , A α , A β , nα and Q α each of which has the same meaning as in embodiment C1a.

[0347] Embodiment F1c A process as generally described above for preparing a compound of formula 3 from a compound of formula 4, comprising: [ka] By using a base and an electrophile, X α Addition of the X group α , R α , R β , A α , A β , nα and Q α each of which has the same meaning as in embodiment C1b. β is H.

[0348] Embodiment F2a The process of embodiment F1a includes dissolving the compound of formula 4 in a suitable solvent containing a base such as sodium hydride at a specified temperature, typically by cooling and stirring (e.g., stirring, etc.), for a period of time exemplified as about 20 minutes; adding an electrophile exemplified by diphenyl disulfide; phenyl hypochlorite; or phenyl hypobromite dissolved in a suitable solvent at substantially the same temperature; and stirring the reaction mass at substantially the same temperature for a period of time. The reaction mass is quenched, for example, with NH4Cl solution, extracted with a suitable solvent, typically two or more times, and the combined organic layers are washed, dried with Na2SO4, and concentrated to obtain the corresponding compound of formula 3. This process can be carried out by adding R β is H.

[0349] Embodiment F2b The process of embodiment F1b comprises dissolving the compound of formula 4 together with a leaving group source, exemplified by a halogenating reagent (e.g., a bromine source), in a suitable solvent at a specific temperature, and optionally adding a base and / or a catalyst (catalyst components including one or more of catalyst; pre-catalyst; co-catalyst). The reaction mass is stirred (e.g., stirred, etc.) at substantially the same temperature, for example, for about 2 hours, and the reaction mass is quenched and extracted with a suitable solvent. Preferably, the mass is washed again, and / or the combined organic layers are washed, optionally dried, for example, with Na2SO4, and concentrated to obtain the corresponding compound of formula 3.

[0350] Embodiment F3 The process of any one of embodiments F2a or F2b, further comprising purifying the compound of Formula 3 obtained from the above process.

[0351] Embodiment F4 The process of any one of embodiments F1-F3, wherein the electrophile is either diphenyl disulfide or phenyl hypochlorite.

[0352] Embodiment G1 Conserved markers having the following structure, and salts thereof, for example: [ka] (In the formula, R β , Q α , Q β and R π has the same meaning as defined in embodiment A2).

[0353] Embodiment G2 A conserved marker compound of formula D obtained by exposing tetflupyrrolimet to sunlight. [ka]

[0354] Embodiment DD1 A conserved marker compound of the formula: [ka] (In the formula, R β , Q α , A β , A α and nα have the same meaning as defined in embodiment A2).

[0355] Embodiment DD2 A conserved marker compound of the formula: [ka] (In the formula, R β , Q α , A β , and R π has the same meaning as defined in embodiment A2).

[0356] Embodiment DD3 A conserved marker compound of the formula: [ka] (In the formula, R π and R ζ has the same meaning as defined in embodiment A2).

[0357] Embodiment DD4 A conserved marker compound of the formula: [ka] (In the formula, R β , Q α , A β , and R π has the same meaning as defined in embodiment A2).

[0358] Embodiment DD5 A conserved marker compound of the formula: [ka] (In the formula, each R ζ has the same meaning as defined in embodiment A2).

[0359] Embodiment DD6 A conserved marker compound of the formula: [ka]

[0360] Embodiment DD7 A conserved marker compound of the formula: [ka]

[0361] Embodiment DD8 A conserved marker compound of the formula: [ka]

[0362] Embodiment DD9 A conserved marker compound of the formula: [ka]

[0363] Embodiment DD10 A conserved marker compound of the formula: [ka]

[0364] Embodiment DD11 A conserved marker compound of the formula: [ka]

[0365] Embodiment H1 In the following general scheme, a process for preparing a storage marker compound from a corresponding saturated target compound, wherein the saturated target is exposed to sunlight for a time sufficient to form a detectable amount of the corresponding storage marker, as measured by analytical methods exemplified by HPLC and particularly HPLC-MS. [ka] (In the formula, R β , A β , A α , R ζ and nα have the same meaning as defined in embodiment A2).

[0366] Embodiment H2 In the following general scheme, a process for preparing a conserved marker compound from a corresponding saturated target compound is provided, comprising: [ka] A process comprising exposing a composition (such as a solution) of a saturated target to sunlight for a time sufficient to form a detectable amount of a corresponding storage marker in the composition, particularly an amount above the limit of quantification, using an analytical technique exemplified by HPLC-MS.

[0367] Embodiment H2a In the following scheme, a process for preparing a corresponding preserved marker compound from a saturated target compound, which is (3S,4S)-2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide, comprising: [ka] A process comprising exposing a composition (such as a solution) of (3S,4S)-2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide to sunlight for a time sufficient to form a detectable amount, particularly an amount above the limit of quantitation, of a corresponding storage marker in the composition using an analytical technique exemplified by HPLC-MS.

[0368] Embodiment H3 The process of any one of embodiments H2 or H2a, wherein the composition comprises a solution, particularly an aqueous solution, preferably maintained at a predetermined level of pH acidity / basicity, preferably by a method exemplified by the inclusion of an appropriate buffer in the aqueous solution.

[0369] Embodiment H4 The process of embodiment H3, wherein the solution of the saturated target is maintained at a level of acidity / basicity exemplified by an aqueous solution of the saturated target having a pH selected from about 4±1; 7±1; and 10±1, preferably by including an effective concentration of an appropriate buffer in the aqueous solution.

[0370] Embodiment H5 The process of any one of embodiments H2; H2a; H3; and H4, wherein the rate at which the corresponding storage marker is formed from the saturated target compound upon exposure to sunlight is further mediated by selecting the acidity / basicity of the composition comprising the saturated target.

[0371] Embodiment H6 The process of any one of embodiments H3, H4, and H5, wherein the composition is an aqueous solution and the rate at which the corresponding storage marker is formed from the saturated target upon exposure to sunlight is mediated by selecting the pH of the aqueous solution of the saturated target.

[0372] Embodiment H7 1. A process for minimizing the rate of conversion of 2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide in a composition to a corresponding storage marker, the process comprising minimizing and / or avoiding exposure of the composition to sunlight and / or mitigating the conversion effects of exposure to sunlight.

[0373] Embodiment H8 A process for minimizing the rate of conversion of tetoflurilpyrrolimet in the composition to its corresponding storage marker, the process comprising minimizing the time and extent to which the composition is exposed to sunlight and / or mitigating the conversion effects of exposure to sunlight.

[0374] Embodiment H9 A process for minimizing the rate of conversion of tetoflurilpyrrolimet to a corresponding storage marker in a composition, the process comprising including in the composition an ingredient; an excipient; an adjuvant; a carrier; or any additive that can mitigate at least one of the conversion effects of exposure to sunlight or that can slow the rate at which the conversion would occur upon exposure to sunlight in the absence of the ingredient, excipient, adjuvant, carrier, or additive.

[0375] Embodiment H10 A process for minimizing the rate of conversion of tetflupyrrolimet to a corresponding storage marker in a product containing a tetflupyrrolimet composition (including a solution thereof) during the manufacturing, packaging, labeling, transportation, and storage of the product, comprising mitigating or overcoming the effects of exposure of the product to sunlight by containing the composition within a light-resistant, preferably substantially opaque, packaging and / or container (e.g., a container-closure system) that protects the contents from the conversion effects of sunlight by a light-resistant or opaque covering, or by the use of secondary packaging, or by the specific properties of the material from which it is constructed, including any coating applied thereto, including a clear, colorless, or translucent container that is made light-resistant within an amber container, wherein light-resistant and opaque are related to the wavelengths of light that mediate the conversion of tetflupyrrolimet to a corresponding storage marker.

[0376] Embodiment H11 The process and / or composition of any one of Embodiments H1-H10, wherein the saturated target compound, preferably tetoflurilpyrrolimet, is in a liquid, solution, emulsion, or suspension composition.

[0377] Embodiment H12 1. A process for minimizing the rate at which an aqueous solution of tetflupyrrolimet is converted to the corresponding storage marker compound when the solution is exposed to sunlight, the process comprising maintaining the pH of the aqueous solution in the range of about 6 to about 8, preferably about 7.

[0378] Embodiment H13 A process for determining the period of time that a storage composition containing a saturated target compound, particularly a tetflupyrrolimet composition, has been exposed to sunlight during storage, the process comprising measuring and quantifying the relative content of a corresponding storage marker compound compared to the content of the saturated target in the composition, and assessing the period of exposure to sunlight by reference to a standard calibrated conversion rate in one or more reference compositions containing the saturated target compound.

[0379] Embodiment H14 The process of embodiment H13, wherein said relative content measurement and quantification is exemplified by calculating the ratio of the respective areas under the resolved characterization peaks of each compound in the test sample by appropriate HPLC analysis.

[0380] Embodiment H15 The process of any one of embodiments H13 and H14, wherein the standard calibration rate is determined for a reference composition having the same acidity / basicity as the stored test composition.

[0381] Embodiment H16 The process of any one of embodiments H13, H14, and H15, wherein the standard calibration rate is determined relative to a reference composition packaged in the same container system as the stored test composition.

[0382] Embodiment I1 A preserved packaged composition comprising a detectable amount of a preserved marker compound in combination with the corresponding saturated target compound to which it was converted by a process exemplified by the process of embodiment H2.

[0383] Embodiment I2 In particular, the following formula [ka] and any isomers or enantiomers thereof, as exemplified by (3S,4S)-2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide of the formula: [ka] in combination with a saturated target compound of the formula [ka] The preserved packaged composition of embodiment I1, comprising a detectable, preferably measurable, amount of a preserved marker compound.

[0384] Embodiment I3 The preserved packaged composition of any one of embodiments I1 and I2, wherein the composition comprises a solution, particularly an aqueous solution, of a saturated target maintained at a predetermined level of acidity / basicity, preferably pH, preferably by a method exemplified by the inclusion of an appropriate buffer system in the aqueous solution.

[0385] Embodiment I4 The storage packaging composition of embodiment 13, wherein the saturated target solution is maintained at a level of acidity / basicity exemplified by an aqueous solution of the saturated target having a pH selected from about 4±1; about 7±1; and about 10±1, preferably by including a suitable buffer in the aqueous solution at a concentration effective to maintain the level of acidity / basicity.

[0386] Embodiment I5 Conserved marker compounds, particularly compounds of the formula [ka] When exposed to sunlight during storage, the compound of formula [ka] The stored packaged composition of any one of embodiments I1-I4, wherein the rate at which the compound is formed is further mediated by selection of the acidity / basicity of the saturation target composition over the storage period.

[0387] Embodiment I6 A packaged aqueous composition of tetflupyrolimet, wherein the tetflupyrolimet is represented by the following formula, including any isomer, enantiomer, or mixture thereof, when the composition is exposed to sunlight during storage: [ka] a packaged aqueous composition of tetoflurilmet, characterized in that the rate at which the compound is converted to a corresponding storage marker of tetoflurilmet is minimized, and the composition is adapted to maintain a pH in the range of about 6 to about 8, preferably about 7, during storage by including in the composition an ingredient, excipient, or other component exemplified by a buffer or buffer system.

[0388] Embodiment I7 2'-Fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide, in particular tetflupyrrolimet, which is a compound of the formula: [ka] to a corresponding storage marker is minimized, and the product is adapted to limit, reduce, minimize, or substantially avoid the time and extent of exposure of the composition within the product to sunlight during storage, said minimization being compared to an agricultural tetflupyrrolimet product without such adaptation.

[0389] Embodiment I8 During the manufacturing, packaging, labeling, shipping, or storage of the tetflupyrrolimet composition, [ka] 1. An agricultural product comprising a composition protected to a detectable degree against sunlight-mediated conversion of a compound of formula (I) to a corresponding preservation marker compound, characterized in that the product is contained within a substantially light-resistant, preferably opaque, packaging and / or container-closure system that protects the contents from the effects of sunlight, including any coatings applied thereto, including clear, colorless or translucent containers that are made light-resistant by specific properties of the materials that make up the composition, by an opaque cover, or by the use of secondary packaging, or within an amber container.

[0390] Embodiment I9 The following formula [ka] 1. A tetoflurilpyrrolimet composition characterized by a minimized rate or extent of sunlight-mediated conversion of tetoflurilpyrrolimet to a corresponding storage marker of tetoflurilpyrrolimet, the composition comprising at least one component, excipient, adjuvant, carrier, or additive that can mitigate the conversion effect of exposure to sunlight or that can decrease the rate at which such conversion would occur upon exposure to sunlight in the absence of such component, excipient, adjuvant, carrier, or additive.

[0391] Embodiment I10 A tetflupyrrolimet composition that is stabilized to at least a measurable extent against sunlight-mediated conversion to a corresponding storage marker during manufacturing, packaging, labeling, shipping, and storage, characterized in that the composition comprises at least one component, excipient, adjuvant, carrier, or additive that can mitigate the conversion effects of exposure to sunlight and / or slow the rate at which such conversion would occur without such component, excipient, adjuvant, carrier, or additive.

[0392] Embodiment I11 An article of manufacture comprising a tetflupyrrolimet composition that has been shielded from sunlight-mediated conversion to a corresponding storage marker during any of the manufacturing, packaging, labeling, shipping, or storage of the composition, wherein the article of manufacture comprises the tetflupyrrolimet composition contained within substantially light-resistant, preferably opaque, packaging, substantially as detailed in embodiment H10.

[0393] Embodiment I12 A tetflupyrrolimet composition that is at least measurably stabilized against conversion to a corresponding storage marker or that displays a measurably reduced conversion rate to a corresponding storage marker during manufacturing, packaging, labeling, shipping, and storage, as compared to a standard calibrated conversion rate in one or more reference compositions comprising tetflupyrrolimet, wherein the composition: a) a buffer that maintains the pH of the composition at 7±1; b) UV absorbers; c) Suitable dyes, colorants, or pigments, such as components that exhibit substantially the same absorption spectrum as that of tetflupyrrolimet; d) Components that can reduce the amount of sunlight that hits the material; e) opacifiers; f) reflective pigments such as titanium dioxide; g) a light-protective coating covering at least a portion of the tetflupyrrolimet in the composition; h) a complex of tetflupyrrolimet with a complexing agent, exemplified by, for example, an inclusion complex with cyclodextrin; and wherein the reference composition comprises tetflupyrrolimet free of said component.

[0394] f Embodiment I14 A buffered tetflupyrrolimet composition containing less than a measurable amount, preferably less than a detectable amount, of a corresponding storage marker compound after storage in a sunlight environment for a period equal to or greater than two months.

[0395] Embodiment I15 The product and / or composition of any one of embodiments I1 to I12, wherein the saturation target is preferably tetflupyrrolimet in a liquid, solution, emulsion, or suspension composition.

[0396] Embodiment J1 A crystalline polymorphic form I of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide, which exhibits at least one of the following properties: Infrared spectrum substantially as shown in FIG. Powder X-ray diffraction pattern substantially as shown in FIG. Powder X-ray diffraction pattern with a differential peak at 9.6 2θ (±0.20); A powder X-ray diffraction pattern having at least four characteristic peaks at 2θ (±0.20) of 9.6, 15.0, 17.3, 17.9, 21.6 and 24.6.

[0397] Embodiment J2 Crystalline polymorphic form I of tetflupyrrolimet, which exhibits at least one of the following properties: Infrared spectrum substantially as shown in FIG. Powder X-ray diffraction pattern substantially as shown in FIG. Powder X-ray diffraction pattern with a differential peak at 9.6 2θ (±0.20); A powder X-ray diffraction pattern having at least four characteristic peaks at 2θ (±0.20) of 9.6, 15.0, 17.3, 17.9, 21.6 and 24.6.

[0398] Embodiment J3 A composition comprising crystalline polymorphic Form I of tetoflurilmet as defined in any one of embodiments J1 or J2.

[0399] Embodiment J4 An agrochemical composition, preferably a herbicidal composition, comprising crystalline polymorph Form I of any one of embodiments J1 and J2 and a herbicidally acceptable diluent or carrier.

[0400] Embodiment J5 An agrochemical composition, preferably a herbicidal composition, prepared from crystalline polymorphic Form I of any one of embodiments J1 and J2.

[0401] Embodiment K1 A crystalline polymorphic Form II of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide, which exhibits at least one of the following properties: Infrared (IR) absorption spectrum substantially as shown in FIG. An infrared (IR) absorption spectrum having at least one characteristic peak selected from values ​​expressed as cm −1 (±1 cm −1 ) at 1678, 1546, 1395, 946, 924, 885, 825 and 662. Powder X-ray diffraction pattern substantially as shown in FIG. a powder X-ray diffraction pattern having a differential peak at 6.9 2θ (±0.20); A powder X-ray diffraction pattern having at least four characteristic peaks expressed in 2θ (±0.20) selected from the following values: 6.9, 11.2, 17.7, 23.5 and 26.3.

[0402] Embodiment K2 Crystalline polymorphic Form II of tetflupyrrolimet, which exhibits at least one of the following properties: Infrared (IR) absorption spectrum substantially as shown in FIG. An infrared (IR) absorption spectrum having at least one characteristic peak selected from values ​​expressed as cm −1 (±1 cm −1 ) at 1678, 1546, 1395, 946, 924, 885, 825 and 662. Powder X-ray diffraction pattern substantially as shown in FIG. a powder X-ray diffraction pattern having a differential peak at 6.9 2θ (±0.20); A powder X-ray diffraction pattern having at least four characteristic peaks expressed in 2θ (±0.20) selected from the following values: 6.9, 11.2, 17.7, 23.5 and 26.3.

[0403] Embodiment K3 A composition comprising crystalline polymorph Form II according to any one of embodiments K1 or K2.

[0404] Embodiment K4 An agrochemical composition comprising crystalline polymorph Form II according to any one of embodiments K1 and K2, preferably comprising a herbicidal composition and an agronomically, preferably herbicidally, acceptable diluent or carrier.

[0405] Embodiment K5 An agrochemical composition, preferably a herbicidal composition, prepared from crystalline polymorph Form II according to any one of embodiments K1 and K2.

[0406] Embodiment K6 A crystallization method for preparing the crystalline polymorph Form I of any one of embodiments J1 and J2, comprising recrystallization from tert-butyl methyl ether.

[0407] Embodiment K6a A method for preparing crystalline polymorphic Form I of any one of embodiments J1 and J2, comprising: 1. Dissolving (3R,4S)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxylic acid in acetonitrile (200 mL); 2. Adding 2-fluoroaniline and N-methylimidazole; 3. Mixing the resulting contents at ambient temperature for a period of time exemplified by 10 minutes; 4. adding chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate; 5. Stirring the resulting mixture at ambient temperature for a period of time exemplified by 10 hours; 6. Removing the solvent, for example by evaporation; 7. Dissolving the residue in, for example, dichloromethane; 8. Washing with, for example, aqueous sodium sulfate and brine; 9. Drying and concentrating under reduced pressure to obtain a crude product; 10. Recrystallizing the crude product from tert-butyl methyl ether.

[0408] Embodiment K7 A method for preparing crystalline polymorph Form II according to any one of embodiments K1 and K2, comprising trituration with heptane.

[0409] Embodiment K7a A process for preparing crystalline polymorph Form II according to any one of embodiments K1 and K2, comprising: 1. Dissolving N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide in diethyl ether; 2. Adding, for example, CuBr.SMe2, 3. Adding, for example, 2,2'-bis(diphenylphosphaneyl)-1,1'-binaphthalene; 4. Stirring the reaction mass for a period of time such as 20 minutes; 5. Cooling the reaction mass; 6. Adding, for example, trimethylsilyl trifluoromethanesulfonate; 7. Stirring for a period of time such as 20 minutes; 8. Adding 3-(trifluoromethyl)phenyl)magnesium bromide; 9. Stirring for a period of time exemplified by 2 hours; 10. Quenching the reaction mass, for example, in aqueous NH4Cl; 11. Extracting with ethyl acetate; 12. Washing the combined organic layers with brine solution; 13. Drying over Na2SO4 and concentrating to obtain the crude product; 14. Purification by column chromatography using, for example, ethyl acetate / hexane (20:80) as the eluent; 15. A method comprising: triturating the resulting solid with heptane (5 mL).

[0410] Embodiment M1 The following formula: [ka] (In the formula, each R ζ A saturated target of Formula 1 as defined in embodiment B1 combined with an amount of any one of a marker, impurity, degradative compound having (wherein A1 is as defined in any one of embodiments A1 to A52 and B1).

[0411] Embodiment M2 The following formula: [ka] A saturated target of Formula 1 as defined in embodiment B1 in combination with an amount of any one of a marker, impurity, degradative compound having the formula:

[0412] Embodiment M3 The following formula: [ka] A saturated target of Formula 1 as defined in embodiment B1 in combination with an amount of any one of a marker, impurity, degradative compound having the formula:

[0413] Embodiment M4 The following formula: [ka] (In the formula, each R θ and each R ζ A saturated target of Formula 1 as defined in embodiment B1 combined with an amount of any one of a marker, impurity, degradative compound having (wherein R is as defined in embodiment A2).

[0414] Embodiment N1 General procedure for preparation of conserved markers from saturated targets: [ka] (In the ceremony R β , A β , A α and R ζ has the same meaning as defined in embodiment A2).

[0415] Embodiment N2 General procedure for the preparation of storage markers useful for pH-dependent calibration, based on three aqueous compositions of saturated targets, each buffered at a different pH. Three lots of approximately 50 mg of saturated target are each suspended in approximately 2 ml of 2% acetonitrile in water and sonicated for approximately 20 minutes. Approximately 0.1 ml of one of three different buffers is added to each of pH=4, pH=7 and pH=10, respectively. Each of the three buffer solutions is filtered, introduced into a quartz tube, and exposed to natural sunlight for approximately two months. Analysis by HPLC-MS shows the formation of the corresponding storage marker in each solution at pH-related concentrations.

[0416] Embodiment P1 A compound of the formula [ka] or its salt or N-oxide (In the formula, Each R ζ has the same meaning as defined in embodiment A2).

[0417] Embodiment P1a A synthetic intermediate compound for preparing saturated targets of the formula: [ka] or a salt or N-oxide thereof (wherein R ζ has the same meaning as defined in embodiment A2).

[0418] Embodiment P2 A compound of the formula [ka] or a salt or N-oxide thereof.

[0419] Embodiment P2a A synthetic intermediate compound for preparing saturated targets of the formula: [ka] or a salt or N-oxide thereof.

[0420] Embodiment P3 A compound of the formula [ka] or a salt or N-oxide thereof.

[0421] Embodiment P3a A synthetic intermediate compound for preparing saturated targets of the formula: [ka] or a salt or N-oxide thereof.

[0422] Embodiment Q1 A compound of the formula [ka] or its salt or N-oxide (In the formula, Each R ζ has the same meaning as defined in embodiment A2).

[0423] Embodiment Q2 A compound of the formula [ka] or a salt or N-oxide thereof.

[0424] Embodiment Q3 A compound of the formula [ka] or a salt or N-oxide thereof. [Example]

[0425] Preparation A Preparation of N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide as an illustrative example of a synthetic intermediate compound of Embodiment E1 from N-methylpyrrolidone (1-methylpyrrolidin-2-one). For example, 1-methylpyrrolidin-2-one in THF is cooled to and maintained at −75° C. to −78° C. Lithium diisopropylamide in, for example, THF is added.

[0426] The reaction mass is stirred, for example, for about 30 minutes. 1-Fluoro-2-isocyanatobenzene, for example, dissolved in THF, is added dropwise, for example, over a period of about 5 minutes.

[0427] The reaction mass is allowed to warm to ambient temperature and stirred, for example for about 2 hours.

[0428] The reaction mixture is quenched, for example, with saturated NH4Cl and extracted, for example, with ethyl acetate.

[0429] The combined organic layers are washed with saturated NaCl solution, dried, for example, over Na2SO4, and concentrated to give the crude compound.

[0430] The crude compound is purified by column chromatography using, for example, ethyl acetate / hexane as the eluent to give N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide. [ka]

[0431] Examples: 10.08 mmol of 1-methylpyrrolidin-2-one (1 gm) in 10 ml of THF (10 vol) was cooled to 75° C. to 78° C. 20.16 mmol (2.16 gm) of 2M lithium diisopropylamide in 10.1 ml of THF was added at the same temperature of about −75° C. to −78° C.

[0432] The reaction mass was stirred at about -75°C to -78°C for about 30 minutes.

[0433] 10.08 mmol of 1-fluoro-2-isocyanatobenzene (1.4 gm) dissolved in THF (5 ml) was added dropwise over approximately 5 minutes.

[0434] The reaction mass was warmed to about 20° C. to −25° C. and stirred for approximately 2 hours.

[0435] The reaction mixture was quenched with saturated NH4Cl and extracted with ethyl acetate.

[0436] The combined organic layers were washed with saturated NaCl solution, dried over Na2SO4 and concentrated to give the crude compound.

[0437] The crude compound was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as eluent to give 400 mg of N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide as a light brown solid, which approximated a yield of about 17%, and was about 88% pure when analyzed by HPLC. 1 H-NMR(DMSO-d6):δ 10.08(s,1H)8.04-7.98(m,1H),7.29-7.24(m,1H),7.17-7.12(m,2H),3.7 3-3.68(t,8.8Hz,1H),3.39-3.36(m,2H),2.77(s,3H),2.25-2.20(m,2H). LCMS(EI): m / z 237.3 [M+1].

[0438] Preparation B Preparation of the synthetic intermediate N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)pyrrolidine-3-carboxamide as an example of a compound of formula 3 as defined above from N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide. N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide is dissolved in, for example, THF, and then sodium hydride is added thereto at a temperature of, for example, about 0°C to -5°C.

[0439] The reaction mass is stirred, for example, for about 20 minutes, at a temperature of, for example, about 0° C. to −5° C. Diphenyl disulfide, for example dissolved in THF, is then added, for example, at a temperature of, for example, about 0 to 5° C.

[0440] The reaction mass is stirred, for example at about 20°C to 25°C, for example for about 12 hours.

[0441] The reaction mass is quenched with, for example, aqueous NH4Cl and extracted with two lots of, for example, ethyl acetate (twice).

[0442] The combined organic layers are washed with, for example, saturated NaCl solution, dried with, for example, Na2SO4, and concentrated to give the crude compound.

[0443] The crude compound is purified by column chromatography, for example on silica gel, using, for example, ethyl acetate / hexane as eluent to give N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)pyrrolidine-3-carboxamide as a solid. [ka]

[0444] Examples: 21.18 mmol of N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide (5 gm) was dissolved in 50 ml of THF (10 Vol) and 42.37 mmol of sodium hydride (1 g) was added at a temperature of about 0°C to -5°C.

[0445] The reaction mass was stirred for about 20 minutes at a temperature of about 0° C. to −5° C. 25.42 mmol of diphenyl disulfide (5.5 g) dissolved in THF (5 ml) was added at a temperature of about 0 to 5° C.

[0446] The reaction mass was stirred at about 20°C to 25°C for approximately 12 hours.

[0447] The reaction mass was quenched into aqueous NH4Cl solution and extracted with two lots of about 50 ml of ethyl acetate (twice).

[0448] The combined organic layers were washed with saturated NaCl solution, dried over Na2SO4 and concentrated to give the crude compound.

[0449] The crude compound was purified by column chromatography on silica gel using ethyl acetate / hexane as eluent to give 3.8 gm of N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)pyrrolidine-3-carboxamide as an off-white solid, which approximated a yield of about 52% and had a purity of about 98% by LC-MS analysis. 1 H-NMR(DMSO-d6):δ 10.16(s,1H)8.15-8.13(t,8Hz,1H),7.50-7.43(m,3H),7.38-7.34(m,2H),7.24-7.29(m,1H),7.19-7.1 1(m,2H),3.30-3.27(dd,8Hz,1H),3.22-3.25(m,1H),2.81(s,3H)2.70-2.62(m,1H),2.22-2.16(m,1H). LCMS(ES): m / z 345.4 [M+1].

[0450] Preparation C Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide as an example of an unsaturated precursor from N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)pyrrolidine-3-carboxamide. N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)pyrrolidine-3-carboxamide is dissolved in, for example, acetic acid and stirred for, for example, about 20 minutes. Then, for example, meta-chloroperoxybenzoic acid is added portionwise, for example, at ambient temperature. The reaction mass is stirred for, for example, about 2 hours.

[0451] The reaction mass is quenched with, for example, aqueous NaHCO3 solution and extracted twice with, for example, ethyl acetate. The combined organic layers are concentrated to give the crude compound. [ka]

[0452] Examples: 0.29 mol of N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)pyrrolidine-3-carboxamide (100 mg) was dissolved in 2 ml of acetic acid (20 volumes) and stirred for approximately 20 minutes to obtain a substantially clear solution. 0.29 mmol of meta-chloroperbenzoic acid (50 mg mCPBA) was added in portions at approximately 20°C to 25°C. The reaction mass was stirred at approximately 20°C to 25°C for approximately 2 hours. The reaction mass was then quenched with aqueous NaHCO3 and extracted twice with ethyl acetate. The combined organic layers were concentrated to obtain the crude compound. Analysis of the crude material by LC-MS revealed approximately 48% yield of N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide. 1 H-NMR(DMSO-d6):δ 11.16(s,1H),8.41-8.36(dt,8Hz,1H),8.09(s,1H)7.35-7.30(m,1H),7.23-7.12(m,2H),4.26(s,2H),3.03(s,3H).LCMS(EI):m / z 393.4 [M+1].

[0453] Preparation D1 Synthesis of (3S,4S)—N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an exemplary saturated target from the corresponding unsaturated precursor, N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide using trimethylsilyl chloride and BINAP. N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide is dissolved in, for example, diethyl ether, and then copper(I) bromide dimethyl sulfide complex is added, followed by R-BINAP. [ka]

[0454] The reaction mass is stirred, for example, for about 20 minutes. The reaction mass is maintained at a low temperature, for example, at a temperature of about -20°C to -25°C. Trimethylsilyl chloride is added and stirred, for example, for about 10 minutes. Then, for example, a solution of 3-(trifluoromethyl)phenyl)magnesium bromide is added and stirred, for example, for about 2 hours. The reaction mass is quenched, for example, with aqueous NH4Cl solution and extracted, for example, with ethyl acetate. The combined organic layers are washed, for example, with saturated brine solution, dried, for example, with Na2SO4, and concentrated to obtain the crude product. [ka]

[0455] Examples: 2.13 mmol of N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (500 mg) was dissolved in 25 mL of diethyl ether. 0.1 mmol of copper(I) bromide dimethyl sulfide complex (22 mg CuBr.SMe) was added, followed by 0.12 mmol of R-BINAP (approximately 75 mg) at a temperature of approximately -20°C to 25°C.

[0456] The reaction mass was stirred at approximately -20°C to -25°C for about 20 minutes.

[0457] The reaction mass was maintained at about -20°C to -25°C. About 4.7 mmol of trimethylsilyl chloride (about 506 mg) was added and stirred for about 10 minutes. 6.39 mmol of 1.62 M, 3-(trifluoromethyl)phenyl)magnesium bromide solution (1.6 gm, 3.9 ml) was added at a temperature of about -20 to -25°C and stirred for about 2 hours.

[0458] The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate. The combined organic layers were washed with saturated brine solution, dried over Na2SO4, and concentrated to give about 1 g of crude product with a purity of about 54% as determined by quantitative HPLC analysis, representing a crude assay-corrected yield of approximately 77%. 1 H-NMR(DMSO-d6):δ 10.11(s,1H),7.99-7.95(m,1H)7.74(s,1H),7.69-7.68(m,1H),7.63-7.58(m,2H),7.28-7.24(m, 1H),7.15-7.12(m,2H),4.08-4.02(m,2H),3.82-3.77(t,8Hz,1H),3.48-3.47(m,1H),2.84(s,3H). LCMS(ES): m / z 381.5 [M+1].

[0459] Preparation D2 Synthesis of (3S,4S)—N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an exemplary saturated target from N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide as the corresponding unsaturated precursor using trimethylsilyl trifluoromethanesulfonate and (S)—N-((S)-1-(butylamino)-1-oxo-3-phenylpropan-2-yl)-2-(((E)-2-(diphenylphosphaneyl)benzylidene)amino)-3-methylbutanamide as the ligand. [ka]

[0460] 2.13 mmol of N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (500 mg) was dissolved in 25 mL of diethyl ether. 0.1 mmol of copper(I) bromide dimethyl sulfide complex (22 mg CuBr.SMe) was added, followed by 0.12 mmol of (S)-N-((S)-1-(butylamino)-1-oxo-3-phenylpropan-2-yl)-2-(((E)-2-(diphenylphosphanyl)benzylidene)amino)-3-methylbutanamide (76 mg) at 20-25 °C. [ka]

[0461] The reaction mass was stirred for approximately 20 minutes at about 20° C. to 25° C. The reaction mass was cooled and maintained at −20° C. to −25° C. and trimethylsilyl trifluoromethanesulfonate (1 g) was added. [ka] was added and stirred for about 10 minutes.

[0462] 6.39 mmol of 1.62 M, 3-(trifluoromethyl)phenyl)magnesium bromide (1.6 gm, 3.9 ml) [ka] was added at a temperature of about -20 to -25°C and stirred for approximately 2 hours. The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate. The combined organic layers were washed with saturated brine solution, dried over Na2SO4, and concentrated to give the product, which was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as eluent to give 210 mg of (anti)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an off-white solid in approximately 26% yield and with a purity of about 67% as analyzed by HPLC. The product contained a 1:1.32 ratio of enantiomers, such as R, R / S, and S, by chiral HPLC analysis.

[0463] Preparation D3 Synthesis of (3S,4S)—N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an exemplary saturated target, avoiding the use of trimethylsilyl-type Lewis acids such as TMSI, TMSCl, TMSOTf, etc., from N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide as the corresponding unsaturated precursor. 2.13 mmol of N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (500 mg) was dissolved in 25 ml of diethyl ether. 0.12 mmol of R-BINAP (approximately 75 mg) was added at a temperature of approximately 20 to 25°C, and the reaction mass was stirred for approximately 20 minutes. 6.39 mmol of 1.62 M, 3-(trifluoromethyl)phenyl)magnesium bromide (1.6 gm, 3.9 ml) was added at a temperature of approximately -20 to -25°C, and the mixture was stirred for approximately 2 hours.

[0464] The reaction mass was quenched with aqueous NH4Cl and extracted twice with ethyl acetate (2 x 25 mL). The combined organic layers were washed with saturated brine solution, dried over Na2SO4, and concentrated to give 260 mg of crude product, which was (anti)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an off-white solid in 32% yield with a purity of approximately 94% as determined by HPLC.

[0465] Preparation D4 Synthesis of (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an exemplified saturated target from N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide as the corresponding unsaturated precursor using boron trifluoride-diethyl ether complex, BF3.Et2O. 0.42 mmol of N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (100 mg) was dissolved in 5 ml of diethyl ether.

[0466] 0.02 mmol of copper(I) bromide dimethyl sulfide complex (4 mg CuBr.SMe) was added, followed by the addition of 0.02 mmol of BINAP (15 mg) at 20–25 °C.

[0467] The reaction mass was stirred at about 20°C to 25°C for about 20 minutes.

[0468] The reaction mass was cooled and maintained at about -20°C to about -25°C and 0.92 mmol of boron trifluoride diethyl etherate (0.12 mL) was added and stirred for approximately 20 minutes.

[0469] About 1.26 mmol of 3-(trifluoromethyl)phenyl)magnesium bromide (0.78 mL of 1.62 M) was added at about −20° C. to −25° C., and the mixture was stirred for approximately 2 hours.

[0470] The reaction mass was quenched with aqueous NH4Cl and extracted twice with ethyl acetate (2 x 5 mL). The combined organic layers were washed with saturated brine solution, dried over Na2SO4, and concentrated to give 300 mg of crude (anti)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide in greater than 6% yield with a purity of approximately 12% as determined by HPLC.

[0471] Preparation E Preparation of storage markers from three compositions of tetoflurilmet as an exemplary saturation target, each buffered at a different pH. [ka] Approximately 50 mg of each of the three lots of tetflupyrrolimet is suspended in approximately 2 ml of an aqueous solution of 2% acetonitrile and sonicated for approximately 20 minutes.

[0472] To each was added approximately 0.1 ml of a different buffer solution (pH=4, pH=7, and pH=10, respectively).

[0473] Each of the three solutions is filtered, introduced into a quartz tube, and exposed to natural sunlight for approximately two months.

[0474] Analysis by HPLC-MS showed the formation of the storage marker in each solution.

[0475] Solutions buffered at pH 4 and pH 10 contained approximately an order of magnitude higher concentrations of the storage marker compared to the solution buffered at pH=7.

[0476] LC / MS method for saturated target

[0380] and conserved marker-impurity

[0286] Column: Agilent Zorbax Eclipse XDB C18, 150 x 4.6 mm ID, 5.0 μm Injection volume: 5μL Oven temperature: 40°C Detector: UV, λ=230, 250, 280nm Solvent delivery system conditions at 0 ml / min flow rate:

[0477] [Table 1]

[0478] Preparation F Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide from (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide. [ka] Flame-dry a 5 mL round-bottom flask and purge with argon.

[0479] Add 0.009 mmol (2 mg) of Stryker's reagent [(PPh3)CuH]6 as a precatalyst / catalyst and 0.0017 mmol (2 mg) of either (R)-DTBM-SEGPHOS or (S)-(+)-DTBM-SEGPHOS as a precatalyst / catalyst. [ka]

[0480] 1 mL of THF is added, and the solution is cooled to approximately 0°C. 3.36 mmol (224 μL) of polymethylhydrosiloxane (PMHS) is added as a hydride source, e.g., via syringe, followed by 1.81 mmol of t-BuOH (173 μL) and 0.83 mmol of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide (313 mg). The mixture is stirred at approximately 0°C until the reaction is complete, as evidenced by quantitative TLC, typically within 3-12 hours.

[0481] The reaction is quenched by pouring into saturated NaHCO3, diluted with aqueous diethyl ether (Et2O / H2O), and then stirred at ambient temperature for approximately 2 hours.

[0482] The aqueous layer is extracted twice with diethyl ether and the combined organic layers are washed with brine, dried over anhydrous MgSO4, filtered and concentrated by rotary evaporation.

[0483] The resulting crude material is purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as the eluent to give (anti)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an off-white solid in about 70% yield with approximately 90% purity as determined by HPLC. A ratio of about 1:9 enantiomers is typically obtained by chiral HPLC analysis. Depending on the choice of chiral catalyst component, the enantiomeric excess can be directed toward the desired product. This and other specific preparations can also be carried out using alternative reagents and conditions that will be understood by those skilled in these arts to have equivalent function and / or effectiveness.

[0484] Preparation G Synthesis of 1-methyl-2-oxopyrrolidine-3-carboxylic acid: [ka] 50.5 mmol of 1-methylpyrrolidin-2-one (5 g) was dissolved in 50 ml of THF (10 volumes) and cooled to and maintained at approximately -75°C to -78°C.

[0485] 101 mmol of 2M lithium diisopropylamide (10.2 gm, 50 ml) was added at about -75 to -78°C. The reaction mass was stirred at -75 to -78°C for approximately 30 minutes. The reaction mass was added dropwise onto solid CO2 and stirred for about 1 hour. The reaction mass was gradually warmed to about 20 to 25°C and stirred for about 1 hour. The reaction mixture was quenched with dilute HCl, extracted with 10% isopropyl alcohol in dichloromethane (4 x 25 ml), dried over Na2SO4 and concentrated to give 2.2 gm of crude product.

[0486] 1-Methyl-2-oxopyrrolidine-3-carboxylic acid was obtained as a brown oil in 30.5% yield and approximately 58% purity by HPLC.

[0487] Preparation H Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide using propylphosphonic anhydride (T3P) [ka] 6.99 mmol of 1-methyl-2-oxopyrrolidine-3-carboxylic acid (1 g) was dissolved in 20 ml of dimethylformamide (20 vol) and cooled to approximately 0-5°C. 20.97 mmol of triethylamine (2.1 g) and 7.68 mmol of 2-fluoroaniline (850 mg) were added, followed by 13.98 mmol of T3P (9 ml of a 50% solution in EtOAc) at 0-5°C. The reaction mass was stirred at approximately 0-5°C for approximately 2 hours. The reaction mass was added to water and extracted with 2 x 150 ml of ethyl acetate. The combined organic layers were washed with water followed by brine solution, dried over sodium sulfate, and concentrated to give the crude product. The crude product was dissolved in 5 ml of dichloromethane and precipitated with 20 ml of n-heptane, and the resulting solid was stirred and filtered to give 700 mg of N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide as an off-white solid in 42.4% yield with a purity of approximately 99% by HPLC analysis.

[0488] Preparation I Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide via acyl chloride [ka] 13.98 mmol of 1-methyl-2-oxopyrrolidine-3-carboxylic acid (2 g) was dissolved in 20 ml of dichloromethane (10 vol). 2.73 mmol of dimethylformamide (0.2 ml) was added and cooled to about 0-5°C. 20.97 mol of oxalyl chloride (2.6 g) was added at about 0-5°C. The reaction mass was stirred at about 0-5°C for approximately 2 hours. Acyl chloride formation was monitored by TLC by quenching in ethyl alcohol.

[0489] The reaction mass was concentrated to dryness, diluted with fresh dichloromethane and added to a stirred solution of 13.98 mmol of 2-fluoroaniline (1.5 gm) and 27.96 mmol of triethylamine (2.8 g) in 10 ml of dichloromethane (5 volumes) at about 0°C to 5°C.

[0490] The reaction mass was warmed to about 20°C-25°C and stirred for approximately 2 hours. The reaction mass was quenched with water and extracted with dichloromethane (2 x 150 ml). The combined organic layers were washed with water followed by brine solution, dried over sodium sulfate and concentrated to give the crude product. 500 mg of N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide was obtained. Yield 15.1%, purity 88.8% by LCMS.

[0491] Preparation J Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylselenyl)pyrrolidine-3-carboxamide [ka] 63.5 mmol (15 g) of N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide was dissolved in 60 ml of THF. 127.1 mmol of NaH (3.0 g) was added at about 0-5°C. The reaction mass was stirred at about 0-5°C for approximately 20 minutes. 69.9 mmol of phenylselenyl bromide (16.5 g) dissolved in THF was added at about 0-5°C and stirred at 0-5°C for approximately 2 hours. The reaction mass was quenched into ice-cold water and extracted with ethyl acetate. The combined organic layers were concentrated to give the crude compound, which was purified by column chromatography on silica gel using ethyl acetate / hexane as the eluent to give 24 g of N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylselenyl)pyrrolidine-3-carboxamide as an off-white solid. Yield=96%, purity=97.1% by LCMS. 1 H-NMR(DMSO-d6):δ 10.26(s,1H),8.20-8.16(m,1H),7.59-7.56(m,2H),7.47-7.43(m,1H),7.35-7.31(m,2H),7.27-7.22(m,1H),7.19-7.1 5(m,1H),7.13-7.11(m,1H),3.30-3.25(m,1H),3.18-3.12(m,1H),2.77(s,3H),2.55-2.64(m,1H),2.18-2.13(m,1sH). LCMS(EI):m / z 393.4(M+1).

[0492] Preparation K A process scheme starting from the compound of Embodiment E1 via the compound of Embodiment C1a, then starting from the compound of Embodiment E1 via the unsaturated precursor compound of Embodiment A1 or Embodiment A2, and thence using a saturated target exemplified by, but not limited to, tetflupyrrolimet. Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide [ka] 38.2 mmol of N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylselanyl)pyrrolidine-3-carboxamide (15 g) was dissolved in 150 ml of dichloromethane (10 volumes of MDC). 76.5 mmol of HO (2.6 ml) was added at approximately 0-5°C. The reaction mass was stirred at 0-5°C for approximately 2 hours. The reaction mass was quenched with ice-cold saturated NaHCO solution. The resulting solid was stirred, filtered, and dried under vacuum. The resulting solid was suspended in 150 ml of n-heptane, stirred, filtered, and dried to give 7.1 g of N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (unsaturated precursor) as an off-white solid. Yield=79.3%, purity=98.1% by LCMS. 1 H-NMR(DMSO-d6):δ 11.16(s,1H),8.41-8.36(dt,8Hz,1H),8.09(s,1H)7.35-7.30(m,1H),7.23-7.12(m,2H),4.26(s,2H),3.03(s,3H).LCMS(EI):m / z 393.4 [M+1].

[0493] Preparation L Tetoflupyrrolimet Polymorphic Form I Preparation of polymorphs: [ka] (3R,4S)-1-Methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxylic acid (21.2 g, 73.8 mmol) (WO 2018 / 175226) was dissolved in acetonitrile (200 mL), and 2-fluoroaniline (9.02 g, 81.2 mmol) and N-methylimidazole (30.3 g, 369 mmol) were added to the solution. The resulting mixture was stirred at ambient temperature for 10 minutes, and chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (22.8 g, 81.2 mmol) was added to the mixture in one portion. The resulting mixture was stirred at ambient temperature for 10 hours, then the solvent was evaporated and the residue was dissolved in dichloromethane (500 mL), washed with saturated aqueous sodium sulfate (2×100 mL) and brine (1×100 mL), dried and concentrated under reduced pressure to give the crude product, which was recrystallized from tert-butyl methyl ether (20 mL) to give (3S,4S)—N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide (10.1 g, 36%) with a chiral enantiomeric ratio of greater than 99:1 by chiral HPLC.

[0494] Preparation M (Tetoflurilpyrrolimet Polymorphic Form II) [ka] In a 50 mL two-neck round-bottom flask, N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (500 mg, 2.13 mmol) was dissolved in dry diethyl ether (25 mL) and CuBr.SMe (22 mg, 0.1 mmol) was added, followed by 2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene (79 mg, 0.12 mmol) at ambient temperature. The reaction mass was stirred at ambient temperature for 20 minutes. The reaction mass was cooled to -20 to -25 °C using dry ice / acetonitrile, and trimethylsilyl trifluoromethanesulfonate (1 gm, 4.68 mmol) was added and stirred for 20 minutes. 1.62 M 3-(trifluoromethyl)phenyl)magnesium bromide was added via a 5 mL syringe (1.6 gm, 6.39 mmol 3.9 ml) at −20 to −25° C. and stirred for 2 hours, at which point TLC analysis indicated the reaction was complete (30:70 ethyl acetate:hexane, R of starting material 0.3). f , R f Product 0.5). The reaction mass was quenched into aqueous NH4Cl (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated brine solution (100 mL), dried over Na2SO4, and concentrated in a 250 mL round-bottom flask by rotating at 60 rpm under 600 mmHg vacuum at 40 °C for 30 min to give the crude product (1 g), which was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane (20:80) as the eluent. The resulting solid was triturated with heptane (5 mL) to give 360 ​​mg of anti-(3,4)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an off-white solid (44.3% yield, 94.6% purity by HPLC) with a chiral enantiomeric ratio of 50.5:49.4 by chiral HPLC.

[0495] Preparation N Synthesis of 4-ethyl-N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide using organozinc. [ka] (S)-N-((S)-1-(butylamino)-1-oxo-3-phenylpropan-2-yl)-2-(((E)-2-(diphenylphosphaneyl)benzylidene)-amino)-3-methylbutanamide (75 mg, 0.12 mmol) and copper(I) trifluoromethanesulfonate benzene complex (CuOTf) CH (25 mg, 0.05 mmol) were dissolved in toluene (6 mL, 20 volumes), N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (300 mg, 1.28 mmol) was added, and the mixture was stirred at 20-25 °C for 10 min. The reaction mass was cooled to -35 to -30 °C, and diethylzinc (3.84 mL, 1 M, 3 equiv.) was added to the reaction mixture. The reaction mass was kept stirring at -35 to 30°C for 4 hours. The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with saturated brine solution, dried over Na2SO4, and concentrated to give the crude product, which was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as eluent to give 120 mg of 4-ethyl-N-(2-fluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide as an off-white solid (yield 35.5%, purity 88.9% HPLC and 58.3% LCMS purity) with a chiral enantiomeric ratio of 49.4:49.4 by chiral HPLC. LCMS(ES): m / z 265.2(M+1).

[0496] Preparation O Synthesis of N-(2,3-difluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide using propylphosphonic anhydride (T3P). [ka] 1-Methyl-2-oxopyrrolidine-3-carboxylic acid (5 g, 34.9 mmol) was dissolved in dimethylformamide (20 ml, 4 volumes) and cooled to 0°-5°C. Triethylamine (10.5 g, 103.9 mmol), 2,3-difluoroaniline (4.9 g, 37.9 mmol), followed by T3P propylphosphonic anhydride (44 g, 138.3 mmol; 50% solution in EtOAc) were added at 0°-5°C. The reaction mass was stirred at 0°-5°C for 2 hours. The reaction mass was added to water and extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with water followed by brine solution, dried over sodium sulfate, and concentrated to give a solid.

[0497] To this was added solid heptane (10 volumes), stirred for 1 hour, filtered and dried under vacuum to give 8 g of N-(2,3-difluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide as an off-white solid in 90.9% yield and 98.9% purity by LCMS. 1 H NMR(DMSO-d6):δ 10.27(s,1H),7.95-7.77(m,1H),7.21-7.16(m,2H),3.74-3.69(t,18Hz,1H),3.43-3.32(m,2H),2.89(s,3H),2.32-2.20(m,2H).LCMS(EI):m / z 255.2(M+1).

[0498] Preparation P Synthesis of N-(2,3-difluorophenyl)-1-methyl-2-oxo-3-(phenylselanyl)pyrrolidine-3-carboxamide: [ka] N-(2,3-difluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide (2 g, 7.8 mmol) was dissolved in THF (20 ml) and NaH (0.629 g, 26.2 mmol) was added at 0-5°C. The reaction mass was stirred at 0-5°C for 20 minutes. Phenylselenyl bromide (2 g, 8.5 mmol) dissolved in THF (5 mL) was added at 0-5°C and stirred for 2 hours. The reaction mass was quenched in cold water and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were concentrated to give the crude compound, which was purified by column chromatography on silica gel using ethyl acetate / hexane as the eluent to give 2.2 g of N-(2,3-difluorophenyl)-1-methyl-2-oxopyrrolidine-3-carboxamide as a pale yellow solid. Yield 68.7%, purity 98.2% by LCMS. 1H NMR(DMSO-d6):δ 10.4(s,1H),7.99-7.94(m,1H),7.58-7.56(m,2H),7.47-7.43(m,1H),7.35-7.31(m,2H),7.20-7.12(m ,2H),3.31-3.27(m,1H),3.18(m,1H),2.79(s,3H),2.64-2.55(m,1H),2.18-2.13(m,1H).LCMS(EI):m / z 411.2(M+1).

[0499] Preparation Q Synthesis of N-(2,3-difluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide [ka] N-(2,3-Difluorophenyl)-1-methyl-2-oxo-3-(phenylselenyl)pyrrolidine-3-carboxamide (2 g, 4.8 mmol) was dissolved in dichloromethane (20 ml, 10 volumes) and HO (1.1 g, 32.3 mmol; 30% solution) was added at 0-5 °C. The reaction mass was stirred at 0-5 °C for 2 hours. The reaction mass was quenched into ice-cold saturated NaHCO solution and extracted with dichloromethane (2 × 50 mL). The organic layer was washed with NaHCO solution (3 × 20 mL), dried over NaSO, and concentrated to give the crude product. The crude compound was suspended in IPA (5 mL) and stirred for 2 h, and the solid was filtered and dried to give 1 g of N-(2,3-difluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide as a pale yellow solid (83.3% yield, 96.1% purity by LCMS). 1H NMR(CDCl3):δ 11.1(s,1H),8.24-8.20(m,1H),8.0-7.99(bt,1.6Hz,1H)7.10-7.03(m,1H),6.99-6.90(m,1H),4.12-4.11(bd,2H),3.16(s,3H).LCMS(EI):m / z 253.2(M+1).

[0500] Preparation R Synthesis of N-(2,3-difluorophenyl)-1-methyl-2-oxo-4-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidine-3-carboxamide. [ka] In a 25 mL two-necked round-bottom flask, 5-bromo-2-(trifluoromethyl)pyridine (0.80 g, 3.57 mmol) was dissolved in dry diethyl ether (8 mL, 10 volumes). The reaction mass was cooled to -78 to -70 °C, and n-butyllithium (4.26 mL, 2.5 M, 3 equiv.) was added to the reaction mixture. The reaction mass was stirred at -78 to 70 °C for 1 hour. In a separate flask, N-(2,3-difluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (0.3 g, 1.19 mmol), copper(I) bromide dimethyl sulfide complex (12.2 mg, 0.059 mmol), and 2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene (44.4 mg, 0.071 mmol) in EtO (9 mL, 30 vol) were taken and added, and the reaction mixture was cooled to -78 to 70 °C. To this reaction mass, lithiated 5-bromo-2-(trifluoromethyl)pyridine was added dropwise at -78 to 70 °C and stirred for 1 hour. The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with saturated brine solution, dried over NaSO and concentrated to give the crude product, which was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as eluent to give 60 mg of N-(2,3-difluorophenyl)-1-methyl-2-oxo-4-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidine-3-carboxamide as a pale yellow solid in 12.7% yield and 67.1% purity by LCMS. 1H NMR(CDCl3):δ 10.06(s,1H),7.96-7.89(m,2H),7.03-6.99(m,2H),6.93- 6.89(m,2H),4.21-4.18(m,1H),3.87-3.82(m,1H),3.65-3.63(m,1H),3.54-3.49(m,1H),3.05(s,3H).LCMS(ES):m / z 400.3(M+1).

[0501] Preparation S Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidine-3-carboxamide [ka] In a 25 mL two-necked round-bottom flask, 5-bromo-2-(trifluoromethyl)pyridine (0.84 g, 3.73 mmol) was dissolved in dry diethyl ether (8 mL, 10 volumes). The reaction mass was cooled to -78 to -70 °C, and n-butyllithium (4.4 mL, 2.5 M, 3 equiv.) was added to the reaction mixture. The reaction mass was stirred at -78 to 70 °C for 1 hour. In a separate flask, N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (0.3 g, 1.28 mmol), copper(I) bromide dimethyl sulfide complex (13 mg, 0.063 mmol), and 2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene (47 mg, 0.075 mmol) were taken in EtO (9 mL, 3 volumes) and the reaction mixture was cooled to -78 to 70 °C. To this reaction mass (RM), lithiated 5-bromo-2-(trifluoromethyl)pyridine was added dropwise at -78 to 70 °C and stirred for 1 hour. The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with saturated brine solution, dried over NaSO and concentrated to give the crude product, which was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as eluent to give 50 mg of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidine-3-carboxamide as an oily liquid (yield 10.2%, purity 49.1% by LCMS). LCMS(ES): m / z 382.3(M+1).

[0502] Preparation T Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide from N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide (Procedure 1) [ka] In a 25 mL round-bottom flask (RBF), N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide (100 mg, 0.26 mmol) was dissolved in acetic acid (5 ml, 50 volumes). The reaction mass was cooled to 0-5 °C and Zn powder (0.17 g, 2.64 mmol) was added. The RM was stirred at 20-25 °C for 12 h. The RM was filtered and concentrated to give the crude product. Crude LCMS showed 30.6% anti-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide. LCMS(ES): m / z 381.3(M+1).

[0503] Preparation U Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide from N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide (Preparation Procedure No. 2) [ka] N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide (50 mg, 0.13 mmol) was dissolved in methanol (5 ml, 50 volumes) in a 25 mL RBF. The reaction mass was cooled to 0-5 °C and nickel(II) chloride hexahydrate (15 mg, 0.06 mmol) was added, followed by sodium borohydride (5 mg, 0.13 mmol). The RM was stirred at 20-25 °C for 12 h. The reaction was monitored by LCMS. LCMS showed formation of approximately 15% of the desired mass. LCMS(ES): m / z 381.3(M+1).

[0504] Preparation V Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide from N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide [ka] N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide (50 mg, 0.13 mmol) was dissolved in methanol (5 mL, 50 volumes) in a 25 mL RBF, and tris(triphenylphosphine)rhodium(I) chloride (12 mg, 0.013 mmol) was added. The RM was stirred under H pressure. A hydrogen bladder was used to pressurize the mixture at 20-25 °C for 12 h. LCMS was used to monitor the reaction. The RM was quenched with 2 N NaOH solution (0.2 mL), extracted with ethyl acetate (2 × 5 mL), and concentrated to give the crude product. Crude LCMS indicated formation of approximately 10% of the desired mass. LCMS(ES): m / z 381.2(M+1).

[0505] Preparation W Synthesis of (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide from N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (procedure-number 3). [ka] In a 25 mL two-neck RBF, 1-bromo-3-(trifluoromethyl)benzene (0.28 g, 1.28 mmol) was dissolved in diethyl ether (3 mL, 10 volumes). The reaction mass was cooled to -78 to -70 °C, and n-butyllithium (1.02 mL, 2.5 M, 2 equiv.) was added to the reaction mixture. The RM was stirred at -78 to 70 °C for 1 h. This lithiated solution was used for the reaction with N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (Intermediate

[0234] ). In a separate flask, N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (0.1 g, 0.427 mmol), copper bromide dimethyl sulfide complex (4 mg, 0.021 mmol), and (S)—N-((S)-1-(butylamino)-1-oxo-3-phenylpropan-2-yl)-2-(((E)-2-(diphenylphosphaneyl)benzylidene)amino)-3-methylbutanamide (15 mg, 0.025 mmol) in EtO (5 mL) were taken and cooled to −78 to 70° C. To this reaction mass was added lithiated 1-bromo-3-(trifluoromethyl)benzene at −78 to 70° C. and stirred for 4 hours. The reaction was monitored by LCMS and TLC. TLC showed the formation of a new spot, and LCMS showed the presence of the desired mass. The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with saturated brine solution and dried over Na2SO4. The organic layer was concentrated under reduced pressure below 45 °C to give the crude product. The crude product obtained was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as the eluent. 30 mg of anti-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide was obtained as a pale yellow solid (yield 18.5%, purity 30.9% by LCMS). LCMS(ES): m / z 381.2(M+1).

[0506] Preparation Synthesis of (3S,4S)—N-(2,3-difluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide. [ka] In a 25 mL two-neck RBF, 1-bromo-3-(trifluoromethyl)benzene (0.8 g, 3.57 mmol) was dissolved in dry diethyl ether (10 mL, 12.5 volumes). The reaction mass was cooled to -78 to -70 °C, and then n-butyllithium (2.8 mL, 2.5 M, 2 equiv.) was added to the reaction mixture. The RM was stirred at -78 to -70 °C for 1 h. This lithiated solution was used for the reaction with N-(2,3-difluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (Intermediate

[0252] ).

[0507] In a separate flask, N-(2,3-difluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (0.3 g, 1.19 mmol), copper bromide dimethyl sulfide complex (12 mg, 0.059 mmol), and (S)-N-((S)-1-(butylamino)-1-oxo-3-phenylpropan-2-yl)-2-(((E)-2-(diphenylphosphaneyl)benzylidene)amino)-3,3-dimethylbutanamide (43 mg, 0.071 mmol) were taken in EtO (6 mL, 20 volumes). The resulting reaction mass was cooled to -78 to 70 °C, followed by the addition of lithiated 1-bromo-3-(trifluoromethyl)benzene at -78 to 70 °C. The reaction mass was then stirred at -78 to 70°C for 4 hours, after which the reaction mass was warmed to 20 to 25°C and maintained at 20 to 25°C for 12 hours. The reaction mass was monitored by TLC and LCMS. TLC showed the formation of a new spot, and LCMS similarly showed the formation of the desired mass. The reaction mass was then quenched with saturated aqueous NH4Cl, followed by extraction with ethyl acetate (3 x 25 mL). The combined ethyl acetate layers were washed with saturated brine solution and dried over Na2SO4. The ethyl acetate was then evaporated under reduced pressure below 45°C to obtain the crude compound. The resulting crude product was then purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as the eluent. 55 mg of N-(2,3-difluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide was obtained as a pale yellow solid (11.2% yield, 72.3% purity by LCMS). LCMS(ES):m / z 399(M+1).

[0508] Preparation Y Synthesis of N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxopyrrolidine-3-carboxamide using propylphosphonic anhydride (T3P) [ka] 1-Methyl-2-oxopyrrolidine-3-carboxylic acid (5 g, 34.9 mmol) was dissolved in dimethylformamide (20 mL, 4 volumes) and cooled to 0-5°C. Triethylamine (10.5 g, 103.9 mmol), 2,6-difluoropyridin-3-amine (5 g, 38.4 mmol), followed by propylphosphonic anhydride (T3P) (44 g, 138.3 mmol; 50% solution in EtOAc) were added at 0-5°C. The reaction mass was stirred at 0-5°C for 2 hours. The reaction mass was added to water and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with water followed by brine solution. The organics were dried over sodium sulfate and concentrated to give a solid.

[0509] To this solid was added 10 V of n-heptane (10 volumes) and stirred for 1 hour. The solid was then filtered and dried under vacuum to give 5.5 g of N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxopyrrolidine-3-carboxamide as an off-white solid (61.7% yield, 91.6% purity by LCMS). 1 H NMR(DMSO-d6):δ 10.30(s,1H),8.60-8.54(m,1H),7.19-7.16(m,1H),3.71-3.67(t,18Hz,1H),3.43-3.32(m,2H),2.89(s,3H),2.31-2.20(m,2H).LCMS(EI):m / z 256.2(M+1).

[0510] Preparation Z Synthesis of N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxo-3-(phenylselanyl)pyrrolidine-3-carboxamide [ka] To a stirred solution of NaH (1.25 g, 52.08 mmol) in THF (10 mL) at 0-5 °C, N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxopyrrolidine-3-carboxamide (4 g, 15.68 mmol) dissolved in THF (20 mL) was added. The reaction mass was stirred at 0-5 °C for 20 minutes. Phenylselenyl bromide (4.07 g, 17.25 mmol) dissolved in THF (10 mL) was added at 0-5 °C and stirred for 2 hours. The reaction mass was quenched into cold water and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were concentrated to give the crude compound, which was purified by column chromatography on silica gel using ethyl acetate / hexane as eluent to give 4.2 g of N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxo-3-(phenylselanyl)pyrrolidine-3-carboxamide as a pale yellow solid in 65.6% yield and 99.2% purity by LCMS. 1H NMR(DMSO-d6):δ 10.23(brs,1H),8.71-8.64(m,1H),7.59-7.56(m,2H),7.47-7.43(m,1H),7.35-7.31(m,2H),7.19-7.16(m, 1H),3.39-3.28(m,1H),3.24-3.18(m,1H),2.79(s,3H),2.63-2.55(m,1H),2.19-2.14(m,1H).LCMS(EI):m / z 412.2(M+1).

[0511] Preparation AA Synthesis of N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide: [ka] N-(2,6-Difluoropyridin-3-yl)-1-methyl-2-oxo-3-(phenylselenyl)pyrrolidine-3-carboxamide (4 g, 9.73 mmol) was dissolved in dichloromethane (40 mL, 10 volumes) and HO (2.2 g, 64.8 mmol; 30% aqueous solution) was added at 0-5 °C. The reaction mass was stirred at 0-5 °C for 2 h. The reaction mass was quenched with a saturated solution of NaHCO at 0-5 °C, followed by extraction with dichloromethane (2 × 100 mL). The organic layer was washed with NaHCO solution (4 × 50 mL), dried over anhydrous NaSO, and concentrated to give the crude product. The crude compound was suspended in IPA (5 mL) and stirred for 2 h, and the solid was filtered and dried to give 1.5 g of N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide as a pale yellow solid in 62.5% yield and 91.6% purity by LCMS. 1H NMR(CDCl3):δ 11.1(s,1H),8.98-8.92(m,1H),8.0(s,1H),6.83(m,1H)4.13(s,2H),3.15(s,3H).LCMS(EI):m / z 254.2(M+1).

[0512] Preparation AB Synthesis of (3R,4R)-N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxo-4-(4-(trifluoromethyl)phenyl)-pyrrolidine-3-carboxamide: [ka] In a 25 mL two-neck RBF, N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (300 mg, 1.18 mmol) was dissolved in dry diethyl ether (10 mL), and CuBr.SMe (12 mg, 0.05 mmol) was added, followed by (R)-2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene (44 mg, 0.071 mmol) at 20-25 °C. The reaction mass was stirred for 20 min at 20-25 °C. The reaction mass was cooled to -20 to -25 °C using dry ice / acetonitrile, and trimethylsilyl trifluoromethanesulfonate (0.57 g, 2.6 mmol) was added and stirred for 20 min. 4-(trifluoromethyl)phenyl)magnesium bromide (2.2 mL, 1.6 M) was added at −20 to −25° C. and stirred for 2 h, at which point TLC analysis indicated the reaction was complete (50:50 ethyl acetate:hexane, R f Starting material = 0.3, R f Product = 0.5. The reaction mass was quenched into aqueous NH4Cl (20 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with saturated brine solution (100 mL), dried over Na2SO4, and concentrated to give the crude product, which was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane (20:80) as eluent to give 120 mg of (3R,4R)-N-(2,6-difluoropyridin-3-yl)-1-methyl-2-oxo-4-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as a pale yellow solid (24.6% yield, 89.8% purity by LCMS) with a chiral enantiomeric ratio of 47.5:47.8 by chiral HPLC. 1H NMR(CDCl3):δ 10.07(s,1H),8.76-8.69(m,1H)7.66-7.64(m,2H),7.51-7.48(m,2H),6.79-6.76(m,1H),4.16-4.09 (m,1H),3.83-3.79(m,1H),3.65-3.62(d,9.6Hz,1H),3.50-3.56(m,1H),3.07(s,3H).LCMS(ES):m / z 400.3(M+1).

[0513] Preparation AC Synthesis of 1-benzyl-N-(2-fluorophenyl)-2-oxopyrrolidine-3-carboxamide using propylphosphonic anhydride (T3P). [ka] 1-Benzyl-2-oxopyrrolidine-3-carboxylic acid (3 g, 13.69 mmol) (see WO 2010 / 142801) was dissolved in dimethylformamide (15 mL, 5 volumes) and cooled to 0-5°C. Triethylamine (4.15 g, 41.0 mmol), 2-fluoroaniline (1.67 g, 15.06 mmol), followed by propylphosphonic anhydride (T3P) (8.7 g, 27.36 mmol; 50% solution in EtOAc) were added at 0-5°C. The reaction mass was stirred at 0-5°C for 2 hours. The reaction mass was added to water and extracted with ethyl acetate (2 x 100 ml). The combined organic layers were washed with water followed by brine solution, dried over sodium sulfate, and concentrated to give a solid. Heptane (10 vol) was added to the solid, stirred for 1 hour, filtered, and dried under vacuum to give 4.0 g of 1-benzyl-N-(2-fluorophenyl)-2-oxopyrrolidine-3-carboxamide as an off-white solid in 95.2% yield and 94.6% purity by LCMS. 1H NMR(DMSO-d6):δ 10.12(s,1H),8.06-8.01(m,1H),7.37-7.30(m,2H),7.28-7.24(m,4H),7.20-7.14( m,2H),4.44(s,2H),3.85-3.81(t,J=8Hz,1H),3.36-3.22(m,2H),2.31-2.22(m,2H). LCMS(EI):m / z 313.3(M+1).

[0514] Preparation AD Synthesis of 1-benzyl-N-(2-fluorophenyl)-2-oxo-3-(phenylselanyl)pyrrolidine-3-carboxamide: [ka] To a stirred solution of NaH (974 mg, 40.59 mmol) in THF (10 mL) at 0-5 °C was added 1-benzyl-N-(2-fluorophenyl)-2-oxopyrrolidine-3-carboxamide (3.8 g, 12.17 mmol) dissolved in THF (20 mL, 5.2 volumes). The reaction mass was stirred at 0-5 °C for 20 minutes. Phenylselenyl bromide (3.16 g, 13.39 mmol) dissolved in THF (10 mL) was added at 0-5 °C and stirred for 2 hours. The reaction mass was quenched into cold water and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were concentrated to give the crude compound, which was purified by column chromatography on silica gel using ethyl acetate / hexane as eluent to give 5.1 g of 1-benzyl-N-(2-fluorophenyl)-2-oxo-3-(phenylselenyl)pyrrolidine-3-carboxamide as a pale yellow solid (89.4% yield, 98.6% purity by LCMS). 1H NMR (DMSO-d6): δ 10.12(brs,1H),8.33-8.29(t,J=8Hz,1H),7.61-7.59(m,2H),7.40-7.30(m,8H),7.12-7.10(m,3H),4.56- 4.41(dd,2H),3.26-3.12(m,2H),2.68-2.60(m,1H),2.28-2.22(m,1H). LCMS(EI):m / z 469.3(M+1).

[0515] Preparation AE Synthesis of 1-benzyl-N-(2-fluorophenyl)-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide: [ka] 1-Benzyl-N-(2-fluorophenyl)-2-oxo-3-(phenylselanyl)pyrrolidine-3-carboxamide (5 g, 10.68 mmol) was dissolved in dichloromethane (50 mL, 10 volumes) and HO (2.4 g, 71.22 mmol; 30% solution) was added at 0-5 °C. The reaction mass was stirred at 0-5 °C for 2 hours. The reaction mass was quenched into ice-cold saturated NaHCO solution and extracted with dichloromethane (3 × 100 mL). The organic layer was washed with NaHCO solution (2 × 100 mL), dried over NaSO, and concentrated to give the crude product. The crude compound was suspended in IPA (10 mL, 2 volumes) and stirred for 2 hours, and the solid was filtered and dried to give 2.2 g of 1-benzyl-N-(2-fluorophenyl)-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide as an off-white solid in 66.6% yield and 94.4% purity by LCMS. LCMS(EI):m / z 311.2(M+1).

[0516] Preparation AF Synthesis of (3S,4S)-1-benzyl-N-(2-fluorophenyl)-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide [ka] In a 25 mL two-neck RBF, 1-benzyl-N-(2-fluorophenyl)-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (300 mg, 0.96 mmol) was dissolved in dry diethyl ether (9 mL) and added with CuBr.SMe (mg, mmol) followed by (R)-2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene (10 mg, 0.04 mmol) at 20-25 °C. The reaction mass was stirred for 20 min at 20-25 °C. The reaction mass was cooled to -20 to -25 °C using dry ice / acetonitrile, and trimethylsilyl trifluoromethanesulfonate (0.46 g, 2.1 mmol) was added and stirred for 20 min. (3-(trifluoromethyl)phenyl)magnesium bromide (1.8 mL, 1.6 M) was added at −20 to −25° C. and stirred for 2 h. The reaction mass was quenched into aqueous NH4Cl (20 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with saturated brine solution (100 mL), dried over Na2SO4, and concentrated to give the crude product, which was purified by column chromatography on silica gel (60–120 mesh) using ethyl acetate / hexane as eluent to give 50 mg of 1-benzyl-N-(2-fluorophenyl)-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an oily liquid. Yield 16.6%, purity 42.5% by LCMS. 1H NMR(DMSO-d6):δ 10.15(s,1H),8.0-7.97(m,1H)7.69(s,1H),7.65-7.56(m,3H),7.39-7.35(m,2H),7.32-7.30(m,4H),7.29-7.24(m, 2H),4.54-4.42(m,2H),4.19-4.17(m,1H),4.10-4.08(q,J=8Hz,1H),3.80--3.75(t,J=12Hz,1H),3.48-3.46(m,1H). LCMS(ES): m / z 457.3(M+1).

[0517] preparation ag Synthesis of (3S,4R)-N-(2,3-difluorophenyl)-1-methyl-4-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-2-oxopyrrolidine-3-carboxamide [ka] In a 25 mL two-neck RBF, 3-bromo-1-methyl-5-(trifluoromethyl)-1H-pyrazole (810 mg, 3.57 mmol) was dissolved in dry diethyl ether (10 mL, 12.5 volumes). The reaction mass was cooled to -78 to -70 °C, and n-butyllithium (4.28 mL, 2.5 M, 3.0 equiv.) was added to the reaction mixture. The RBF was stirred at -78 to 70 °C for 1 h. In a separate flask, N-(2,3-difluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (300 mg, 1.19 mmol), copper(I) bromide dimethyl sulfide complex (12 mg, 0.059 mmol), and 2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene (44 mg, 0.071 mmol) were taken in dry diethyl ether (9 mL, 30 volumes) and the reaction mixture was cooled to -78 to 70 °C. To this RM, lithiated N-(2,3-difluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide was added dropwise at -78 to 70 °C and stirred for 1 hour. The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with saturated brine solution, dried over Na2SO4, and concentrated to give the crude product, which was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as eluent to give 30 mg of (3S,4R)-N-(2,3-difluorophenyl)-1-methyl-4-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-2-oxopyrrolidine-3-carboxamide as a colorless liquid together with its enantiomer in 6% yield and 43.2% purity by LCMS. LCMS(ES): m / z 403.3(M+1).

[0518] Preparation AH Synthesis of (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide using (CuOTf)2.C6H6 N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (500 mg, 2.13 mmol) was dissolved in dry diethyl ether (20 mL, 4 volumes), and copper(I) bromide dimethyl sulfide complex (22 mg, 0.1 mmol) and (S)-N-((S)-1-(butylamino)-1-oxo-3-phenylpropan-2-yl)-2-(((E)-2-(diphenylphosphaneyl)benzylidene)amino)-3-methylbutanamide (76 mg, 0.12 mmol) were added at 20-25 °C and stirred for 20 min at 20-25 °C. The reaction mass was cooled to -17 to -23 °C, and trimethylsilyl trifluoromethanesulfonate (1 g, 4.68 mmol) was added and stirred for 10 min. (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide was added at -17 to -23 °C and stirred for 2 h. The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with saturated brine solution, dried over Na2SO4, and concentrated to give 960 mg of crude (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as a colorless liquid with a chiral enantiomeric ratio of 1:1.43 (excess S,S enantiomer) according to chiral HPLC. [ka]

[0519] Preparation AI Synthesis of 1-methylpiperidin-2-one [ka] Sodium hydride (9.0 g, 378.7 mmol) in THF (50 mL, 5.5 vol) was taken at 0-5 °C and piperidin-2-one (25 g, 252.5 mmol) was added and dissolved in THF (50 mL, 10 vol). After stirring for 30 minutes, methyl iodide (89.5 g, 631.3 mmol) was added dropwise to the reaction mixture. The RM was slowly warmed to 20-25 °C and stirred for 6 hours. The reaction mass was quenched with dilute HCl and extracted with 10% MeOH:DCM (2 x 250 mL). The combined organic layers were dried over sodium sulfate and concentrated to give the crude compound, which was purified by column chromatography on silica gel using ethyl acetate / hexane as the eluent to give 27.0 g of 1-methylpiperidin-2-one as a colorless liquid (yield 94.7%, purity 94.5% by LCMS). 1H NMR (DMSO-d6): δ 3.23-3.20(m,1H),2.78(s,3H),2.18-2.15(t,Jis 12Hz,2H),1.73-1.65(m,4H). LCMS(EI):m / z 114.0(M+1).

[0520] Preparation AJ Synthesis of 1-methyl-2-oxopiperidine-3-carboxylic acid: [ka] Sodium hydride (5.3 g, 221.23 mmol) in THF (50 mL, 9.4 vol) was taken at 0-5°C, and 1-methylpiperidin-2-one (5 g, 44.24 mmol) was added and dissolved in THF (25 mL, 5 vol). The RM was warmed to 60-65°C and stirred at this temperature for 1 h. After stirring for 1 h, diethyl carbonate (31.3 g, 265.26 mmol) was added dropwise to the reaction mixture and stirred at 60-65°C for 12 h. The reaction mass was quenched into cold water and extracted with 2-MeTHF. The aqueous layer was acidified with HCl and extracted with 10% IPA:DCM (5 x 50 mL). The combined organic layers were dried over NaSO and concentrated to give the crude product. The crude compound was suspended in IPA (5 volumes) and stirred for 2 hours, the solid was filtered and dried to give 4.7 g of 1-methyl-2-oxopiperidine-3-carboxylic acid as an off-white solid, 68.1% yield, 94.7% purity by LCMS. 1H NMR (DMSO-d6): δ 12.56(s,1H),3.33-3.20(m,3H),2.82(s,3H),1.99-1.90(m,1H),1.88-1.69(m,3H). LCMS(EI):m / z 158.1(M+1).

[0521] Preparation AK Synthesis of N-(2,3-difluorophenyl)-1-methyl-2-oxopiperidine-3-carboxamide [ka] 1-Methyl-2-oxopiperidine-3-carboxylic acid (4 g, 25.4 mmol) was dissolved in dimethylformamide (20 ml, 5 volumes) and cooled to 0°-5°C. Triethylamine (7.7 g, 76.4 mmol), 2,3-difluoroaniline (3.6 g, 28.0 mmol), followed by T3P (32.4 g, 101.9 mmol; 50% solution in EtOAc) were added at 0°-5°C. The reaction mass was stirred at 0°-5°C for 2 hours. The reaction mass was added to water and extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with water followed by brine solution, dried over sodium sulfate, and concentrated to give a solid. To this was added solid heptane (10 volumes), stirred for 1 hour, filtered and dried under vacuum to give 2.1 g of N-(2,3-difluorophenyl)-1-methyl-2-oxopiperidine-3-carboxamide as an off-white solid in 29.4% yield and 92.2% purity by LCMS. 1H NMR(DMSO-d6):δ 10.29(s,1H),7.83-7.7.78(m,1H),7.20-7.13(m,2H),3.62-3.58(t,16Hz,1H),3.3 7-3.25(m,2H),2.89(s,3H),2.05-2.0(m,2H),1.99-1.85(m,1H),1.76-1.70(m,1H). LCMS(EI):m / z 269.2(M+1).

[0522] Preparation AL Synthesis of N-(2,3-difluorophenyl)-1-methyl-2-oxo-3-(phenylselenyl)piperidine-3-carboxamide [ka] N-(2,3-difluorophenyl)-1-methyl-2-oxopiperidine-3-carboxamide (2 g, 7.46 mmol) was dissolved in THF (20 ml, 10 volumes) and NaH (0.89 g, 37.3 mmol) was added at 0-5°C. The reaction mass was stirred at 0-5°C for 30 minutes. Phenylselenyl bromide (1.76 g, 7.46 mmol) dissolved in THF (5 mL) was added at 0-5°C and stirred for 2 hours. The reaction mass was quenched in cold water and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were concentrated to give the crude compound, which was purified by column chromatography on silica gel using ethyl acetate / hexane as the eluent to give 2.6 g of N-(2,3-difluorophenyl)-1-methyl-2-oxo-3-(phenylselenyl)piperidine-3-carboxamide as a pale yellow solid. Yield 83.8%, purity 93.1% by LCMS. 1H NMR(DMSO-d6):δ 10.94(s,1H),7.98-7.94(m,1H),7.53-7.51(m,2H),7.45-7.41(m,1H),7.34-7.31(m,2H),7.19-7. 11(m,2H),3.40-3.31(m,2H),2.93(s,3H),2.23-2.17(m,1H),2.19-1.88(m,2H),1.67-1.64(m,1H). LCMS(EI):m / z 425.2(M+1).

[0523] Preparation AM Synthesis of N-(2,3-difluorophenyl)-1-methyl-2-oxo-1,2,5,6-tetrahydropyridine-3-carboxamide [ka] N-(2,3-Difluorophenyl)-1-methyl-2-oxo-3-(phenylselenyl)piperidine-3-carboxamide (2.5 g, 5.89 mmol) was dissolved in MDC (25 ml, 10 volumes) and HO (1.3 g, 39.30 mmol; 30% solution) was added at 0-5 °C. The reaction mass was stirred at 0-5 °C for 2 hours. The reaction mass was quenched into ice-cold saturated NaHCO solution and extracted with dichloromethane (2 × 50 mL). The organic layer was washed with NaHCO solution (3 × 20 mL), dried over NaSO, and concentrated to give the crude product. The crude compound was suspended in IPA (5 mL) and stirred for 2 h, the solid was filtered and dried to give 1.2 g of N-(2,3-difluorophenyl)-1-methyl-2-oxo-1,2,5,6-tetrahydropyridine-3-carboxamide as a pale yellow solid in 80% yield and 98.3% purity by LCMS. 1H NMR(DMSO-d6):δ 12.32(s,1H),8.18-8.13(m,1H),7.86-7.84(t,Jis8Hz,1H)7.23-7.11(m,2H),3.53-3.49(t,Jis16Hz,2H),2.99(s,3H),2.66-2.61(m,2H). LCMS(EI):m / z 267.2(M+1).

[0524] Preparation AN Synthesis of anti-N-(2,3-difluorophenyl)-4-(4-fluorophenyl)-1-methyl-2-oxopiperidine-3-carboxamide [ka] In a 25 mL two-neck RBF, 1-bromo-4-fluorobenzene (530 mg, 3.0 mmol) was dissolved in dry THF (6 mL, 11 volumes). The reaction mass was cooled to -78 to -70 °C, and n-butyllithium (1.8 mL, 2.5 M, 1.5 equiv.) was added to the reaction mixture. The RBF was stirred at -78 to 70 °C for 1 h. In a separate flask, N-(2,3-difluorophenyl)-1-methyl-2-oxo-1,2,5,6-tetrahydropyridine-3-carboxamide (250 mg, 0.93 mmol), copper(I) bromide dimethyl sulfide complex (9 mg, 0.046 mmol), and 2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene (35 mg, 0.056 mmol) were taken in THF (5 mL, 20 volumes) and the reaction mixture was cooled to -78 to 70 °C. To this RM, lithiated 1-bromo-4-fluorobenzene was added dropwise at -78 to 70 °C and stirred for 1 hour. The reaction mass was quenched with aqueous NH4Cl and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with saturated brine solution, dried over Na2SO4, and concentrated to give the crude product, which was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane as eluent to give 40 mg of anti-N-(2,3-difluorophenyl)-4-(4-fluorophenyl)-1-methyl-2-oxopiperidine-3-carboxamide as an off-white solid in 11.7% yield and approximately 90% purity by LCMS. 1H NMR (DMSO-d6): δ 9.91(s,1H),7.54-7.50(m,1H),7.32-7.29(m,2H),7.14-7.06(m,4H),3.84- 3.81(d,1H),3.55-3.42(m,3H),2.96(s,3H),2.07-1.96(m,2H). LCMS(ES): m / z 363.3(M+1).

[0525] Preparation ANa Synthesis of (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide using (R)-(+)-1,1'-Bi(2-naphthol) in methyl tert-butyl ether as solvent. [ka] In a 25 mL flask A, (R)-(+)-1,1'-Bi(2-naphthol) (91 mg, 0.320 mmol) was taken in 2 mL of anhydrous methyl tert-butyl ether at 20-25 °C and stirred for 50 min. In flask B, (3-(trifluoromethyl)phenyl)magnesium bromide (5.3 mL, 4.26 mmol, 0.8 M in EtO) was slowly added to bis-[2-(N,N-dimethylaminoethyl ether) (683 mg, 4.27 mmol) in 3 mL of dry methyl tert-butyl ether under nitrogen at 0-5 °C, followed by stirring for 30 min. Mixture A was then introduced into mixture B at 0-5 °C. The RM was then warmed to 20-25 °C and stirred for 1 h. The RM was then cooled to 0-5 °C, and N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (500 mg 2.13 mmol) in methyl tert-butyl ether (5 mL) was added dropwise. The mixture was warmed to 20-25 °C and stirred for 12 h. The reaction was concentrated to 10% The mixture was quenched with aqueous HCl and extracted with ethyl acetate (25 mL × 2). The combined organic layers were dried over anhydrous NaSO and evaporated in vacuo to give 800 mg of crude product. The crude product was purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate / hexane (20:80) as the eluent, and purified by chiral HPLC to give 50 mg of (3S,4S)-N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide with a chiral enantiomeric ratio of 1:2 (R,R enantiomer:S,S enantiomer). LCMS(ES): m / z 381.2(M+1).

[0526] Preparation AO Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide To a stirred solution of NaH (0.94 g, 39.47 mmol) in THF (10 mL) at 0-5 °C was added N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide (1.5 g, 3.94 mmol) in THF (10 mL). The reaction mass was stirred at 0-5 °C for 20 min. Diphenyl disulfide (1.29 g, 5.92 mmol) in THF (10 mL) was added at 0-5 °C. The RM was stirred at 20-25 °C for 48 h. The reaction mass was quenched into cold water and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were concentrated to give the crude compound, which was purified by column chromatography on silica gel using ethyl acetate / hexane as eluent to give 1.5 g of N-(2-fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide as an off-white solid in 78.9% yield and 96.6% purity by LCMS. 1H NMR(DMSO-d6):δ 10.28(s,1H),7.68-7.64(m,1H),7.57-7.55(m,1H),7.52-7.42(m,5H),7.38-7.32(m,1 H),7.19-7.02(m,2H),4.05-3.97(m,2H),3.37-3.33(m,1H),2.91(s,3H).LCMS(EI):m / z 489.3(M+1).

[0527] Preparation AP Synthesis of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide [ka] N-(2-Fluorophenyl)-1-methyl-2-oxo-3-(phenylthio)-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide (1.5 g, 3.07 mmol) was dissolved in dichloromethane (15 mL, 10 volumes) and m-CPBA (1.05 g, 6.14 mmol) was added at 20-25 °C. The reaction mass was stirred at 20-25 °C for 4 hours. The reaction mass was quenched into ice-cold saturated NaHCO solution and extracted with dichloromethane (2 × 50 mL). The organic layer was washed with NaHCO solution (2 × 50 mL), dried over NaSO, and concentrated to give a solid. The solid was suspended in heptane (10 mL) and stirred for 2 h, and the solid was filtered and dried to give 600 mg of N-(2-fluorophenyl)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-2,5-dihydro-1H-pyrrole-3-carboxamide as an off-white solid (54.5% yield, 82.8% purity by LCMS). 1H NMR(CDCl3):δ 11.52(s,1H),8.40-8.36(m,1H),7.92-7.90(m,1H),7.79(s,1H),7.73-7.71(m,1 H),7.61-7.57(m,1H),7.14-7.04(m,3H),4.33(s,2H),3.21(s,3H).LCMS(EI):m / z 379.2(M+1).

[0528] It will be appreciated by those skilled in the art that various functional groups can be converted into other functional groups to provide different saturated target compounds encompassed by the above-defined general formula 1. For a valuable resource illustrating the interconversion of functional groups in a simple and straightforward manner, see Larock, RC, Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Ed., Wiley-VCH, New York, 1999.

[0529] It is recognized that some of the reagents and reaction conditions described above for preparing saturated target compounds and corresponding novel and inventive intermediates may be incompatible with certain functional groups present in the inventive intermediates from which they are prepared. In these cases, incorporating protection / deprotection sequences or functional group interconversions into the synthesis can be helpful in obtaining the desired products. The use and selection of protecting groups will be apparent to those skilled in the art of chemical synthesis (see, for example, Greene, TW; Wuts, PGM Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991).

[0530] Those skilled in the art will recognize that in some cases, after the introduction of a given reagent as illustrated in any individual scheme, it may be necessary to perform additional routine synthetic steps not specifically described in order to complete the synthesis of, inter alia, saturated target compounds encompassed by general formula 1 as defined above and the novel and inventive intermediates detailed herein. Those skilled in the art will also recognize that it may be necessary to perform combinations of steps shown in the above schemes in an order other than that implied by the particular schemes illustrated to prepare compounds that include saturated target compounds.

[0531] Those skilled in the art will also recognize that saturated target compounds, including compounds encompassed by general formulas II, III, IV, and D as described and defined herein, as well as the intermediates, impurities, markers, and decomposable compounds of the present invention, can be subjected to a variety of electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.

[0532] Without further elaboration, it is believed that one skilled in the art using the present disclosure can utilize the present invention to its fullest extent. Accordingly, the above examples, descriptions of the described embodiments and processes should be construed as merely illustrative and not limiting of the present disclosure in any way.

[0533] The inventors claim protection for all embodiments of the present invention, and if inoperable embodiments are inadvertently included within the broad description or definition, the inventors make it clear that all inoperable embodiments are expressly and unconditionally excluded from the claims for protection. In other words, inoperable embodiments are, by definition, outside the scope of the protection sought.

[0534] The inventors claim protection for all novel and unobvious embodiments of the invention, and if non-novel embodiments are inadvertently included within the broad description or definition, the inventors clarify that all such anticipated embodiments are excluded from the claims for protection. In other words, if a multi-component embodiment including several compounds is determined upon inspection to contain an anticipated member of a group of encompassed components, by definition the inventors did not intend to include it, and the compound is, and always has been, outside the scope of protection sought. An error in inadvertently including an anticipated compound within a broad compound list due to textural inaccuracy should be remedied by deleting the erroneous group member without affecting the remaining compounds in that list or group.

Claims

1. A process B1 for preparing a saturated target of formula 1 from an unsaturated precursor of formula 2, comprising the following scheme: 【Chemistry 1】 including 1,4-based substitutions exemplified by 1,4-additions using Grignard reagents, organolithium reagents, organozinc reagents, hydrogenation, hydride sources, electron sources (reduction exemplified by Zn / AcOH) or enzymes, wherein R β , A α , A β , nα, Q α and R ε Each of has the same meaning as defined for Compound A2, R α is H, halogen, or substituted or unsubstituted alkyl, aryl, heterocyclic, naphthyl, C(O)OC 6 H 5 , -C(O)OC 6 H 4 Esters, including aliphatic and aromatic esters exemplified by -C(O)NHC 6 H 5 amides, including aliphatic and aromatic amides exemplified by -C(O)NHNHC 6 H 5 Carbon-containing groups exemplified by hydrazine amides, thioesters, thionoesters, including aliphatic and aromatic exemplified by -C(O)NHOC 6 F 5 ); and -C(S)SC 6 H 5 ) and the like, R α is not bonded to the ring via an O or N atom, so that, for example, R α is not -OMe, and whenever H is added to the 4-position of said 1,4 system, R α is not H, R γ is H or a carbon-containing group such as substituted or unsubstituted alkyl, aryl, naphthyl, etc. R δ is H or a carbon-containing group such as substituted or unsubstituted alkyl, aryl, naphthyl, and the like.

2. Process B1; B1b; B1c; B1d; B2; B2a; B3; B3a; B4; B5; B6; B6a; B7; B8; B9; B10; B11; B12; B13; B14; B15; B16; ;B16b;B16c;B16d;B17;B18;B18a;B18b;B18c;B18d;B19;B19a;B19b;B19c;B20;B21a;B21b;B21c;B22;B 23; B24; B25; B26; B27a; B27b; B28a; B28b; B29a; B29b; B30a; B30b; B31; B32; B33; B34; B35; B36; B37; B38; B39; B40; B41; B42; B43; B44; B45; B46; B47; B48; B49; B50; and B51, or a process selected from: a) Process B1b for preparing a saturated target of formula 1 from an unsaturated precursor of formula 2, comprising: 【Chemistry 2】 including 1,4-based substitutions exemplified by Grignard reagents, organolithium reagents, organozinc reagents, hydrogenation, hydride sources, electron sources, reduction exemplified by Zn / AcOH, or 1,4-addition using enzymes; R β , A α , A β , nα, Q α and R ε Each of has the same meaning as defined for Compound A2, R α is H, halogen, or esters, including substituted or unsubstituted alkyl, aryl, heterocyclic, naphthyl, aliphatic and aromatic esters, e.g., C(O)OC 6 H 5 , or -C(O)OC 6 H 4 F), amides including aliphatic and aromatic, such as -C(O)NHC 6 H 5 ), hydrazine amides, including aliphatic and aromatic, such as -C(O)NHNHC 6 H 5 ), thioesters, thionoesters, and -C(O)NHOC 6 F 5 );-C(S)SC 6 H 5 ) and similar compounds such as R γ is H or a carbon-containing group such as substituted or unsubstituted alkyl, aryl, naphthyl, etc. R δ is H or a substituted or unsubstituted carbon-containing group such as alkyl, aryl, naphthyl, etc., provided that: R α is not bonded to the ring via an O or N atom, so that, for example, R α is not -OMe, and whenever H is added to the 4-position of said 1,4 system, A α R, except when N(Me) α is not H, but R β is m-(trifluoromethyl)benzene, m-(trifluoromethyl)benzene, or 6-(trifluoromethyl)pyridin-3-yl, then R α can be H as in the following scheme: 【Chemistry 3】 ,process; b) Process B1c for preparing a saturated target from a corresponding unsaturated precursor according to any one of processes B1 and B1b, comprising reacting said unsaturated precursor with a nucleophile exemplified by a Grignard reagent, an organolithium reagent, an organozinc reagent, a hydrogen source, e.g. H 2 1,4-substitution, e.g., 1,4-addition, of said unsaturated precursor is carried out in combination with an electron source, exemplified by Zn / Pd / C, or a hydride source, or Zn / AcOH, and at least one solvent to obtain a saturated target as defined by the formula: 【Chemistry 4】 Preferably, depending on the reaction conditions, one or more of the isomers exemplified by the trans isomer or the cis isomer is in excess. 【Chemistry 5】 c) A process B1d for preparing a saturated target from a corresponding unsaturated precursor, comprising substituting said unsaturated precursor 1,4 system, for example by 1,4-addition, using a Grignard reagent, an organolithium reagent, an organozinc reagent, hydrogenation or a hydrogenation source, the resulting saturated target product having an excess of one or more possible isomers, said process comprising: 【Chemistry 6】 【Chemistry 7】 【Chemistry 8】 and related combinations thereof; d) Process B2 according to any one of processes selected from B1; and B1b, comprising the steps of: an unsaturated precursor; a nucleophile exemplified by a Grignard reagent; an organolithium reagent; an organozinc reagent; H 2 a process comprising combining a hydrogen or hydride source such as Zn / Pd / C, or an electron source such as Zn / AcOH, and a solvent to effect 1,4-based substitution of said unsaturated precursor, such as a 1,4-addition reaction, to obtain a saturated target; e) A process B2a for preparing a saturated target of formula 1 from an unsaturated precursor of formula 2, comprising: 【Chemistry 9】 including 1,4-based substitutions such as Grignard reagents, organolithium reagents, organozinc reagents, 1,4-additions using hydrogenation or hydride sources; The saturated target product has an excess of one or more possible isomers, R α , R β , A α , A β , nα, Q α and R ε Each of has the same meaning as defined for Compound A2, R γ is H or R α and R δ is H or R α A process in which f) Process B3 according to any one of Process B2 and Process B2a, comprising combining an unsaturated precursor, a nucleophile such as a Grignard reagent, an organolithium reagent, an organozinc reagent, or a hydride source, a solvent, and one or more catalytic components selected from a catalyst; a pre-catalyst and a co-catalyst, respectively, to effect 1,4-based displacement of the unsaturated precursor, such as a 1,4-addition reaction, to obtain a saturated target; g) Process B3a according to any one of Process B2 and Process B2a, comprising combining an unsaturated precursor, a nucleophile such as a Grignard reagent, an organolithium reagent, an organozinc reagent, or a hydride source, a solvent, and one or more catalytic components selected from a catalyst, a pre-catalyst, and a co-catalyst, respectively, to effect a 1,4-based displacement of said unsaturated precursor, such as a 1,4-addition reaction, to obtain a saturated target, said saturated target product having an excess of one or more of said possible isomers; h) Process B4 as described in any one of Process B2; B2a; B3; B3a, comprising including in said combination an additive that is a source of a reversibly bound adduct to said unsaturated precursor, such as a Lewis acid, to provide an improvement in 1,4-addition reactions to said unsaturated precursor to obtain a saturated target, in any of the following schemes or any combination thereof, wherein RGA is the reversibly bound adduct; 【Chemistry 10】 The improvements provided include protecting a portion of the unsaturated precursor from undesired reactions; increasing pathway selectivity; increasing selectivity for a particular desired isomer; increasing the reactivity of the unsaturated precursor; and increasing the reactivity of R such as a Grignard reagent, as required. δ allowing for a reduction in the amount of the source; R α , R β , R γ , A α , A β , nα, Q α And R ε and R δ has the same meaning as defined in any one of Processes B1; B1a; B1b; B2 and B2a; i) process B5 as defined in any one of processes B2; B2a; B3; B3a; and B4, further comprising the step of purifying the obtained saturated target product; j) process B6 according to any one of processes B2; B2a; B3; B3a; B4; and B5, further comprising the step of crystallizing the obtained saturated target product; k) Process B6a according to any one of processes B2; B2a; B3; B3a; B4; and B5, further comprising a step of subjecting the saturated target obtained by any one of processes B2; B2a; B3; B3a; B4 to a process such as spray drying, freeze drying, or adsorption of a solution of the saturated target onto a solid support material to obtain an amorphous solid saturated target product; l) Process B7 according to any one of Processes B2 to B6, further comprising combining one or more catalytic components selected from an unsaturated precursor, a nucleophile such as a Grignard reagent, an organolithium reagent, an organozinc reagent, or a hydride source, a solvent; a catalyst; a pre-catalyst; and a co-catalyst, and an additive that is a source of a reversibly bound adduct to obtain a saturated target by carrying out a 1,4-addition reaction, and purifying and crystallizing the reaction product to obtain a crystalline purified saturated target product; m) Process B8 B7, wherein the combining step comprises a Grignard reagent; an organolithium reagent, an organozinc reagent, or a hydride source, together with a solvent such as diethyl ether, and two or more catalyst components each selected from a catalyst; a pre-catalyst; a co-catalyst, and mixtures thereof, and a Lewis acid; n) Process B9 according to any one of processes B1 to B8, further comprising dissolving the unsaturated precursor in a solvent such as diethyl ether and preferably, for example, both CuBr.SMe. 2 (Copper (I) bromide dimethyl sulfide complex) and adding one or more catalyst components including a catalyst; a pre-catalyst; a co-catalyst, such as a combination of R-BINAP or (S)—N-((S)-1-(butylamino)-1-oxo-3-phenylpropan-2-yl)-2-(((E)-2-(diphenylphosphanyl)benzylidene)amino)-3-methylbutanamide; 【Chemistry 11】 agitating the reaction mass, e.g., by stirring or mixing in a continuous reactor or the like; optionally adding a source of a Lewis acid, e.g., trimethylsilyl chloride, which reversibly bonds to said unsaturated precursor; continuing stirring for an appropriate time, e.g., about 20 minutes; adjusting the temperature to an optimum level, preferably low, e.g., −20° C. to −25° C.; adding a nucleophile, e.g., a Grignard reagent, or a hydride source, or the like; stirring for a period of time to achieve an optimum product by balancing parameters, represented by consideration of desired quality, and acceptable yield, within a reasonable reaction time; 4 quenching the reaction mass with aqueous Cl or the like, optionally extracting with a suitable solvent, optionally washing the combined organic layers with, for example, saturated brine solution, and optionally washing with, for example, Na 2 SO 4 and optionally concentrating to obtain said saturated target product; o) Process B10 according to process B9, further comprising the step of purifying the obtained saturated target product; Process B11 according to any one of Processes B9 and B10, further comprising the step of p) crystallizing the obtained saturated target product; q) Process B12 according to Process B1, In a first vessel A, the unsaturated precursor is dissolved in a solvent such as diethyl ether, stirred, optionally cooling the reaction mass to a suitable temperature such as 20° C. to −25° C., adding a Lewis acid such as trimethylsilyl chloride, and stirring; in a second vessel B, one or more catalysts; pre-catalysts; both CuBr.SMe. 2 introducing catalyst components including a co-catalyst such as a combination of (copper(I) bromide dimethylsulfide complex) and R-BINAP; 【Chemistry 12】 adding a nucleophilic component, such as a Grignard reagent, organolithium reagent, organozinc reagent, or a hydride source to vessel B; stirring, adding the contents of vessel A to vessel B, stirring the mass for a period of time, such as 20 minutes, and mixing the reaction mass with, for example, water, NH 4 HCl solution and optionally extracting with a solvent; optionally washing the combined organic layers with, for example, a saturated brine solution and optionally removing, for example, Na 2 SO 4 and optionally concentrating to obtain said saturated target product; r) process B13 according to process B12, further comprising the step of purifying the obtained saturated target; Process B14 according to any one of processes B12 and B13, further comprising the step of: s) crystallizing the obtained saturated target product; t) process B15 according to any one of processes B1 to B14, wherein the unsaturated precursor is any one of compounds A1 to A35, and comprises a 1,4-based displacement of the unsaturated precursor, such as a 1,4-addition using a Grignard reagent, an organolithium reagent, an organozinc reagent, or a hydride source; u) Process B16 according to any one of processes B1 to B15, wherein the unsaturated precursor is represented by the following scheme: 【Chemistry 13】 Compound A10 is represented by the formula: Markers that can be formed by the above scheme have the following structure: 【Chemistry 14】 may include one, some, or all of processes which include displacement of said unsaturated precursor 1,4 systems such as 1,4-addition using Grignard reagents or / and organolithium reagents such as (3-(trifluoromethyl)phenyl)lithium; v) Process B16a according to any one of processes B1 to B15, wherein the unsaturated precursor is represented by the following scheme: 【Chemistry 15】 Compound A10 is represented by the formula: 3-(trifluoromethyl)phenylmagnesium bromide, or a process comprising displacement of said unsaturated precursor 1,4 system, such as 1,4-addition using a Grignard reagent, such as [3-(trifluoromethyl)phenyl]magnesium chloride; w) Process B16b according to any one of processes B1 to B15, wherein the unsaturated precursor is represented by the following scheme: 【Chemistry 16】 Compound A10 is represented by the formula: a process comprising displacement of said unsaturated precursor 1,4 system, such as by 1,4-addition using an organolithium reagent such as 3-(trifluoromethyl)phenyllithium; x) Process B16c according to any one of processes B1 to B15, wherein the unsaturated precursor is represented by the following scheme: 【Chemistry 17】 Compound A10 is represented by the formula: processes involving displacement of unsaturated precursor 1,4 systems, such as by 1,4-addition using organozinc reagents such as 3-(trifluoromethyl)phenylzinc(II) bromide; y) Process B16d according to any one of processes B1 to B15, wherein the unsaturated precursor is represented by the following scheme: 【Chemistry 18】 Compound A10 is represented by the formula: A marker that can be formed by the above scheme has the following structure: 【Chemistry 19】 may include one, some, or all of processes involving displacement of unsaturated precursor 1,4 systems, such as by 1,4-addition using Grignard reagents or / and organolithium reagents, e.g. (3-(trifluoromethyl)phenyl)lithium; z) The following scheme: 【Chemistry 20】 Process B17 as represented by the formula: aa) The following scheme 【Chemistry 21】 Process B18 as represented by the formula: bb) Scheme 【Chemical 22】 Process B18a according to Process B18 as represented by the formula: cc) The following scheme: 【Chemistry 23】 Process B18b according to Process B18 as represented by the formula: dd) The following scheme: 【Chemistry 24】 Process B18c as represented by the formula: ee) The following scheme: 【Chemistry 25】 Process B18d as represented by the formula: ff) The following scheme 【Chemistry 26】 which comprises displacement of the 1,4 system by reduction of the 1-methyl-2H-pyrrol-5-one double bond, such as by use of a hydride source; gg) The following scheme 【Chemistry 27】 Process B19a according to Process B19 as represented by the formula: hh) The following scheme: 【Chemistry 28】 which comprises substitution of the 1,4 system by reduction of the double bond in the 1-methyl-2H-pyrrol-5-one group, for example by use of a hydride source; ii) The following scheme: 【Chemical Formula 29】 which comprises reducing the double bond in the 1-methyl-2H-pyrrol-5-one group to replace the 1,4 system, such as by using a hydride source; jj) The following scheme: 【Chemistry 30】 which comprises reducing the double bond in the 1-methyl-2H-pyrrol-5-one group to replace the 1,4 system, such as by using a hydride source; kk) The following scheme 【Chemistry 31】 A process B21a for obtaining a saturated target from an unsaturated precursor, as represented by: The process includes a 1,4-system displacement, such as by 1,4-addition using a Grignard reagent or a hydride source, and the saturated target is a compound as defined in claim 1 of application PCT / US2014 / 068073, published as WO 2015 / 084796, and Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6 , Y 1 and Y 2 etc. have the meanings defined in claim 1 of application PCT / US2014 / 068073, published as WO 2015 / 084796, and the substituents of the structures of this process are as defined for compound A35a; ll) The following scheme: 【Chemistry 32】 A process B21b for obtaining a saturated target from an unsaturated precursor, as represented by: The process includes a 1,4-system displacement, such as by 1,4-addition using a Grignard reagent or a hydride source, and the saturated target is a compound as defined in claim 1 of application PCT / US2014 / 068073, published as WO 2015 / 084796, and Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6 , Y 1 and Y 2 etc. have the meanings defined in claim 1 of application PCT / US2014 / 068073, published as WO 2015 / 084796, and the substituents of the structures of this process are as defined for compound A35a; mm) The following scheme 【Chemical 33】 A process B21c for obtaining a saturated target from an unsaturated precursor, as represented by: The process includes a 1,4-system displacement, such as by 1,4-addition using a Grignard reagent or a hydride source, and the saturated target is a compound as defined in claim 1 of application PCT / US2014 / 068073, published as WO 2015 / 084796, and Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6 , Y 1 and Y 2 etc. have the meanings defined in claim 1 of application PCT / US2014 / 068073, published as WO 2015 / 084796, and the substituents of the structures of this process are as defined for compound A35a; nn) the following scheme 【Chemical 34】 Process B22 as represented by the formula: oo) The following scheme 【Chemistry 35】 Process B23 as represented by the formula: pp) The following scheme 【Chemical 36】 Process B24 as represented by the formula: qq) The following scheme 【Chemical 37】 Process B25 as represented by the formula: rr) The following scheme 【Chemical Formula 38】 Process B26 as represented by the formula: ss) The following scheme 【Chemical 39】 comprising a 1,4-based substitution of the unsaturated precursor; tt) The following scheme: 【Chemistry 40】 Process B27b as represented by the formula: uu) The following scheme 【Chemistry 41】 Process B28a as represented by the formula: vv) The following scheme 【Chemistry 42】 which comprises displacement of the 1,4 system, such as by 1,4-addition using an organolithium reagent, such as with 1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yllithium; lol) The following scheme 【Chemistry 43】 Process B29a, which includes replacement of the 1,4 system, such as by 1,4-addition, as represented by the formula: xx) the following scheme: 【Chemistry 44】 Process B29b as represented by the formula: yy) the following scheme 【Chemistry 45】 Process B30a as represented by the formula: zz) The following scheme 【Chemistry 46】 which comprises a displacement of the 1,4 system, such as a 1,4-addition using an organolithium reagent, such as 1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yllithium; aaa) process B31 according to any one of processes B1 to B30b, in which an excess of one or more of the possible isomers is obtained; bbb) process B32 according to any one of processes B1 to B30b, wherein an excess of anti isomer is obtained; ccc) process B33 according to any one of processes B1 to B30b, wherein an excess of said syn isomer is obtained; ddd) process B34 according to any one of processes B1 to B33, wherein one or more of the possible chiral isomers is obtained in excess relative to the others; eee) process B35 according to any one of processes B1 to B34, wherein an excess of chiral anti isomer is obtained; fff) process B36 according to any one of processes B1 to B34, in which an excess of chiral anti isomers of S,S configuration is obtained; ggg) process B37 according to any one of processes B1 to B36, wherein magnesium, lithium, zinc, iPrMgCl, iPrMgBr, iPrMgI, hexyllithium, butyllithium, tert-butyllithium, 4-methyl-pentyl-lithium, isobutyllithium or combinations thereof are used to prepare reagents for the displacement of the 1,4 system in-situ and / or prior to use in the displacement reaction; hhh) process B38 according to any one of processes B1 to B36, wherein magnesium halogen exchange or lithium halogen exchange is used to prepare a reagent for the substitution of said 1,4 system in situ and / or prior to use; iii) process B39 according to any one of processes B1 to B38, carried out in the presence of a metal; jjj) process B40 according to process B39, wherein the metal is selected from Cu; Ni; Ti; Co; and Fe; kkk) process B41 according to process B39, wherein the metal is selected from Cu; Ni; and Ti; III) process B42 according to process B39, wherein the metal is Cu; mmm) process B43 according to process B39, wherein the metal is Ni; nnn) process B44 according to any one of processes B39 to B43, wherein the metal is present in a catalytic amount; ooo) process B45 according to any one of processes B1 to B44, optionally carried out in the presence of a chiral compound bound to or part of a solid material or substrate; ppp) process B46 according to process B45, wherein the chiral compound is selected from the group containing naturally occurring, synthetic, modified (e.g. substituted, etc.) amino acids such as N,N-dimethyl-L-prolinium and L-proline; peptides exemplified by (S)-N-((S)-1-butylamino-1-oxo-3-phenylpropan-2-yl-2-(E)-2-diphenylphosphanylbenzylideneamino-3-methylbutanamide; phosphorus ligands such as R-BINAP; proteins; enzymes; and sugars; qqq) process B47 according to any one of processes B45 to B46, wherein the chiral compound is selected from (S)-N-(S)-1-(butylamino-1-oxo-3-phenylpropan-2-yl-2-(E)-2-diphenylphosphanylbenzylideneamino-3-methylbutanamide; rr) process B48 according to any one of processes B45 to B47, wherein the chiral compound is present in a catalytic amount; sss) The Lewis base is, for example, NH 4 + C - (Ammonium chloride); NH 4 + O.H. - (Ammonium hydroxide); NH 3 ; C.N. - ions (e.g., from KCN or NaCN); pyridine; DMA; DMSO; DMF; TEMADA; OH - Ion; PH 3 and H 2 P.O. 3 - Process B49 according to any one of processes B45 to B48, which is present in a post-treatment such as ions; ttt) The Lewis base in the post-treatment is NH 4 + C - (Ammonium chloride); NH 4 + O.H. - (Ammonium hydroxide); NH 3 and CN, e.g. from KCN or NaCN - Process B50 according to process B49, wherein the ions are selected from the group consisting of ions; uuu) Process B51 according to any one of processes B1 to B50, carried out in the presence of a strong base such as, for example, MeMgCl; MeMgBr; iPrMgCl; iPrMgBr; BuLi; tert-BuLi; hexyllithium; NaH; KH.

3. A process selected from any one of processes B16; B16a; B16b; B16c; B16d; B17; B18; B18a; B18b; B18c; B18d; B19; B19a; B19b; and process B19c.

4. A process represented by the following scheme, mediated by exposure of the starting compound to sunlight. 【Chemistry 47】

5. 1. A process for producing a preserved marker compound of formula D, represented by the following scheme: 【Chemistry 48】 A process in which the rate and degree of conversion to the produced storage marker compound of formula D, as well as its amount and its content in a mixture with the composition of the compound from which it is produced, are mediated by the properties of said composition and by its storage history under various defined environmental conditions, particularly exposure to sunlight.

6. Unsaturated precursor compounds A1 of formula 2 and, for example, salts thereof, 【Chemistry 49】 (In the formula, R α is a halogen; a carbon-containing group exemplified by substituted or unsubstituted alkyl, aryl, heterocycle, naphthyl; C(O)OC 6 H 5 , -C(O)OC 6 H 4 Esters, including aliphatic and aromatic esters exemplified by -C(O)NHC 6 H 5 Amides, including aliphatic and aromatic amides exemplified by: -C(O)NHNHC 6 H 5 Hydrazine amides, including aliphatic and aromatic hydrazine amides, thioesters, thionoesters, and, for example, C(O)NHOC 6 F 5 ;-C(S)SC 6 H 5 and similar compounds, where R α is not bonded to the ring via O or N, so R α cannot be -OMe, R β is hydrogen or a carbon-containing group, such as, for example, substituted or unsubstituted alkyl, aryl, naphthyl, heterocycle, etc., bonded to said ring via a C atom or, where applicable, a Si atom, with the proviso that R β is not an amine attached to the ring via N R β is not an ether bonded to the ring through O, R β is not a thioether attached to the ring via S, A α is a C, N, O or S atom with or without substitution such as -N(Me)- or -O-, and if present, A α The substituents of Q in the following structures etc. α , A β may be attached to another part of the molecule, such as 【Chemistry 50】 Each A β each independently represents -CH 2 A C, N, O or S atom with or without substitution by - or -O-, etc., and when present, each A β The substituent of A α , A β , R β may be attached to another part of the molecule, such as, β At least one of 2 is a saturated atom exemplified by nα is 1, 2 or 3; Each Q α are each independently O, S or NR ε and R ε is -N(Me) 2 are C, N, O or S atoms with or without substitution by, etc. R ε The above substituents, if present, may be hydrogen or carbon and / or nitrogen containing groups, such as substituted or unsubstituted alkyl, aryl, naphthyl, heterocycles, etc., bonded to said ring via a C atom, or Si atom, if applicable; ε The substituents of are connected to the Q in the ring via a C atom or, where relevant, a Si atom, as represented in the following structure: α , A β may be attached to another part of the molecule, such as 【Chemistry 51】 Preferably, the ring portion of the unsaturated precursor, labeled P in the structure below, is not aromatic so that all atoms cannot be conjugated, 【Chemistry 52】 Additionally, the double bond of the ring moiety is not part of the outer aromatic ring addition.

7. Unsaturated precursor compounds A2 of formula 2 and, for example, salts thereof, 【Chemistry 53】 wherein the unsaturated precursor does not contain a covalent nitrogen-halogen bond; R α is halogen (Hal.), C 1 ~C 10 Alkyl, C 1 ~C 10 Haloalkyl, R μ Or -C(Q α ) Q β R μ and Optionally, R α can also be used in other parts of the molecule, e.g., Q in a ring. α , A β may be equally bonded, Q β , O, S, NR ε , N.R. π -NR π , N.R. π -O, NR π -S, S-NR π , or O-NR π and R β H, R ε , or Si(R ε ) 3 and A α is a C, N, O or S atom bearing 0-2 substituents, the substituents, if present, being H and / or R θ and optionally, A α is selected from -N(Me)-, -C(Et)H- and -O-, and optionally, when present, A α The substituents of may be attached to another part of the molecule, such as Q, as in the following structure: α , A β are bonded to each other as a ring. 【Chemical 54】 Each A β are each independently a C, N, O or S atom having 0 to 2 substituents, and optionally A β is any one of -N(Me)-, -C(Et)H-, -O-, etc., and each A β The above substituents are H and / or R θ where A on the ring is selected from β At least one of the atoms is CH 2 etc., Optionally, each A β Is, Q α , A α Another part of the molecule such as β may be bonded to each other to form a ring, nα is 1 to 3, Q α , O, S, NR ε and optionally, Q α is A in the ring β may be attached to another part of the molecule, such as Each R θ are each independently halogen (Hal.), hydroxy (OH), cyano (CN), nitro, amino, C 1 ~C 8 Alkyl, C 1 ~C 8 Cyanoalkyl, C 1 ~C 8 Cyanoalkoxy, C 1 ~C 8 Haloalkyl, C 1 ~C 8 Hydroxyalkyl, C 1 ~C 8 Nitroalkyl, C 2 ~C 8 Alkenyl, C 2 ~C 8 Haloalkenyl, C 2 ~C 8 Nitroalkenyl, C 2 ~C 8 Alkynyl, C 2 ~C 8 Haloalkynyl, C 2 ~C 8 Alkoxyalkyl, C 3 ~C 8 Alkoxyalkoxyalkyl, C 2 ~C 8 Haloalkoxyalkyl, C 2 ~C 8 Haloalkoxy haloalkoxy, C 3 ~C 6 Cycloalkyl, cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C 4 ~C 10 Cycloalkylalkyl, C 4 ~C 10 Halocycloalkylalkyl, C 5 ~C 12 Alkylcycloalkylalkyl, C 5 ~C 12 Cycloalkylalkenyl, C 5 ~C 12 Cycloalkylalkynyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Halocycloalkyl, C 4 ~C 10 Alkylcycloalkyl, C 6 ~C 12 Cycloalkyl, C 3 ~C 8 Cycloalkenyl, C 3 ~C 8 Halocycloalkenyl, C 2 ~C 8 Haloalkoxyalkoxy, C 2 ~C 8 Alkoxyalkoxy, C 4 ~C 10 Cycloalkoxyalkyl, C 3 ~C 10 Alkoxyalkoxyalkyl, C 2 ~C 8 Alkylthioalkyl, C 2 ~C 8 Alkylsulfinylalkyl, C 2 ~C 8 Alkylsulfonylalkyl, C 2 ~C 8 Alkylamino, C 2 ~C 8 Dialkylamino, C 2 ~C 8 Halodialkylamino, C 2 ~C 8 Alkylaminoalkyl, C 2 ~C 8 Haloalkylaminoalkyl, C 4 ~C 10 Cycloalkylaminoalkyl, C 3 ~C 10 Dialkylaminoalkyl, -CHO, C 2 ~C 8 Alkylcarbonyl, C 2 ~C 8 Haloalkylcarbonyl, C 4 ~C 10 Cycloalkylcarbonyl, -C(isO)OH, C 2 ~C 8 Alkoxycarbonyl, C 2 ~C 8 Haloalkoxycarbonyl, C 4 ~C 10 Cycloalkoxycarbonyl, C 5 ~C 12 Cycloalkylalkoxycarbonyl, -C(isO)NH 2 , C 2 ~C 8 Alkylaminocarbonyl, C 4 ~C 10 Cycloalkylaminocarbonyl, C 3 ~C 10 Dialkylaminocarbonyl, C 1 ~C 8 Alkoxy, C 1 ~C 8 Haloalkoxy, C 2 ~C 8 Alkoxyalkoxy, C 2 ~C 8 Alkenyloxy, C 2 ~C 8 Haloalkenyloxy, C 3 ~C 8 Alkynyloxy, C 3 ~C 8 Haloalkynyloxy, C 3 ~C 8 Cycloalkoxy, C 3 ~C 8 Halocycloalkoxy, C 4 ~C 10 Cycloalkylalkoxy, C 3 ~C 10 Alkylcarbonylalkoxy, C 2 ~C 8 Alkylcarbonyloxy, C 2 ~C 8 Haloalkylcarbonyloxy, C 4 ~C 10 Cycloalkylcarbonyloxy, C 1 ~C 8 Alkylsulfonyloxy, C 1 ~C 8 Haloalkylsulfonyloxy, C 1 ~C 8 Alkylthio, C 1 ~C 8 Haloalkylthio, C 3 ~C 8 Cycloalkylthio, C 1 ~C 8 Alkylsulfinyl, C 1 ~C 8 Haloalkylsulfinyl, C 1 ~C 8 Alkylsulfonyl, C 1 ~C 8 Haloalkylsulfonyl, C 3 ~C 8 Cycloalkylsulfonyl, formylamino, C 2 ~C 8 Alkylcarbonylamino, C 2 ~C 8 Haloalkylcarbonylamino, C 3 ~C 8 Cycloalkylamino, C 2 ~C 8 Alkoxycarbonylamino, C 1 ~C 6 Alkylsulfonylamino, C 1 ~C 6 Haloalkylsulfonylamino, -SF 5 , -SCN, SO 2 N.H. 2 , C 3 ~C 12 Trialkylsilyl, C 4 ~C 12 Trialkylsilylalkyl, C 4 ~C 12 Trialkylsilylalkoxy, R σ , R η S(=O)=N-,R η S (=O) 2 N, R η -C(=O)-, R η (R η N =) q S (=O) p -Cyano, formyl, C 3 ~C 8 Alkylcarbonylalkyl, -C(C 1 ~C 4 alkyl)=N-O(C 1 ~C 4 alkyl), -C(O)NH 2 , C 2 ~C 6 Cyanoalkyl, C 3 ~C 6 Cycloalkyl, C 4 ~C 8 Cycloalkenyl, arylcarbonyl, arylalkenylalkyl, arylcarbonylalkyl or -CPh=N-O(C 1 ~C 4 alkyl), each of which is R η and optionally substituted on the ring members with up to five substituents independently selected from R θ If is attached to another part of the molecule, the bond is up to 4 C atoms, up to 1 O atom, Up to one S atom and via a saturated, partially unsaturated or fully unsaturated chain containing 2 to 4 atoms selected from up to 2 N atoms, Up to two carbon members of the chain are independently selected from C(=O) and C(=S) and the sulfur atom member of the chain is S(-O). u (-NR ζ ) v and the chain is selected from R η and is optionally substituted with up to five substituents independently selected from R λ is H or R μ and R λ Is, Q α , A β may be attached to another part of the molecule, such as R μ is a phenyl ring or a naphthalenyl ring system, each ring or ring system being unsubstituted or ζ and 8-10 membered bicyclic ring systems, each of which is substituted with carbon atoms and up to 2 O atoms, up to two S atoms, and containing ring members selected from 1 to 4 heteroatoms independently selected from up to 5 N atoms; Up to three C ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently S(=O). u (=NR ζ ) v and each ring or ring system is selected from the group consisting of carbon atom ring members R ζ and R is a nitrogen atom ring member independently selected from η and is unsubstituted or substituted with up to five substituents selected from R π is H or R θ and R ε are -N(Me) 2 R etc. π is a C, N, O or S atom bearing 0-2 substituents selected from α , A β or the like, additionally attached within the ring to another part of the molecule, such as Each R ζ are each independently Hal, OH, CN, nitro, amino, C 1 ~C 8 Alkyl, C 1 ~C 8 Cyanoalkyl, C 1 ~C 8 Cyanoalkoxy, C 1 ~C 8 Haloalkyl, C 1 ~C 8 Hydroxyalkyl, C 1 ~C 8 Nitroalkyl, C 2 ~C 8 Alkenyl, C 2 ~C 8 Haloalkenyl, C 2 ~C 8 Nitroalkenyl, C 2 ~C 8 Alkynyl, C 2 ~C 8 Haloalkynyl, C 2 ~C 8 Alkoxyalkyl, C 3 ~C 8 Alkoxyalkoxyalkyl, C 2 ~C 8 Haloalkoxyalkyl, C 2 ~C 8 Haloalkoxy haloalkoxy, C 3 ~C 6 Cycloalkyl, cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C 4 ~C 10 Cycloalkylalkyl, C 4 ~C 10 Halocycloalkylalkyl, C 5 ~C 12 Alkylcycloalkylalkyl, C 5 ~C 12 Cycloalkylalkenyl, C 5 ~C 12 Cycloalkylalkynyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Halocycloalkyl, C 4 ~C 10 Alkylcycloalkyl, C 6 ~C 12 Cycloalkyl, C 3 ~C 8 Cycloalkenyl, C 3 ~C 8 Halocycloalkenyl, C 2 ~C 8 Haloalkoxyalkoxy, C 2 ~C 8 Alkoxyalkoxy, C 4 ~C 10 Cycloalkoxyalkyl, C 3 ~C 10 Alkoxyalkyl, C 2 ~C 8 Alkylthioalkyl, C 2 ~C 8 Alkylsulfinylalkyl, C 2 ~C 8 Alkylsulfonylalkyl, C 2 ~C 8 Alkylamino, C 2 ~C 8 Dialkylamino, C 2 ~C 8 Halodialkylamino, C 2 ~C 8 Alkylaminoalkyl, C 2 ~C 8 Haloalkylaminoalkyl, C 4 ~C 10 Cycloalkylaminoalkyl, C 3 ~C 10 Dialkylaminoalkyl, -CHO, C 2 ~C 8 Alkylcarbonyl, C 2 ~C 8 Haloalkylcarbonyl, C 4 ~C 10 Cycloalkylcarbonyl, -C(isO)OH, C 2 ~C 8 Alkoxycarbonyl, C 2 ~C 8 Haloalkoxycarbonyl, C 4 ~C 10 Cycloalkoxycarbonyl, C 5 ~C 12 Cycloalkylalkoxycarbonyl, -C(=O)NH 2 , C 2 ~C 8 Alkylaminocarbonyl, C 4 ~C 10 Cycloalkylaminocarbonyl, C 3 ~C 10 Dialkylaminocarbonyl, C 1 ~C 8 Alkoxy, C 1 ~C 8 Haloalkoxy, C 2 ~C 8 Alkoxyalkoxy, C 2 ~C 8 Alkenyloxy, C 2 ~C 8 Haloalkenyloxy, C 3 ~C 8 Alkynyloxy, C 3 ~C 8 Haloalkynyloxy, C 3 ~C 8 Cycloalkoxy, C 3 ~C 8 Halocycloalkoxy, C 4 ~C 10 Cycloalkylalkoxy, C 3 ~C 10 Alkylcarbonylalkoxy, C 2 ~C 8 Alkylcarbonyloxy, C 2 ~C 8 Haloalkylcarbonyloxy, C 4 ~C 10 Cycloalkylcarbonyloxy, C 1 ~C 8 Alkylsulfonyloxy, C 1 ~C 8 Haloalkylsulfonyloxy, C 1 ~C 8 Alkylthio, C 1 ~C 8 Haloalkylthio, C 3 ~C 8 Cycloalkylthio, C 1 ~C 8 Alkylsulfinyl, C 1 ~C 8 Haloalkylsulfinyl, C 1 ~C 8 Alkylsulfonyl, C 1 ~C 8 Haloalkylsulfonyl, C 3 ~C 8 Cycloalkylsulfonyl, formylamino, C 2 ~C 8 Alkylcarbonylamino, C 2 ~C 8 Haloalkylcarbonylamino, C 3 ~C 8 Cycloalkylamino, C 2 ~C 8 Alkoxycarbonylamino, C 1 ~C 6 Alkylsulfonylamino, C 1 ~C 6 Haloalkylsulfonylamino, -SF 5 , -SCN, SO 2 N.H. 2 , C 3 ~C 12 Trialkylsilyl, C 4 ~C 12 Trialkylsilylalkyl, C 4 ~C 12 Trialkylsilylalkoxy, R η , R η S(=O)=N-,R η S (=O) 2 N.R. η -C(=O)- or R η (R η N =) q S (=O) p - and the free bond protruding to the right is R μ etc., and optionally R ζ is another part of the molecule that forms a ring, e.g., Q α , A β etc., Each R η are each independently 1 ~C 3 Alkyl, C 1 ~C 8 Hydroxyalkyl, C 2 ~C 3 Alkenyl, C 2 ~C 3 Alkynyl, C 3 ~C 6 Cycloalkyl, C 2 ~C 3 Alkoxyalkyl, C 1 ~C 3 Alkoxy, C 2 ~C 3 Alkyl carbonyl, C 2 ~C 3 Alkoxycarbonyl, C 2 ~C 3 Alkylaminoalkyl or C 3 ~C 4 dialkylaminoalkyl, optionally R η is another part of the molecule that forms a ring, e.g., Q α , A β etc., Each R σ are each independently phenyl, phenylmethyl (benzyl), pyridinylmethyl, phenylcarbonyl (i.e., benzoyl), phenoxy, phenylethynyl, phenylsulfonyl, or a 5- or 6-membered heterocyclic ring, each R λ and is substituted or unsubstituted at ring members with up to five substituents independently selected from q is 0 to 4; p is 0 to 4; u is 0 to 4; Unsaturated precursor compounds A2 of formula 2 and salts thereof, wherein v is 0-4.

8. The unsaturated precursor compounds of formula 2 selected from the group defined, illustrated or described in any one of claims 6 (A1) and 7 (A2). 【Chemistry 55】 or any compound selected from the group consisting of A2; A2a; A2b; A2c; A2d; A3; A4; A5; A6; A7; A8; A9; A10; A11; A12; A13; A14; A15; A16; A16a; A17; A17a; A18; A19; A20; A21; A22; A23; A24; A25; A26; A27; A28; A29; A30; A31; A32; A33; A34; and A35a: a. Unsaturated precursor compounds A1 of formula 2 according to claim 6 and salts thereof; b. Unsaturated precursor compounds A2 of formula 2 according to claim 7 and salts thereof; c. unsaturated precursor compound A2a, which is compound A2, and salts thereof, nα is 1, R α , R β , Q α , Q β , A β , A α , and R μ has the same meaning as defined for compound A2); d. unsaturated precursor compound A2b which is compound A2 and salts thereof, nα is 2, R α , R β , Q α , Q β , A β , A α , and R μ has the same meaning as defined for compound A2); e. unsaturated precursor compound A2c, which is compound A2, and salts thereof, R β is H, R α , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined for compound A2); f. unsaturated precursor compound A2d which is compound A2 and salts thereof, R α , R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined for compound A2, except that R β is not H). g. an unsaturated precursor compound A3, which is any one of compounds A2, A2a, A2b, A2c, or A2d, and salts thereof, for example, R α is -C(Q α ) Q β R μ or the following structure: 【Chemistry 56】 and R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined for compound A2); h. an unsaturated precursor compound A4, which is any one of compounds A2; A2a; A2b; A2c; or A2d, and salts thereof, wherein R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and 【Chemistry 57】 R β , Q α , Q β , A β , R π , R μ and nα have the same meaning as defined for compound A2); i. an unsaturated precursor compound A5, which is any one of compounds A2; A2c; or A2d, and for example salts thereof, R α is -C(Q α ) Q β R μ and A α is -N(R π ) and nα is 1 as in the ring structure 【Chemistry 58】 R β , Q α , Q β , A β , R π and R μ has the same meaning as defined for compound A2); j. an unsaturated precursor compound A6, which is any one of compounds A2; A2c; and A2d, and salts thereof, for example, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 1, A β is CH as in the ring structure 2 and 【Chemistry 59】 R β , Q α , Q β , R π and R μ has the same meaning as defined for compound A2); k. Unsaturated precursor compound A7, which is any one of compounds A2; A2c; and A2d, and salts thereof, for example, wherein R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 2, A β is CH as in the ring structure 2 and 【Chemistry 60】 R β , Q α , Q β , R π and R μ has the same meaning as defined for compound A2); l. Unsaturated precursor compound A8, which is any one of compounds A2; A2c; and A2d, and salts thereof, for example, wherein R α is -C(O)Q β R μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O as in the ring structure 【Chemistry 61】 R β , Q β , R π and R μ has the same meaning as defined for compound A2); m. Unsaturated precursor compounds A9, which are any one of compounds A2; A2c; and A2d, and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH as in the ring structure 【Chemistry 62】 R β , R π and R μ has the same meaning as defined for compound A2); n. An unsaturated precursor compound A10, which is any one of compounds A2; A2c; and A2d, and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or, as in the ring structure below, R ζ is a phenyl ring substituted with up to five substituents independently selected from 【Chemistry 63】 R β , R π and R ζ has the same meaning as defined for compound A2); o. Compound A2, an unsaturated precursor compound A11 and salts thereof, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is unsubstituted or is R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ and 【Chemistry 64】 R π and R ζ has the same meaning as defined for compound A2); p. Unsaturated precursor compound A12, which is compound A2, and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is unsubstituted or is R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ and 【Chemistry 65】 R ζ has the same meaning as defined for compound A2); q. unsaturated precursor compound A13, which is compound A2, and salts thereof, R α is -C(O)NHR μ and A α is -NH-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is unsubstituted or is R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ and 【Chemistry 66】 R ζ has the same meaning as defined for compound A2); r. unsaturated precursor compound A14, which is compound A2, and salts thereof, R α is -C(O)NHR μ and A α is -NH-, nα is 2, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is unsubstituted or is R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ and 【Chemistry 67】 R ζ has the same meaning as defined for compound A2); s. unsaturated precursor compound A15, which is compound A2, and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 2, a.A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is unsubstituted or is R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ and 【Chemistry 68】 R ζ has the same meaning as defined for compound A2); t. Unsaturated precursor compound A16 having the following structure: 【Chemistry 69】 u. Unsaturated precursor compound A16a having the following structure: 【Chemistry 70】 v. Unsaturated precursor compound A17 having the structure: 【Chemistry 71】 w. A synthetic intermediate compound A17a of an agricultural chemical having the following structure: 【Chemical 72】 x. Unsaturated precursor compound A18 having the following structure: 【Chemical Formula 73】 y. Unsaturated precursor compound A19 having the following structure: 【Chemical 74】 z. Unsaturated precursor compound A20 having the following structure: 【Chemistry 75】 aa. Unsaturated precursor compound A21 having the following structure: 【Chemical 76】 bb. Unsaturated precursor compound A22 having the structure: 【Chemical 77】 cc. Unsaturated precursor compound A23 having the following structure: 【Chemical 78】 dd. Unsaturated precursor compound A24 having the following structure: 【Chemical Formula 79】 ee. Unsaturated precursor compound A25 having the following structure: 【Chemistry 80】 ff. Unsaturated precursor compound A26 having the following structure: 【Chemistry 81】 gg. Unsaturated precursor compound A27 having the following structure: 【Chemistry 82】 hh. Unsaturated precursor compound A28 having the following structure: 【Chemistry 83】 ii. Unsaturated precursor compound A29 having the following structure: 【Chemistry 84】 jj. Unsaturated precursor compound A30 having the following structure: 【Chemistry 85】 kk. Compound A2 is an unsaturated precursor compound A31 and salts thereof, for example, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or, as in the ring structure below, R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H as in the ring structure i. 【Chemistry 86】 R π and R ζ has the same meaning as defined for compound A2); ll. Unsaturated precursor compound A32, which is compound A2, and salts thereof, R α is -C(O)NHR μ and A α is -NH-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or, as in the ring structure below, R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H as in the ring structure 【Chemistry 87】 R ζ has the same meaning as defined for compound A2); mm. unsaturated precursor compound A33 which is compound A2 and salts thereof, R α is -C(O)NHR μ and A α is -NH-, nα is 2, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or, as in the ring structure below, R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H as in the ring structure 【Chemistry 88】 R ζ has the same meaning as defined for compound A2); nn. unsaturated precursor compound A34 which is compound A2 and salts thereof, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 2, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or, as in the ring structure below, R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H as in the ring structure 【Chemistry 89】 R ζ has the same meaning as defined for compound A2), and oo. An unsaturated precursor compound A35a selected from the following structures: 【Chemistry 90】 (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6 , Y1 and Y2 etc. have the meanings defined in claim 1 of International Application PCT / US2014 / 068073, published as WO 2015 / 084796.

9. An unsaturated precursor for use as an agrochemical, preferably as a herbicide synthesis process intermediate and / or marker compound, as defined, illustrated or described in any one of the compounds selected from A1; A2; A2a; A2b; A2c; A2d; A3; A4; A5; A6; A7; A8; A9; A10; A11; A12; A13; A14; A15; A16; A16a; A17; A17a; A18; A19; A20; A21; A22; A23; A24; A25; A26; A27; A28; A29; A30; A31; A32; A33; A34; and A35a of claim 8.

10. 10. A compound as defined, shown or described in any one of compounds selected from A16; A16a; A17; A17a; A18 and A19 of claim 8.

11. 10. A compound as defined, shown or described in compound A16 of claim 8.

12. 10. A compound as defined, shown or described in compound A17 of claim 8.

13. A combination defined, illustrated or described as any one of the following combinations selected from: A41a; A42a; A43a; B1a; B15b; B15d; C2b; C35b; C36b; C37c; C38a; C41; C42a; C43a; E2; M1; M2; M3; M4. a. Each of the following structures 【Chemistry 91】 A41a, a combination of saturated targets, N-oxides and salts thereof of the following formulae, as defined in claim 1 of PCT / US2018 / 035017, published as WO 2018 / 222647, in combination with at least one unsaturated precursor defined by any one of 【Chemistry 92】 (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 9 , J, L, Y and Y2 etc. have the meanings defined in claim 1 of application PCT / US2018 / 035017, published as WO 2018 / 222647; b. each of the following structures: 【Chemistry 93】 A42a is a combination of a saturated target, an N-oxide salt thereof and a stereoisomer thereof, which is a compound as defined in claim 1 of PCT / US2018 / 035015, published as WO 2018 / 222646, of the following formula: 【Chemistry 94】 wherein Q1, Q2, R1, R7, R8, R9, J, Y and W etc. have the meanings defined in claim 1 of application PCT / US2018 / 035015, published as WO 2018 / 222646; c. Each has a structure 【Chemistry 95】 A43a combination of saturated targets and salts thereof of the following formula: 【Chemistry 96】 (In the formula, Q, W 2 , R 1 , R 2 , Y and Z etc. have the meanings defined in claim 1 of application PCT / EP2018 / 057628, published as WO 2018 / 184890; d. in combination with the amount of intermediate unsaturated precursor compound as an impurity produced therefrom selected from Compounds A1-A52 of Process B1 and Formula 2; 【Chemistry 97】 Combination B1a of saturation targets of formula 1 defined in process B1 【Chemistry 98】 e. Combination B15b of a saturated target as defined in process B1 combined with an intermediate unsaturated precursor compound produced as an impurity using any one of processes B1-B14; f. A combination B15d of the saturated target defined in process B1 combined with an intermediate unsaturated precursor compound produced as an impurity by any one of processes B1-B14; g. Combination C2b of a saturated target compound of formula 1 combined with an intermediate compound of formula 3 produced as an impurity, 【Chemistry 99】 The intermediate is a compound defined in any one of compounds C1a; C1b; C1c; and C2, γ has the same meaning as defined in any one of Processes B1, B1a, B1b; B2 and B2a; h. at least one compound defined by any one of the following formulas: 【Chemistry 100】 (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R 6 , Y 1 and Y 2 etc. have the meaning defined in claim 1 of application PCT / US2014 / 068073, published as WO 2015 / 084796, X α =SPh、SePh、SG α 、SeG α G α = alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups) 【Chemistry 101】 C35b, a combination of saturated target compounds having i. at least one compound defined by any one of the following formulas: 【Chemistry 102】 (In the formula, Q, R 1 , R 6 , Y and W etc. have the meanings defined in claim 1 of application PCT / US2020 / 034232, published as WO 2020 / 242946; X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups, 【Chemistry 103】 C36b, a combination of saturated target compounds having j. at least one compound defined by any one of the following formulas: 【Chemistry 104】 (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 7 , Y, A and J etc. have the meanings defined in claim 1 of application PCT / US2016 / 030450, published as WO 2016 / 182780; X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups, 【Chemistry 105】 C37c, a combination of saturated target compounds having k. at least one compound defined by any one of the following structures: 【Chemistry 106】 (In the formula, Q 1 , Q 2 , R B1 and X etc. have the meanings defined in claim 1 of application PCT / EP2020 / 052780, published as WO 2020 / 161147; X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen, alkyl, and haloalkyl groups. The formula (B) as defined in claim 1 (B) below: 【Chemistry 107】 Saturated target compound combination C38a; l. at least one compound, each defined by any one of the following structures: 【Chemistry 108】 (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 9 , J, L, Y, and Y 2 etc. have the meaning defined in claim 1 of application PCT / US2018 / 035017, published as WO 2018 / 222647, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups; alkyl groups; and haloalkyl groups, 【Chemistry 109】 Saturation target combination C41; m. A combination of a saturated target, its N-oxide and stereoisomer C42a, wherein said saturated target is at least one compound defined by any one of the following structures, respectively: 【Chemistry 110】 (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 8 , R 9 , J, Y and W etc. have the meanings defined in claim 1 of application PCT / US2018 / 035015, published as WO 2018 / 222646; X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups, 【Chemistry 111】 a combination which is a compound as defined in claim 1 of application PCT / US2018 / 035015, published as WO 2018 / 222646, having the formula: n. the following structure: 【Chemistry 112】 (In the formula, Q, W 2 , R 1 , R 2 , Y and Z etc. have the meanings defined in claim 1 of application PCT / EP2018 / 057628, published as WO 2018 / 184890; X α SPh, SePh, SG α , SeG α and G α wherein R is an integer from 1 to 5; R is an integer from 1 to 5; and R is an integer from 1 to 5; R is an integer from 1 to 5; and R is an integer from 1 to 5; R is an integer from 1 to 5; and R is an integer from 1 to 5; R is an integer from 1 to 5; and R is an integer from 1 to 5; R is an integer from 1 to 5; and R is an integer from 1 to 5; 【Chemistry 113】 o. Formula 4 produced as an impurity 【Chemistry 114】 (In the formula, R α , R β , A α , A β , nα and Q α has the same meaning as defined for compound A2, R δ and R γ have the same meaning as defined in process B1), and e.g. salts thereof, 【Chemistry 115】 p. The following formula: 【Chemistry 116】 (In the formula, each R ζ A combination M1 of the saturation target of formula 1 as defined in process B1, combined with an amount of any one of the markers, impurities, and degrading compounds having the compounds A1 to A52 and process B1. 【Chemistry 117】 q. The following formula: 【Chemistry 118】 A combination M2 of the saturation target of formula 1 defined in process B1 combined with an amount of any one of a marker, impurity, and degrading compound having 【Chemistry 119】 r. the following formula: 【Chemistry 120】 A combination M3 of the saturation target of formula 1 defined in process B1 combined with an amount of any one of a marker, impurity, and degrading compound having the formula: 【Chemistry 121】 s. the following formula: 【Chemistry 122】 (In the formula, each R θ And each R ζ A combination M4 of a saturation target of formula 1 as defined in process B1 combined with an amount of any one of a marker, impurity, or degradable compound having the formula (I) as defined in compound A2. 【Chemistry 123】

14. Compound C1a; C1b; C1c; C2; C3a; C3b; C4a; C4b; C5a; C5b; C5c; C6a; C6b; C7a; C7b; C8a; 15; C16; C16a; C16b; C16c; C16d; C16e; C16f; C16g; C16h; C17a; C17b; C17c; C17d; A compound as defined, illustrated or described in any one of: C20a; C20b; C21a; C21b; C22a; C22b; C23a; C23b; C24a; C24b; C25a; C25b; C26a; C26b; C27a; C27b; C28a; C28b; C29a; C29b; C30a; C30b; C31a; C31b; C32a; C32b; C33; C34; C35a; C36a; C37a; C37b; C38; C39; C40; C42; and C43, or selected from the group consisting of: (a) Compound C1a of formula 3 and, for example, salts thereof 【Chemical 124】 (In the formula, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; R α , R β , A α , A β , nα and Q α has the same meaning as defined for compound A2); (b) Compound C1b of formula 3 and, for example, salts thereof 【Chemistry 125】 (In the formula, X α is a halogen, R α , R β , A α , A β , nα and Q α has the same meaning as defined for compound A2); (c) Compound C1c of formula 3 and, for example, salts thereof 【Chemistry 126】 (In the formula, X α is N(G α ) 2 , N + (O - ) (G α ) 2 [That is, N(G α ) 2 and the N-oxide of G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; R α , R β , A α , A β , nα and Q α has the same meaning as defined for compound A2); (d) Compound C2 of formula 3 and, for example, salts thereof 【Chemistry 127】 wherein the compound of formula 3 does not contain a covalent nitrogen-halogen bond; X α is halogen, SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; R α , R β , A α , A β , nα and Q α has the same meaning as defined for compound A2); (e) Compounds C3a and, for example, salts thereof of Compound C2 as process intermediates and / or markers, R α is -C(Q α ) Q β R μ and X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups each selected from halogen; alkyl; and haloalkyl; 【Chemistry 128】 R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined for compound A2); (f) Compounds C3b and, for example, salts thereof of Compound C2 as process intermediates and / or markers, R α is -C(Q α ) Q β R μ and X α is halogen, N(G α ) 2, N + (O - ) (G α ) 2 and 【Chemistry 129】 R β , Q α , Q β , A β , A α , R μ and nα have the same meaning as defined for compound A2); (g) Compounds C4a and, for example, salts thereof of Compound C2 as process intermediates and / or markers, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups each selected from halogen; alkyl; and haloalkyl; 【Chemistry 130】 R β , Q α , Q β , A β , R π , R μ and nα have the same meaning as defined for compound A2); (h) Compounds C4b and, for example, salts thereof of Compound C2 as process intermediates and / or markers, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and X α is halogen, N(G α ) 2, N + (O - ) (G α ) 2 and 【Chemistry 131】 R β , Q α , Q β , A β , R π , R μ and nα have the same meaning as defined for compound A2); (i) Compound C5a of Compound C2 and, for example, salts thereof, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 1, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 132】 R β , Q α , Q β , A β , R π and R μ has the same meaning as defined for compound A2); (j) Compound C5b of Compound C2 as process intermediates and / or markers and, for example, salts thereof, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 1, X α is a halogen, 【Chemistry 133】 R β , Q α , Q β , A β , R π and R μ has the same meaning as defined for compound A2); (k) Compound C5c of Compound C2 and, for example, salts thereof, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 1, X α is SPh, SePh, G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 134】 R β , Q α , Q β , A β , R π and R μ has the same meaning as defined for compound A2); (l) Compound C6a and, for example, salts thereof of Compound C2 as process intermediates and / or markers, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 135】 R β , Q α , Q β , R π and R μ has the same meaning as defined for compound A2); (m) Compounds C6b and, for example, salts thereof of Compound C2 as process intermediates and / or markers, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and X α is a halogen, 【Chemistry 136】 R β , Q α , Q β , R π and R μ has the same meaning as defined for compound A2); (n) Compounds C7a and, for example, salts thereof of Compound C2 as process intermediates and / or markers, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 2, A β is CH 2 and X α SPh, SePh, SG α , SeG α G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 137】 R β , Q α , Q β , R π and R μ has the same meaning as defined for compound A2); (o) Compound C7b of Compound C2 as process intermediates and / or markers and, for example, salts thereof, R α is -C(Q α ) Q β R μ and A α is -N(R π ) - and nα is 2, A β is CH 2 and X α is a halogen, 【Chemistry 138】 R β , Q α , Q β , R π and R μ has the same meaning as defined for compound A2); (p) Compound C8a of Compound C2 and, for example, salts thereof, R α is -C(O)Q β R μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 139】 R β , Q β , R π and R μ has the same meaning as defined for compound A2); (q) Compound C8b of Compound C2 and, for example, salts thereof, R α is -C(O)Q β R μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, X α is N + (O - ) (G α ) 2 and 【Chemistry 140】 R β , Q β , R π and R μ has the same meaning as defined for compound A2); (r) Compounds C9a and, for example, salts thereof of Compound C2 as process intermediates and / or markers, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, X α SPh, SePh, SG α , SeG α G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 141】 R β , R π and R μ has the same meaning as defined for compound A2); (s) Compound C9b of Compound C2 and, for example, salts thereof, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, X α is SPh, SePh, 【Chemistry 142】 R β , R π and R μ has the same meaning as defined for compound A2); (t) Compounds C9c and, for example, salts thereof, of Compound C2 as process intermediates and / or markers, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, X α is a halogen, 【Chemistry 143】 R β , R π and R μ has the same meaning as defined for compound A2); (u) Compound C10 of Compound C2 and salts thereof (wherein R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 144】 R β , R π and R ζ has the same meaning as defined for compound A2); (v) Compound C11 of compound C2 and, for example, salts thereof, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents independently selected from R β is unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ and X α is SPh, SePh, 【Chemistry 145】 R π and R ζ has the same meaning as defined for compound A2); (w) Compound C12 of Compound C2 and salts thereof (wherein R α is -C(O)NHR μ and A α is -N(Me)-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ , X α is SPh, SePh, 【Chemistry 146】 R ζ has the same meaning as defined for compound A2); (x) Compound C12a of Compound C2 and salts thereof (wherein R α is -C(O)NHR μ and A α is -N(Me)-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ , X α is a halogen, 【Chemistry 147】 R ζ has the same meaning as defined for compound A2); (y) Compound C12b of Compound C2 and salts thereof (wherein R α is -C(O)NHR μ and A α is -N(Me)-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ , X α is N + (O - ) (G α ) 2 and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 148】 R ζ has the same meaning as defined for compound A2); (z) Compound C13 of Compound C2 and salts thereof (wherein R α is -C(O)NHR μ and A α is -NH-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ , X α SPh, SePh, SG α , SeG α , N + (O - ) (G α ) 2 and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 149】 R ζ has the same meaning as defined for compound A2); (aa) Compound C14 of Compound C2 and salts thereof (wherein R α is -C(O)NHR μ and A α is -NH-, nα is 2, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents independently selected from λ , X α SPh, SePh, SG α , SeG α , N + (O - ) (G α ) 2 and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 150】 R ζ has the same meaning as defined for Compound A); (bb) Compound C15 of Compound C2 and salts thereof (wherein R α is -C(O)NHR μ and A α is -N(Me)-, nα is 2, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β = unsubstituted or R ζ R is a phenyl ring substituted with up to five substituents each independently selected from λ , X α SPh, SePh, SG α , SeG α , N + (O - ) (G α ) 2 and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 151】 R ζ has the same meaning as defined for compound A2); (cc) Compound C16 selected from any one of compounds C1 to C15 and, for example, salts thereof (In the formula, X α is SPh, R α , R β , A α , A β , nα and Q α has the same meaning as for compound A2); (dd) Compound C16a selected from any one of compounds C1 to C15 and, for example, a salt thereof (In the formula, X α is N(Me) 2 and R α , R β , A α , A β , nα and Q α has the same meaning as for compound A2); (ee) Compound C16b having the formula: 【Chemistry 152】 (ff) compound C16c having the formula 【Chemistry 153】 (gg) Compound C16d having the formula: 【Chemistry 154】 (hh) a compound for use as an agrochemical, preferably a herbicide synthesis process intermediate and / or marker compound C16e, of the following structure: 【Chemistry 155】 (ii) a compound for use as an agrochemical, preferably a herbicide synthesis process intermediate and / or marker compound C16f, of the following structure: 【Chemistry 156】 (jj) a compound for use as an agrochemical, preferably a herbicide synthesis process intermediate and / or marker compound C16g, of the following structure: 【Chemistry 157】 (kk) a compound for use as an agrochemical, preferably a herbicide synthesis process intermediate and / or marker compound C16h, of the following structure: 【Chemistry 158】 (ll) Compound C17a having the formula: 【Chemistry 159】 (mm) compound C17b having the formula 【Chemistry 160】 (nn) compound C17c having the formula 【Chemistry 161】 (oo) Compound C17d having the formula 【Chemistry 162】 (pp) a compound for use as an agrochemical, preferably a herbicide synthesis process intermediate and / or marker compound C17f, of the following structure: 【Chemistry 163】 (qq) a compound for use as an agrochemical, preferably a herbicide synthesis process intermediate and / or marker compound C17g, of the following structure: 【Chemistry 164】 (rr) a compound for use as an agrochemical, preferably a herbicide synthesis process intermediate and / or marker compound C17h, of the following structure: 【Chemistry 165】 (ss) a compound for use as an agrochemical, preferably a herbicide synthesis process intermediate and / or marker compound C17i, of the following structure: 【Chemistry 166】 (tt) compound C18a having the formula 【Chemistry 167】 (uu) Compound C18b having the formula: 【Chemistry 168】 (vv) Compound C19a having the formula 【Chemistry 169】 (ww) compound C19b having the formula 【Chemistry 170】 (xx) compound C20a having the formula 【Chemistry 171】 (yy) Compound C20b having the formula: 【Chemistry 172】 (zz) compound C21a having the formula 【Chemistry 173】 (aaa) Compound C21b having the formula: 【Chemistry 174】 (bbb) Compound C22a having the formula 【Chemistry 175】 (ccc) compound C22b having the formula 【Chemistry 176】 (ddd) compound C23a having the formula 【Chemistry 177】 (eee) Compound C23b having the formula: 【Chemistry 178】 (fff) compound C24a having the formula 【Chemistry 179】 (ggg) Compound C24b having the formula: 【Chemistry 180】 (hhh) Compound C25a having the formula 【Chemistry 181】 (iii) Compound C25b having the formula: 【Chemistry 182】 (jjj) Compound C26a having the formula 【Chemistry 183】 (kkk) compound C26b having the formula 【Chemistry 184】 (lll) Compound C27a having the formula 【Chemistry 185】 (mmm) compound C27b having the formula 【Chemistry 186】 (nnn) compound C28a having the formula 【Chemistry 187】 (ooo) Compound C28b having the formula 【Chemistry 188】 (ppp) compound C29a having the formula 【Chemistry 189】 (qqq) Compound C29b having the formula 【Chemistry 190】 (rrr) Compound C30a having the formula 【Chemistry 191】 (sss) Compound C30b having the formula 【Chemistry 192】 (ttt) Compound C31a of Compound C2 and, for example, salts thereof, R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 193】 R π and R ζ has the same meaning as defined for compound A2); (uuu) Compound C31b of Compound C2 and salts thereof (wherein R α is -C(O)NHR μ and A α is -N(R π ) - and nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α is a halogen, 【Chemistry 194】 R π and R ζ has the same meaning as defined for compound A2); (vvv) Compound C32a of Compound C2 and, for example, salts thereof, R α is -C(O)NHR μ and A α is -NH-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 195】 R ζ has the same meaning as defined for compound A2); (www) Compound C32b of Compound C2 and, for example, salts thereof (wherein R α is -C(O)NHR μ and A α is -NH-, nα is 1, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α is a halogen, 【Chemistry 196】 R ζ has the same meaning as defined for compound A2); (xxx) Compound C33 of compound C2 and, for example, salts thereof, R α is -C(O)NHR μ and A α is -NH-, nα is 2, A β is CH 2 and Q α is O, Q β is NH, R μ is a phenyl ring that is unsubstituted or substituted with up to five substituents each independently selected from R; R β is H, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 197】 R ζ has the same meaning as defined for compound A2); (yyy) Compound C34 of Compound C2 and, for example, salts thereof, R α is -C(O)NHR μ and A α is -N(Me)-, nα is 2, A β is CH 2 and Q α is O, Q β is NH, R μ is unsubstituted or R ζ is a phenyl ring substituted with up to five substituents each independently selected from R β is H, X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups; 【Chemistry 198】 R ζ has the same meaning as defined for compound A2); (zzz) compound C35a defined by any one of the following structures: 【Chemistry 199】 (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 3 , R 4 , R6, Y1 and Y2 etc. have the meanings defined in claim 1 of PCT / US2014 / 068073, published as WO 2015 / 084796; X α =SPh、SePh、SG α 、SeG α G α = phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups; alkyl groups; and haloalkyl groups; (aaaa) Compound C36a defined by any one of the following structures: 【Chemistry 200】 (In the formula, Q, R 1 , Y and W have the meanings defined in claim 1 of PCT / US2020 / 034232, published as WO 2020 / 242946; X α =SPh, SePh, SG α , SeG α , and G α = phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups; alkyl groups; and haloalkyl groups; (bbbb) Compound C37a defined by any one of the following formulae: 【Chemistry 201】 (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 7 , Y, A and J etc. have the meanings defined in claim 1 of PCT / US2016 / 030450, published as WO 2016 / 182780; X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups; (cccc) Compound C37b for use as an intermediate and / or marker in the synthesis process of an agrochemical, preferably a herbicide, having any one of the following structures: 【Chemistry 202】 (In the formula, Q 1 , Q 2 , R 1 , R 2 , R 7 , Y, A and J etc. have the meanings defined in claim 1 of PCT / US2016 / 030450, published as WO 2016 / 182780; X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups; (dddd) a compound C38 defined by any one of the following formulae: 【Chemistry 203】 (In the formula, Q 1 , Q 2 , R B1 and X have the meaning defined in claim 1 of PCT / EP2020 / 052780, published as WO 2020 / 161147; X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups; (eeee) Compound C39 defined by any one of the following formulae: 【Chemistry 204】 (In the formula, Q, W 2 , R 1 , Y and Z etc. have the meanings defined in claim 1 of PCT / EP2018 / 069001, published as WO 2019 / 025156; X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups; (ffff) a compound C40 defined by any one of the following formulae: 【Chemistry 205】 (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 9 , J, L, Y, and Y 2 etc. have the meaning defined in claim 1 of PCT / US2018 / 035017, published as WO 2018 / 222647, X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups; (gggg) Compound C42 defined by any one of the following formulae: 【Chemistry 206】 (In the formula, Q 1 , Q 2 , R 1 , R 7 , R 8 , R 9 , J, Y and W etc. have the meanings defined in claim 1 of PCT / US2018 / 035015, published as WO 2018 / 222646; X α SPh, SePh, SG α , SeG α and G α is phenyl substituted with 0 to 5 groups selected from alkyl, haloalkyl, phenyl, halogen groups, alkyl groups, and haloalkyl groups; and (hhhh) formula 【Chemistry 207】 Compound C43 defined by any one of (In the formula, Q, W 2 , R 1 , R 2 , Y and Z, etc. have the meanings defined in claim 1 of PCT / EP2018 / 057628, published as WO 2018 / 184890; X α SPh, SePh, SG α , SeG α and G α is alkyl, haloalkyl, phenyl, and phenyl substituted with 0 to 5 groups selected from halogen groups; alkyl groups; and haloalkyl groups.

15. A compound as defined, depicted or described in Compound C16c.

16. A compound as defined, depicted or described in Compound C17a.

17. As defined, illustrated or described in any one of processes D1a; D1b; D2a; D2b; D3a; D3b; D3c; D4a; D4b; D5a; D5b; D6a; D6b; D7a; D7b; D8a; D8b; D9a; and D9b, or selected from: (a) Process D1a, as generally described above, for preparing an unsaturated precursor of formula 2 from a compound of formula 3, comprising 【Chemistry 208】 Meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (H 2 O 2 ) or the like, α , R α , R β , A α , A β , nα, and Q α each of which has the same meaning as in compound C1a); (b) Process D1b, as generally described above, for preparing an unsaturated precursor of formula 2 from a compound of formula 3, comprising 【Chemistry 209】 A process comprising an elimination reaction utilizing an activating agent such as a base or a Lewis acid, α , R α , R β , A α , A β , nα and Q α each of which has the same meaning as for compound C1a); (c) dissolving the compound of formula 3 in a suitable solvent, such as acetic acid, stirring (e.g., agitating, etc.) for a period of time, such as about 20 minutes, at a suitable temperature, and reacting the compound with meta-chloroperoxybenzoic acid (mCPBA) or hydrogen peroxide (H 2 O 2 and adding an oxidizing agent, exemplified by NaHCO, in small portions. The reaction mass is then stirred at substantially the same temperature for a period of time, e.g., about 2 hours. The reaction mass is stirred at substantially the same temperature for a period of time, e.g., about 2 hours. 3 It can be quenched into an aqueous solution and extracted, typically twice, with a suitable solvent. The combined organic layers can be concentrated to give the corresponding unsaturated precursor of formula 2; (d) Process D2b of process D1a, comprising dissolving the compound of formula 3 in a suitable solvent, for example chlorobenzene, stirring (e.g., by stirring, etc.) for a period of time, for example about 20 minutes, and adding an activating agent, for example a base or a Lewis acid, in portions at a suitable temperature. The reaction mass is then stirred at substantially the same temperature for a period of time, for example about 2 hours. The reaction mass is then stirred with, for example, NH 4 The resulting mixture can be quenched into Cl solution and extracted, typically twice, with a suitable solvent. The combined organic layers can be concentrated to give the corresponding unsaturated precursor of formula 2; (e) The following scheme: 【Chemistry 210】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 211】 Process D3a, comprising the oxidation of a compound of formula: (f) The following scheme: 【Chemistry 212】 The process is exemplified by: 2 O 2 ) to obtain the corresponding unsaturated precursor, 【Chemistry 213】 Process D3b, comprising the oxidation of a compound of formula: (g) The following scheme: 【Chemistry 214】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 215】 Process D3c, comprising the oxidation of a compound of formula: (h) The following scheme: 【Chemistry 216】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 217】 Process D4a, comprising the oxidation of a compound of formula: (i) The following scheme: 【Chemistry 218】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemical 219】 Process D4b, which comprises the oxidation of a compound of formula: (j) The following scheme: 【Chemistry 220】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 221】 Process D5a, comprising the oxidation of a compound of formula: (k) The following scheme: 【Chemical 222】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemical 223】 Process D5b, which comprises the oxidation of a compound of formula: (l) Scheme 【Chemical 224】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 225】 Process D6a, comprising the oxidation of a compound of formula: (m) The following scheme: 【Chemical 226】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemical 227】 Process D6b, which comprises the oxidation of a compound of formula: (n) Scheme 【Chemical 228】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemical 229】 Process D7a, comprising the oxidation of a compound of formula: (o) The following scheme 【Chemistry 230】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 231】 Process D7b, which comprises the oxidation of a compound of formula: (p) The following scheme 【Chemistry 232】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 233】 Process D8a, comprising the oxidation of a compound of formula: (q) The following scheme: 【Chemical 234】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 235】 Process D8b, which comprises the oxidation of a compound of formula: (r) The following scheme 【Chemistry 236】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemistry 237】 Process D9a, which comprises the oxidation of a compound of the formula (s) Scheme 【Chemical 238】 The process is exemplified by: 2 O 2 to obtain the corresponding unsaturated precursor compound, using an oxidizing agent exemplified by 【Chemical 239】 Process D9b, which comprises the oxidation of a compound of formula:

18. For use as an intermediate in the process for the preparation of the corresponding saturated target of formula 1, 【Chemistry 240】 (In the formula, R α , R β , A α , A β , nα and Q α has the same meaning as defined for compound A2, R δ and R γ have the same meaning as defined in Process B) A compound as defined, illustrated or described in Compound E1, or Compound E1 of formula 4, and for example salts thereof. 【Chemical 241】

19. F2a; F2b; F3; and F4, or selected from the group consisting of: (a) A process F1a for preparing a compound of formula 3 from a compound of formula 4, comprising the steps of: 【Chemical 242】 X by using a base and an electrophile α including the addition of a "leaving" group, X α , R α , R β , A α , A β , nα and Q α each of which has the same meaning as compound C1a; (b) A process F1b for preparing a compound of formula 3 from a compound of formula 4, comprising the steps of: 【Chemical 243】 By using a leaving group source such as a halogenating agent, α Addition of a leaving group is included, X α , R α , R β , A α , A β , nα and Q α each of which has the same meaning as in compound C1a; (c) A process F1c for preparing a compound of formula 3 from a compound of formula 4, comprising the steps of: 【Chemical 244】 X by using a base and an electrophile α including the addition of groups, X α , R α , R β , A α , A β , nα and Q α each of which has the same meaning as compound C1b; (d) Process F2a of Process F1a, which comprises dissolving the compound of formula 4 in a suitable solvent containing a base such as sodium hydride at a specified temperature, typically with cooling and stirring (e.g., stirring, etc.) for a period of time exemplified as about 20 minutes, adding an electrophile exemplified by any of diphenyl disulfide; phenyl hypochlorite; phenyl hypobromite dissolved in a suitable solvent at substantially the same temperature, and stirring the reaction mass at substantially the same temperature for a period of time. 4 Cl solution and extracted, typically two or more times, with a suitable solvent, and the combined organic layers are washed and 2 SO 4 and concentrating to give the corresponding compound of formula 3; (e) Process F2b of Process F1b, comprising dissolving the compound of formula 4 together with a leaving group source exemplified by a halogenation reagent (e.g., a bromine source) in a suitable solvent at a particular temperature, and optionally adding a base and / or a catalyst (catalyst components including one or more of catalyst; pre-catalyst; co-catalyst). The reaction mass is stirred (e.g., stirred, etc.) at substantially the same temperature, for example, for about 2 hours, and the reaction mass is quenched and extracted with a suitable solvent. Preferably, the cake is washed again and / or the combined organic layers are washed, optionally with, for example, Na 2 SO 4 and concentrating to give the corresponding compound of formula 3; (f) Process F3, either one of Process F2a or F2b, further comprising purifying the compound of formula 3 obtained from the above process; and (g) Process F4 of any one of Processes F1 to F3, wherein the electrophile used is either diphenyl disulfide or phenyl hypochlorite.

20. A compound as defined, depicted or described in any one of compounds G1; G2; DD1; DD2; DD3; DD4; DD5; DD6; DD7; DD8; DD9; DD10; and DD11, or selected from the group consisting of: (a) a preserved marker G1 having the following structure, and salts thereof: 【Chemistry 245】 (In the formula, R β , Q α , Q β and R π has the same meaning as defined for compound A2); (b) Preserved marker compound G2 of formula D obtained by exposing tetflupyrrolimet to sunlight 【Chemical formula 246】 (c) a conserved marker compound DD1 of the formula: 【Chemical 247】 (In the formula, R β , Q α , A β , A α and nα have the same meaning as defined for compound A2); (d) a conserved marker compound DD2 of the formula: 【Chemical 248】 (In the formula, R β , Q α , A β and R π has the same meaning as defined for compound A2); (e) a conserved marker compound DD3 of the formula: 【Chemical 249】 (In the formula, R π and R ζ has the same meaning as defined for compound A2); (f) a conserved marker compound DD4 of the formula: 【Chemistry 250】 (In the formula, R β , Q α , A β and R π has the same meaning as defined for compound A2); (g) a conserved marker compound DD5 of the formula: 【Chemistry 251】 (In the formula, each R ζ has the same meaning as defined for compound A2); (h) a conserved marker compound DD6 of the formula: 【Chemistry 252】 (i) the conserved marker compound DD7 of the formula: 【Chemistry 253】 (j) the preserved marker compound DD8 of the formula: 【Chemical 254】 (k) the conserved marker compound DD9 of the formula: 【255】 (l) Conserved marker compound DD10 of the formula: 【256】 and (m) A conserved marker compound DD11 of the formula: 【Chemistry 257】

21. Conserved marker compounds as defined, depicted or described in any one of compounds G1; G2; DD1; DD2; DD3; DD4; DD5; DD6; DD7; DD8; DD9; DD10; and DD11, or selected from the group consisting of: (a) a preserved marker G1 having the following structure, and salts thereof: 【Chemistry 258】 (In the formula, R β , Q α , Q β and R π has the same meaning as defined for compound A2); (b) Preserved marker compound G2 of formula D obtained by exposing tetflupyrrolimet to sunlight 【Chemical 259】 (c) a conserved marker compound DD1 of the formula: 【Chemistry 260】 (In the formula, R β , Q α , A β , A α and nα have the same meaning as defined for compound A2); (d) a conserved marker compound DD2 of the formula: 【Chemical 261】 (In the formula, R β , Q α , A β and R π has the same meaning as defined for compound A2); (e) a conserved marker compound DD3 of the formula: 【Chemical 262】 (In the formula, R π and R ζ has the same meaning as defined for compound A2); (f) a conserved marker compound DD4 of the formula: 【Chemical 263】 (In the formula, R β , Q α , A β and R π has the same meaning as defined for compound A2); (g) a conserved marker compound DD5 of the formula: 【Chemical 264】 (In the formula, each R ζ has the same meaning as defined for compound A2); (h) a conserved marker compound DD6 of the formula: 【Chemistry 265】 (i) the conserved marker compound DD7 of the formula: 【Chemical 266】 (j) the preserved marker compound DD8 of the formula: 【Chemical 267】 (k) the conserved marker compound DD9 of the formula: 【Chemical 268】 (l) Conserved marker compound DD10 of the formula: 【Chemical 269】 and (m) A conserved marker compound DD11 of the formula: 【Chemistry 270】

22. A conserved marker compound defined, depicted or described as compound G2.

23. As defined, illustrated or described in any one of Processes H1; H2; H2a; H3; H4; H5; and H6, or selected from the group consisting of: (a) In the following general scheme, a process H1 for preparing a storage marker compound from a corresponding saturated target compound, wherein the saturated target is exposed to sunlight for a sufficient time to form a detectable amount of the corresponding storage marker, as measured by analytical methods exemplified by HPLC and in particular HPLC-MS: 【Chemistry 271】 (In the formula, R β , A β , A α , R ζ and nα have the same meaning as defined for compound A2); (b) Process H2 for preparing a preserved marker compound from a corresponding saturated target compound in the following general scheme: 【Chemical 272】 A process comprising exposing a composition, such as a solution of a saturated target, to sunlight for a time sufficient for a detectable amount, particularly an amount above the limit of quantification, of a corresponding storage marker to be formed in the composition using analytical techniques exemplified by HPLC-MS; (c) Process H2a for preparing a corresponding preserved marker compound from a saturated target compound, which is (3S,4S)-2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide in the following scheme: 【Chemical 273】 a process comprising exposing a composition, such as a solution of (3S,4S)-2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide, to sunlight for a time sufficient for a detectable amount, particularly an amount above the limit of quantification, of a corresponding storage marker to be formed in the composition using analytical techniques exemplified by HPLC-MS; (d) Process H3 of any one of Process H2 or H2a, wherein said composition comprises a solution, in particular an aqueous solution, preferably maintained at a predefined level of pH acidity / basity, preferably by a method exemplified by the inclusion of a suitable buffer in the aqueous solution: (e) Process H4 of Process H3, wherein the solution of the saturated target is maintained at a level of acidity / basicity exemplified by an aqueous solution of the saturated target having a pH selected from about 4±1; 7±1; and 10±1, preferably by including an effective concentration of an appropriate buffer in the aqueous solution; (f) Process H5 of any one of processes H2; H2a; H3; and H4, wherein the rate at which the corresponding storage marker is formed from the saturated target compound upon exposure to sunlight is further mediated by the selection of the acidity / basicity of the composition comprising the saturated target; and (g) Process H6, any one of Processes H3, H4 and H5, wherein the composition is an aqueous solution and the rate at which the corresponding storage marker is formed from the saturated target upon exposure to sunlight is mediated by selecting the pH of the aqueous solution of the saturated target.

24. As defined, illustrated or described in any one of processes H7; H8; H9; H10; H11; and H12, or selected from the group consisting of: (a) Process H7 for minimizing the conversion rate of 2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide in said composition to a corresponding storage marker, comprising minimizing and / or avoiding exposure of said composition to sunlight and / or mitigating the conversion effects of exposure to sunlight; (b) Process H8 of minimizing the conversion rate of tetflupyrrolimet in the composition to a corresponding storage marker, comprising minimizing the time and extent to which the composition is exposed to sunlight and / or mitigating the conversion effects of exposure to sunlight; (c) Process H9 of minimizing the conversion rate of tetflupyrrolimet in its composition to a corresponding storage marker, comprising including in said composition an ingredient; an excipient; an adjuvant; a carrier; or any additive capable of mitigating at least one of the conversion effects of exposure to sunlight or capable of slowing the rate at which said conversion would occur upon exposure to sunlight in the absence of said ingredient, excipient, adjuvant, carrier, or additive; (d) Process H10 for minimizing the rate of conversion of tetflupyrrolimeth in a product containing a tetflupyrrolimeth composition (including a solution thereof) to a corresponding storage marker during manufacture, packaging, labeling, transportation, and storage of the product, comprising mitigating or overcoming the effects of exposure of the product to sunlight by containing the composition within a light-resistant, preferably substantially opaque, packaging and / or container (e.g., a container-closure system) that protects the contents from the conversion effects of sunlight by a light-resistant or opaque covering, or by the use of secondary packaging, or by the specific properties of the material of which it is composed, including any coatings applied thereto, including clear, colorless, or translucent containers that are made light-resistant within an amber container, wherein light-resistant and opaque are related to the wavelengths of light that mediate the conversion of tetflupyrrolimeth to a corresponding storage marker; (e) Process H11 and / or composition of any one of Processes H1-H10, wherein said saturated target compound, preferably tetflupyrrolimet, is in a liquid, solution, emulsion or suspension composition; and (f) A process for minimizing the rate at which an aqueous solution of tetflupyrrolimet is converted to a corresponding storage marker compound when the solution is exposed to sunlight, comprising maintaining a pH of the aqueous solution in the range of about 6 to about 8, preferably about 7, Process H12.

25. As defined, illustrated or described in any one of Processes H13; H14; H15; and H16, or selected from the group consisting of: (a) a process H13 for determining the period during which a storage composition comprising a saturated target compound, in particular a tetflupyrrolimetic composition, has been exposed to sunlight during storage, comprising measuring and quantifying the relative content of the corresponding storage marker compound compared to the content of the saturated target in said composition, and evaluating the period of exposure to sunlight by reference to a standard calibrated conversion rate in one or more reference compositions comprising the saturated target compound; (b) Process H14 of Process H13 by a method in which said measuring and quantification of said relative content is exemplified by calculating the ratio of the respective areas under the resolved characterization peaks of each compound in the test sample by suitable HPLC analysis; (c) Process H15 of any one of Processes H13 and H14, wherein the standard calibration rate is determined for a reference composition having the same acidity / basicity as the stored test composition; and (d) Process H16, any one of processes H13, H14 and H15, wherein said standard calibration rate is determined relative to a reference composition packaged in the same container system as the stored test composition.

26. A storage packaging composition as defined, illustrated or described in any one of compositions I1; I2; I3; I4; I5 and I13, or selected from the group consisting of: (a) a preserved packaged composition I1 comprising a detectable amount of a preserved marker compound in combination with the corresponding saturated target compound to which it has been converted by said process exemplified by process H2; (b) In particular, the formula 【Chemical 274】 Illustrated by (3S,4S)-2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide of the formula: 【Chemistry 275】 In combination with a saturated target compound of the formula 【Chemical 276】 a preserved packaged composition I2 of composition I1, comprising a detectable, preferably measurable, amount of a preserved marker compound; (c) a storage packaged composition I3 of any one of compositions I1 and I2, wherein the composition comprises a solution, particularly an aqueous solution, of a saturated target maintained at a predefined level of acidity / basity, preferably pH, preferably by a method exemplified by the inclusion of an appropriate buffer system in the aqueous solution; (d) a storage packaging composition I4 according to composition I3, wherein the saturated target solution is maintained at said acidity / basicity level exemplified by an aqueous solution of the saturated target having a pH selected from about 4±1; about 7±1; and about 10±1, preferably by including in the aqueous solution a suitable buffer at a concentration effective to maintain said acidity / basicity level; and (d) a preserved marker compound, in particular a compound of the formula 【Chemical 277】 When exposed to sunlight during storage, the compound of formula 【Chemical 278】 a storage packaged composition I5 of any one of compositions I1-I4, wherein the rate at which the compound is formed is further mediated by the selection of the acidity / basicity of the saturation target composition over the storage period; (e) A preserved packaged composition I13 comprising a saturated target compound with less than a measurable, preferably less than a detectable, amount of a corresponding preserved marker compound after storage in a sunlight environment for more than two months.

27. A packaged aqueous composition of tetoflupyrrolimet as defined and described in composition I6, or A packaged aqueous composition I6 of tetoflupyrrolimet, wherein the tetoflupyrrolimet is represented by the following formula, including any isomer, enantiomer or mixture thereof when the composition is exposed to sunlight during storage: 【Chemical 279】 a rate at which the conversion of the active ingredient to a corresponding storage marker of tetrahydrofuran is minimized, and the composition is adapted to maintain a pH in the range of about 6 to about 8, preferably about 7, during storage by including in the composition an ingredient, excipient, or other component exemplified by a buffer or buffer system.

28. An agricultural product as defined, illustrated or described in any one of Products I7 or I8, or selected from the group consisting of: (a) An agricultural product comprising a composition of 2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide, in particular tetflupyrrolimet, having the formula: 【Chemistry 280】 to a corresponding storage marker is minimized, and said product is adapted to limit, reduce or minimize, or substantially avoid the time and extent of exposure of said composition within said product to sunlight during storage, said minimization being compared to an agricultural tetoflupyrrolimetic product without said adaptation; and (b) During the manufacture, packaging, labeling, transportation, or storage of the tetflupyrrolimet composition, 【Chemistry 281】 an agricultural product comprising said composition detectably protected against sunlight-mediated conversion of said compound to a corresponding storage marker compound, Agricultural product I8, characterized in that said product comprises said composition contained and / or protected from light within a substantially light-resistant, preferably opaque, packaging and / or container-closure system that protects the contents from the effects of sunlight, including any coating applied thereto, including a transparent, colorless or translucent container that is made light-resistant due to the specific properties of the materials that make up said composition, by an opaque cover or by the use of a secondary packaging or in an amber container.

29. A composition as defined, illustrated or described in any one of Products I7 or I8, or selected from the following: (a) An agricultural product comprising a composition of 2'-fluoro-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxanilide, in particular tetflupyrrolimet, having the formula: 【Chemical 282】 to a corresponding storage marker is minimized, and said product is adapted to limit, reduce or minimize, or substantially avoid the time and extent of exposure of said composition within said product to sunlight during storage, said minimization being compared to an agricultural tetoflupyrrolimetic product without said adaptation; and (b) During the manufacture, packaging, labeling, transportation, or storage of the tetflupyrrolimet composition, 【Chemistry 283】 an agricultural product comprising said composition detectably protected against sunlight-mediated conversion of said compound to a corresponding storage marker compound, Agricultural product I8, characterized in that said product comprises said composition contained and / or protected from light within a substantially light-resistant, preferably opaque, packaging and / or container-closure system that protects the contents from the effects of sunlight, including any coating applied thereto, including a transparent, colorless or translucent container that is made light-resistant due to the specific properties of the materials that make up said composition, by an opaque cover or by the use of a secondary packaging or in an amber container.

30. A tetflupyrrolimet composition as defined, illustrated, or described in any one of compositions I9; I10; and I12, or selected from the following: (a) a compound represented by the following formula: 【Chemical 284】 19. A composition of tetoflupyrrolimet characterized by a minimized rate or extent of sunlight-mediated conversion of tetoflupyrrolimet to a corresponding storage marker of a composition comprising at least one ingredient, excipient, adjuvant, carrier or additive capable of mitigating the transforming effect of exposure to sunlight or slowing down the rate at which said transforming would occur upon exposure to sunlight in the absence of said ingredient, excipient, adjuvant, carrier or additive; (b) a tetflupyrrolimet composition I10 that is at least measurably stabilized against sunlight-mediated conversion to a corresponding storage marker during manufacturing, packaging, labeling, shipping, and storage, characterized in that said composition comprises at least one component, excipient, adjuvant, carrier, or additive that can mitigate the conversion effects of exposure to sunlight and / or decrease the rate at which said conversion would occur without said component, excipient, adjuvant, carrier, or additive; (c) a tetoflupyrrolimetic composition I12 that is at least measurably stabilized against conversion to a corresponding storage marker or that displays a measurably reduced rate of conversion to a corresponding storage marker during manufacturing, packaging, labeling, shipping, and storage, as compared to a standard calibrated conversion rate in one or more reference compositions comprising tetoflupyrrolimetic, said composition being: i) a buffer that maintains the pH of the composition at 7±1; ii) UV absorbers; iii) Suitable dyes, colorants, or pigments, such as components that exhibit substantially the same absorption spectrum as that of tetraflupyrrolimet; iv) Components capable of reducing the amount of sunlight hitting the material; v) opacifying agents; vi) reflective pigments such as titanium dioxide; vii) a light-protective coating covering at least a portion of the tetflupyrrolimet in the composition; viii) a complex of tetflupyrrolimeth with a complexing agent, exemplified by an inclusion complex with cyclodextrin; wherein said reference composition comprises tetflupyrrolimeth free of said component.

31. Products as defined, illustrated or described in any one of Products I11 and I15, or selected from the following: (a) an article of manufacture I11 comprising a tetoflupyrrolimetic composition that is shielded from sunlight-mediated conversion to a corresponding storage marker during any of the manufacturing, packaging, labeling, shipping, or storage of said composition, characterized in that said article of manufacture comprises said tetoflupyrrolimetic composition contained within a light-fast, preferably opaque, package, substantially as detailed in Process H10; and (b) The product of any one of Compositions I1-I12 and / or Composition I15, wherein the saturation target is preferably wherein the tetflupyrrolimet is in a liquid, solution, emulsion, or suspension composition.

32. A buffered tetflupyrrolimethane composition as defined, shown or described in composition I14; or A buffered tetflupyrrolimethane composition comprising less than a measurable amount, preferably less than a detectable amount, of a corresponding preserved marker compound after storage in a sunlight environment for a period equal to or greater than two months.

33. The crystalline polymorphic form I of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide or tetflupyrrolimet, as defined by any one of crystalline polymorphs J1 or J2, or selected from the following group: (a) A crystalline polymorph J1, Form I, of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide, exhibiting at least one of the following properties: Infrared spectrum substantially as shown in FIG. A powder X-ray diffraction pattern substantially as shown in FIG. A powder X-ray diffraction pattern having a differential peak at 9.6 2θ (±0.20); an X-ray powder diffraction pattern having at least four characteristic peaks at 9.6, 15.0, 17.3, 17.9, 21.6 and 24.6 2θ (±0.20); and (b) A crystalline polymorph J2 of tetflupyrrolimet, Form I, exhibiting at least one of the following characteristics: Infrared spectrum substantially as shown in FIG. A powder X-ray diffraction pattern substantially as shown in FIG. A powder X-ray diffraction pattern having a differential peak at 9.6 2θ (±0.20); An X-ray powder diffraction pattern having at least four characteristic peaks at 9.6, 15.0, 17.3, 17.9, 21.6 and 24.6 2θ (±0.20).

34. Composition J3; a composition as defined in any one of J4 and J5 or selected from the following group: (a) composition J3 comprising crystalline polymorphic form I of tetflupyrrolimet, as defined by any one of crystalline polymorphs J1 or J2; (b) an agrochemical, preferably herbicidal, composition J4 comprising one of the crystalline polymorphic form I of the crystalline polymorphs J1 and J2 and a herbicidally acceptable diluent or carrier; and (c) An agrochemical composition, preferably a herbicide composition J5, prepared from crystalline polymorphic form I of any one of crystalline polymorphs J1 and J2.

35. The crystalline polymorphic form II of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide or tetflupyrrolimet, defined as any one of the crystalline polymorphs K1 and K2, or selected from the following group: (a) A crystalline polymorph K1, Form II, of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide, exhibiting at least one of the following properties: Infrared (IR) absorption spectrum substantially as shown in FIG. an infrared (IR) absorption spectrum having at least one characteristic peak selected from values ​​expressed as cm-1 (±1 cm-1) at 1678, 1546, 1395, 946, 924, 885, 825 and 662; A powder X-ray diffraction pattern substantially as shown in FIG. A powder X-ray diffraction pattern having a differential peak at 6.9 in 2θ (±0.20); an X-ray powder diffraction pattern having at least four characteristic peaks expressed in 2θ (±0.20) selected from the following values: 6.9, 11.2, 17.7, 23.5, and 26.3; and (b) A crystalline polymorph K2, Form II, of Tetflupyrrolimet, exhibiting at least one of the following characteristics: Infrared (IR) absorption spectrum substantially as shown in FIG. an infrared (IR) absorption spectrum having at least one characteristic peak selected from values ​​expressed as cm-1 (±1 cm-1) at 1678, 1546, 1395, 946, 924, 885, 825 and 662; A powder X-ray diffraction pattern substantially as shown in FIG. A powder X-ray diffraction pattern having a differential peak at 6.9 in 2θ (±0.20); A powder X-ray diffraction pattern having at least four characteristic peaks expressed in terms of 2θ (±0.20) selected from the following values: 6.9, 11.2, 17.7, 23.5 and 26.

3.

36. Amorphous solid forms of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide or tetflupyrrolimet prepared by a process exemplified by any one of: precipitation; spray drying; freeze drying; adsorption in or on a solid support; solid solution in a polymer, wax, sugar, or salt, and complexation with a polyelectrolyte or cyclodextrin.

37. A combination of solid forms of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide or tetflupyrrolimet, comprising at least two selected from the group consisting of crystalline polymorphic form I of the compound of N-(2-fluorophenyl)-1-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]-3-pyrrolidinecarboxamide or tetflupyrrolimet; crystalline polymorphic form II and crystalline polymorphic form II.

38. Composition K3; any one of compositions K4 and K5, or selected from the following group: (a) composition K3 comprising crystalline polymorphic form II according to any one of crystalline polymorphs K1 or K2; (b) an agrochemical, preferably a herbicidal composition K4, comprising the crystalline polymorph form II according to any one of the crystalline polymorphs K1 and K2 and an agrochemically, preferably herbicidally, acceptable diluent or carrier; and (c) An agrochemical composition, preferably a herbicide composition K5, prepared from the crystalline polymorphic form II according to any one of the crystalline polymorphs K1 and K2.

39. Method K6, and K6a, or any one of the preparation methods defined and / or described in the following group: (a) a crystallization method for preparing the crystalline polymorphic form I according to any one of the crystalline polymorphs J1 and J2, comprising recrystallization from tert-butyl methyl ether, K6; (b) A process K6a for preparing crystalline polymorphic form I according to any one of crystalline polymorphs J1 and J2, comprising the steps of: i) dissolving (3R,4S)-1-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxylic acid in acetonitrile (200 mL); ii) adding 2-fluoroaniline and N-methylimidazole; iii) mixing the resulting contents at ambient temperature for a period of time exemplified by 10 minutes; iv) adding chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate; v) stirring the resulting mixture at ambient temperature for a period exemplified by 10 hours; vi) removing the solvent, for example by evaporation; vii) dissolving the residue, for example in dichloromethane; viii) washing with, for example, water, aqueous sodium sulfate and brine; ix) drying and concentrating under reduced pressure to obtain a crude product; x) recrystallizing the crude product from tert-butyl methyl ether.

40. Method K7, and K7a or a preparation method as defined and / or described in any one selected from the group consisting of: (a) a process for preparing crystalline polymorphic form II, K7 according to any one of crystalline polymorphs K1 and K2, comprising trituration with heptane; and (b) A method for preparing crystalline polymorph form II K7a according to any one of crystalline polymorphs K1 and K2, comprising the steps of: i) dissolving N-(2-fluorophenyl)-1-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide in diethyl ether; ii) For example, CuBr.SMe 2 Adding iii) adding, for example, 2,2'-bis(diphenylphosphaneyl)-1,1'-binaphthalene; iv) stirring the reaction mass for an exemplary period of 20 minutes; v) cooling the reaction mass; and vi) adding, for example, trimethylsilyl trifluoromethanesulfonate; vii) stirring for 20 minutes; viii) adding 3-(trifluoromethyl)phenyl)magnesium bromide; ix) stirring for an exemplary period of 2 hours; x) Treating the reaction mass with, for example, NH 4 quenching in aqueous Cl; xi) extracting with ethyl acetate; xii) washing the combined organic layers with a brine solution; xiii) Na 2 SO 4 and concentrating to obtain a crude product. xiv) purification by column chromatography, for example using ethyl acetate / hexane (20:80) as eluent; xv) triturating the resulting solid with heptane (5 mL).

41. As defined, illustrated or described in any one of steps N1 and N2, or selected from the following group: (a) General procedure N1 for preparation of conserved markers from saturating targets: 【Chemistry 285】 (In the formula, R β , A β , A α and R ζ has the same meaning as defined for compound A2), (b) General procedure N2 for the preparation of storage markers useful for pH-dependent calibration, based on three aqueous compositions of a saturated target, each buffered at a different pH: Approximately 50 mg of each of the three lots of saturated target is suspended in approximately 2 ml of 2% aqueous acetonitrile and sonicated for approximately 20 minutes; Add approximately 0.1 ml of one of three different buffers, pH=4, pH=7, and pH=10, respectively; The three buffer solutions are each filtered, introduced into a quartz tube, and exposed to natural sunlight for approximately two months. Analysis by HPLC-MS shows the formation of the corresponding storage markers in each solution at pH-related concentrations.

42. A compound as defined, illustrated or described in any one of compounds P1; P1a; P2; P2a; P3; P3a; Q1; Q2; and Q3, or selected from: (a) Compound P1 of the following formula: 【Chemistry 286】 or a salt or N-oxide thereof (In the formula, Each R ζ has the same meaning as defined for compound A2); (b) a synthetic intermediate compound P1a for preparing a saturated target of the formula 【Chemistry 287】 or a salt or N-oxide thereof, R ζ has the same meaning as defined for compound A2); (c) Compound P2 of the following formula: 【Chemistry 288】 or a salt or N-oxide thereof; (d) Synthetic intermediate compound P2a for preparing saturated targets of the formula: 【Chemical 289】 or a salt or N-oxide thereof; (e) Compound P3 of the following formula: 【Chemistry 290】 or a salt or N-oxide thereof; (f) Synthetic intermediate compound P3a for preparing saturated targets of the formula: 【Chemical 291】 or a salt or N-oxide thereof; (g) Compound Q1 of the following formula: 【Chemical 292】 or its salt or N-oxide (In the formula, Each R ζ has the same meaning as defined for compound A2); (h) Compound Q2 of the following formula: 【Chemical 293】 or a salt or N-oxide thereof; and (i) Compound Q3 of the following formula: 【Chemical 294】 or a salt or N-oxide thereof.

43. A process, method or composition as defined, illustrated or described in any one of Preparations A; B; C; D1; D2; D3; D4; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; X; Y; Z; AA; AB; AC; AD; AE; AF; AG; AH; AI; AJ; AK; AL; and AM.

44. The unsaturated precursor of any one of compounds A1 to A35 is Process B15a, which is used as an intermediate in the process for the preparation of a saturated target as defined in any one of processes B1 to B14.

45. Process B15c, which comprises the use of an unsaturated precursor of any one of processes B1 as an intermediate in a process for the preparation of a saturated target in any one of processes B1 to B14.

Citation Information

Patent Citations

  • Asymmetrical catalytic hydrogenation of 3-alkyl-2-ethoxycarbonyl-substituted annular conjugated ketene and application thereof

    CN108863787A

  • pyrrolidinone herbicide

    JP2017506210A

  • Substituted cyclic amides and their use as herbicides

    JP2018522832A

  • Process for the preparation of 3-carboalkoxypyrrolidones

    WO1990007499A1

  • Methods for preparation of jasmonate compounds

    WO2019135243A1